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Abstract 
 
Although various drugs have been developed to treat different diseases such as cancer, the 
therapeutic effects of many drugs have been limited by their undesirable properties such as poor 
solubility, poor bioactivity, rapid clearance in blood and non-specific distribution. Nanoparticles as 
carriers have received more and more attention in the last two decades due to their ability of 
overcoming these obstacles and enhancing the therapeutic efficiency of the conventional drugs. In 
this thesis, various kinds of nanoparticles were developed aiming at improving the therapeutic 
efficiency and targeted delivery of anti-cancer drug and gene.   
Curcumin is a promising anti-cancer drug but its applications in cancer therapy are limited due to its 
poor solubility, short half-life and low bioavailability. In this thesis, magnetic-polymer core-shell 
nanoparticles based on non-toxic, biocompatible and biodegradable polymers such as silk fibroin, 
alginate and chitosan were prepared and optimized to improve the uptake efficiency and cell growth 
inhibition effect of curcumin towards cancer cells. The size, zeta potential, surface morphology, drug 
loading / release profile, in vitro uptake and growth inhibition effect to cancer and normal cells of 
these curcumin loaded nanoparticles were investigated. The results indicated that the curcumin 
loaded particles exhibited enhanced uptake efficiency and growth inhibition effect on MDA-MB-231 
cancer cells compared with free curcumin. Higher uptake efficiency and cytotoxicity to 
MDA-MB-231 cells than normal human dermal fibroblast cells were observed, suggesting they have 
specific effects against cancer cells. Moreover, in vitro targeted delivery of curcumin to specific 
areas of cells was achieved with the presence of an external magnetic field, suggesting these 
magnetic nanoparticles are promising for targeted delivery of drugs to desired sites applying 
  
magnetic forces.  
Apart from drug delivery the applications of magnetic nanoparticles in gene delivery was also 
investigated. Polyethyleneimine is one of the most efficient non-viral transfection agents for gene 
delivery due to its high cationic charge density. In this thesis, silk fibroin was selected to fabricate 
magnetic-silk / polyethyleneimine core-shell nanoparticles and silk-polyethyleneimine nanoparticles 
for the transfection of an anticancer gene (c-myc antisense oligodeoxynucleotides) into 
MDA-MB-231 breast cancer cells and human dermal fibroblast cells. The results illustrated that the 
cytotoxicity of magnetic-silk / polyethyleneimine core-shell nanoparticles was significantly lower 
than polyethyleneimine coated magnetic nanoparticles which is widely studied as a gene delivery 
carrier. The magnetic-silk / polyethyleneimine core-shell nanoparticles were capable of delivering 
c-myc antisense oligodeoxynucleotides into MDA-MB-231 cells and significantly inhibiting the cell 
growth. Employing magnetic-silk / polyethyleneimine core-shell nanoparticles, high uptake 
efficiency of c-myc antisense oligodeoxynucleotides was achieved within 20 min via magnetofection. 
In addition, magnetic-silk / polyethyleneimine core-shell nanoparticles exhibited higher cytotoxic 
effect against MDA-MB-231 breast cancer cells than normal human dermal fibroblast. Moreover, in 
vitro targeted delivery of oligodeoxynucleotides can be achieved using magnetic-silk / 
polyethyleneimine core-shell nanoparticles under a magnetic field. 
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1. Introduction 
1.1. Drug delivery systems 
1.1.1. Nanocarriers improve therapeutic effect of conventional drugs  
Although various drugs have been developed to treat different diseases such as cancer, the 
therapeutic effects of many drugs have been limited by their undesirable properties such as poor 
solubility, poor stability, poor bioactivity, rapid clearance in blood and non-specific distribution 1-2. 
Therefore, to overcome these obstacles and enhance the therapeutic efficiency of the conventional 
drugs, nanocarriers are being developed 2. For instance, the poor solubility of hydrophobic drugs 
such as curcumin (CUR) can be improved by nanocarriers. CUR is a Food and Drug Administration 
(FDA) approved medicine 3 and has been largely employed for medical applications attributed to its 
anti-oxidant 4-6, anti-inflammatory 7-9, wound healing 10-11 and anti-bacterial 12-13 activities.  Recent 
research also indicated that CUR demonstrated impressive anti-cancer properties 14-17. It has been 
reported that CUR showed the ability to inhibit the carcinogenesis in various cell lines including 
breast, colon and gastric cancer cells, which made it promising for cancer therapy 16. However, 
despite all the promising properties, the solubility of CUR is very poor in aqueous solution, leading 
to its poor bioavailability and limited therapeutic effect for cancer treatment 18-20. By encapsulating 
CUR in nanocarriers, including lipid based nanoparticles 21-25, polymer nanoparticles 26-32 and 
inorganic nanoparticles 33, the solubility and bioavailability of CUR have been improved and 
enhanced therapeutic effect can be achieved. The poor pharmacokinetics (PK) of some anti-cancer 
drugs is one of the greatest obstacles of their therapeutic effects 2. The rapid clearance of drugs or 
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drug loaded nanoparticles in the bloodstream is mainly promoted by protein adsorption 34. The 
adsorbed proteins on the surface of drugs or nanoparticles tend to facilitate the opsonisation of 
therapeutic agents and promote their aggregation. The majority of opsonised drugs or particles can 
be eliminated by a receptor-mediated mechanism within a few minutes 34. The rapid clearance and 
short half-life of anti-cancer drugs such as doxorubicin (DOX) normally results in the necessity of 
increased injection dose or injection frequency to reach the efficacious responses 35. However, 
increasing the dose of toxic anti-cancer drugs may cause undesired side effects to the human body 
or healthy tissue and should be avoided. Encapsulation of the drugs into nanocarriers, which are 
designed to provide protection to the encapsulated cargo generally will lead to an increased half-life 
and enhanced therapeutic effect of drugs 35. For example, Harivardhan et al. compared the 
pharmacokinetics of free DOX and DOX loaded poly(butyl cyanoacrylate) nanoparticles after they 
were injected into albino rats 36. The results indicated that most of the free injected DOX was rapidly 
cleared within 2 h, where total clearance was after 8 hours. On the other hand, DOX loaded 
poly(butyl cyanoacrylate) nanoparticles showed a significantly longer elimination time 36. 
Modification of nanocarriers can be made to further improve the PK of drug loaded carriers. For 
example, it has been reported that the coating or incorporation of poly(ethylene glycol) (PEG) into 
nanoparticles can decrease the drug clearance by immune recognition 2. Gabizon et al. investigated 
the PK of DOX loaded liposomes containing polyethylene glycol-derivatized 
distearoylphosphatidylethanolamine (PEG / DSPE) in rodents and dogs and found that the plasma 
concentrations of DOX in animals treated with PEG / DSPE-containing liposomes were significantly 
higher than those without PEG / DSPE 37.  
Another major obstacle of the therapeutic effect of free drugs is their undesired biodistribution (BD) 
35. Conventional free drugs especially small molecular forms are distributed non-specifically in the 
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body in which they will not only reach tumour sites but also healthy tissue 1. The nonspecific 
accumulation of drugs in healthy tissue both lowers the drug concentration at tumour sites, limiting 
the anti-cancer effect and increases the risk of undesired side effects to healthy tissue 1. Increasing 
the drug dose to obtain a higher drug concentration at tumour sites provides a better therapeutic 
effect for cancer treatment. However, with this approach, drug concentrations are also greatly 
increased in the healthy tissue, increasing the toxicity effect, thus causing stronger side effects. By 
using nanocarriers, the problem of poor biodistribution can be minimised, due to the enhanced 
permeability and retention (EPR) effects 2.  
 
Fig. 1.1 Schematic representation of drug delivery by nanocarriers. The accumulation of the drug at tumour 
sites is promoted by the EPR effect. Anti-cancer drug loaded nanocarriers extravasate from the blood through 
gaps in vascular endothelial cells and accumulate in tumour sites, but not in normal tissue.  
As shown in Fig. 1.1, in the tumour sites of the human body, blood vessels are remodelled to enable 
leukocyte extravasation, thus increasing the vascular permeability and enabling the extravasation 
and accumulation of nanocarriers at tumour sites 2. As the tumour grows the original blood vessels 
are incapable to supply enough nutrients and oxygen to supply the tissue and thus signal molecules 
such as cytokines are released resulting in the formation of new blood vessels at the tumour sites, a 
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process known as angiogenesis 2. Unlike blood vessels in normal tissue which possess tightly 
arranged endothelial cells, the angiogenic blood vessels possess large gaps between endothelial 
cells, which tend to further promote the extravasation of drug loaded nanocarriers and the 
accumulation of these carriers at the tumour sites 2. Therefore, nanocarriers within the appropriate 
size range cannot pass through the gaps in normal blood vessels, but can largely extravasate from 
blood vessels in tumour tissue 2. Since the extravasation of nanocarriers into tumour sites via the 
EPR effect is a size dependent process, it is important to investigate the suitable size range of 
carriers for drug delivery. For the efficient delivery of drugs to the cancer sites, the optimum size 
range of drug carriers is generally accepted to be about 50 - 200 nm 38. Particles with a size less 
than 50 nm will easily extravasate through the discontinuous endothelium of liver, spleen and bone 
marrow, and are less likely to be accumulated at the desired sites. On the other hand, particles with 
diameters larger than 200 nm may not pass through the porous vasculature of the tumour to reach 
the tumour site and will be eliminated more easily by the immune system 38. It is worth noting that 
the EPR effect is not the only factor to alter the targeted accumulation of carriers 2. The circulation 
time of carriers, degree of tumour vascularization and  the degree of angiogenesis can also affect 
their accumulation at tumour sites 2. Normally, a longer half-life results in a higher accumulation of 
carriers at tumour sites; tumours with less vascularization lead to less accumulated carriers; small 
pre-angiogenic tumours tend to accumulate carriers poorly 2. Moreover, ligand modified 
nanocarriers containing drugs can bind to specific receptors on the surface of cancer cells before 
entering the cells, thus achieving targeted drug delivery 2. 
In summary, the therapeutic effect of many conventional drugs is limited by their poor solubility, 
undesirable PK and BD. The nonspecific distribution of free drugs leads to the undesired 
accumulation of drugs in healthy tissue which will result in increased toxicity and undesired side 
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effects. The deployment of nanocarriers can overcome these problems by targeted delivering drugs 
to tumour sites via the EPR effect and providing protection to avoid rapid clearance 1. 
1.1.2.  Properties of nanocarriers affecting drug delivery 
As previously mentioned in Section 1.1.1, nanocarriers can be employed to improve the PK and BD 
of drugs to obtain an enhanced therapeutic effect. Normally, if the release rate of the encapsulated 
drug from carriers is very low, then the PK and BD of the encapsulated drug are the same as the PK 
and BD of drug carriers 2. On the other hand, if the drug is rapidly released, the PK and BD of the 
encapsulated drug will be similar to that of free drug 2. In most of drug delivery applications, the 
release rate of drugs is altered to achieve a sustained slow release to avoid rapid clearance and 
high injection frequency. Therefore, it is required for drug carriers to possess desirable PK and BD 
such as long circulation half-life, capable of accumulating at the tumour sites via the EPR effect. 
Conventional non-modified nanocarriers are generally rapidly cleared from the blood stream by the 
reticuloendothelial system (RES), which is an immune system including organs such as the liver 
and spleen 39. Therefore, in order to develop nanocarriers suitable for targeted delivery, it is 
important to investigate the properties of carriers that affect their performance in the process of 
targeted delivery. Recent studies indicated a few crucial properties of nanocarriers that play 
important roles in targeted drug delivery including particle size, surface charge and hydrophobicity 
1-2, 35.   
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1.1.2.1. The effect of nanoparticle size  
One of the advantages of nanoparticles is their tuneable size 1. As mentioned in Section 1.1.1 
nanocarriers can accumulate in tumour tissues by taking the advantage of the EPR effect 2. For 
effective accumulation, the size of nanocarriers should be within a size range of 50-200 nm. Smaller 
carriers (< 50 nm) are more likely to leak through the gaps of endothelial cells in the liver or spleen 
and larger carriers (>200) are more difficult to extravasate from the discontinuous blood vessels in 
tumour tissue 38. Particle size also plays an important role in altering the circulation time of carriers 
in blood 34. As previously mentioned in Section 1.1.1, the key factor in the clearance of nanocarriers 
by RES is protein adsorption. The adsorption of proteins on the surface of nanocarriers leads not 
only to the aggregation of the carriers but also their opsonisation, marking them for clearance by 
phagocytic cells in RES organs 34. Larger particles (> 200 nm) are reported more likely to be 
captured by phagocytic cells in the RES such as liver and spleen 34-35. For example, Fang et al. 
compared protein adsorption and phagocytic uptake of PEG-PHDCA (poly methoxypolyethylene 
glycol cyanoacrylate-co-n-hexadecyl cyanoacrylate) nanoparticles of three sizes: 80, 170 and 240 
nm after incubation with serum for 2 h 40.The results indicated that protein adsorption was 6%, 23% 
and 34% respectively for the sizes. The blood clearance of large particles was twice as fast as that 
of small nanoparticles 40.  
1.1.2.2. The effect of nanoparticle surface charge 
The surface charge of nanocarriers can significantly affect their circulation half-life, cellular uptake 
efficiency as well as BD in the drug delivery process. It was previously reported that particles with 
positively charged amino groups on their surface are more likely to be cleared by phagocytic cells 
than particles with negatively charged sulfate, hydroxyl and carboxyl groups on their surface 34. This 
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can be attributed to the electrostatic interactions between particles and cell surfaces. Positive 
nanoparticles tend to adsorb on negatively charged cell surfaces, therefore increasing their chance 
to be internalized by cells.  
For some applications, such as gene transfection which requires the condensation of negative DNA, 
passing through the cell membrane, escaping from the endosome and delivering the DNA to cell 
nucleus, positive nanocarriers such as polyethyleneimine or chitosan nanoparticles have been used 
41-45. However, positive surface charge on carriers can also increase their chance of protein 
adsorption causing rapid clearance by the RES ad well as nonspecific uptake 34. In contrast, 
negative particles show a lower chance of nonspecific uptake and clearance by RES 34. Yamamoto 
et al. compared the BD of neutral Tyr- PEG / PDLLA and negative Tyr-Glu-PEG / PDLLA micelles in 
mice and found that the anionic micelles exhibited a 10 times lower distribution into the liver and 
spleen than the neutral ones 4 h after injection than neutral micelles 46. This indicates that the 
electrostatic repulsion between negative carriers and the negative cell surfaces reduced their 
nonspecific cellular uptake, strongly suggesting that the surface charge of nanocarriers is an 
important factor affecting their circulation half-life and BD 34. From this, one can infer that altering 
the surface charge of nanocarriers can result in a better control of circulation time and nanocarrier 
distribution for the desired applications.  
1.1.2.3. The effect of hydrophobicity  
The surface hydrophobicity of nanocarriers is also an important factor that affects their circulation 
half-life and distribution 1. Serum proteins are more likely to adsorb onto particles with a higher 
hydrophobicity, thus highly hydrophobic nanocarriers have a greater chance to be cleared by 
macrophages 1. Gessner et al. compared the protein adsorption on latex particles with varying 
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surface hydrophobicity after incubation in human plasma for 5 min at 37°C 47. The data showed that 
with decreasing hydrophobicity, protein adsorption decreased. Therefore, in order to achieve 
prolonged circulation time in the blood stream, nanocarriers should ideally possess hydrophilic 
surface 1. A common method to provide carriers with a hydrophilic surface is coating with PEG, a 
hydrophilic polymer 2.  
In summary, in order to improve the circulation half-life and BD of encapsulated drug, nanocarriers 
need to be carefully engineered to possess suitable properties such as appropriate size range, 
surface charge and hydrophobicity. Further to the targeted delivery of drugs via the EPR effect, 
another method known as magnetic targeting, that usually used to enhance accumulation of 
magnetic nanocarriers at the target cells, can provide more specific delivery of drugs 1, 48. In this 
thesis, Fe3O4 magnetic nanoparticles are employed to fabricate magnetic core-shell nanoparticles 
for targeted drug delivery. The mechanism and properties of drug delivery by magnetic 
nanoparticles are discussed in the following Section 1.1.3.   
1.1.3. Magnetic nanoparticles for drug delivery 
Magnetic nanoparticles (MNPs) are a kind of nanomagnetic material with small particle size, large 
surface area, magnetic response and superparamagnetism 49. MNPs are widely employed in 
magnetic resonance imaging (MRI), magnetic hyperthermia and drug delivery due to their magnetic 
property 49. For the application of drug delivery, MNPs are usually employed in the form of 
superparamagnetic magnetic nanoparticles of a particle size smaller than 30 nm 50. Fe3O4 and 
γ-Fe2O3 are the most frequently used superparamagnetic iron oxide nanoparticles (SPIONs) and 
both materials are ferromagnetic in larger sizes 50. However, when their size is decreased to below 
30 nm, they become superparamagnetic instead of permanent magnetic, which means that MNPs 
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can be affected by an external magnetic field but do not get attracted to each other 50. The 
superparamagnetism property of SPIONs decreases their risk of aggregation in solution, thus 
making them promising as drug carriers 50. Iron oxide based MNPs are suitable for medical 
applications such as drug delivery because the human body contains a large amount of natural 
occurring iron, meaning that iron oxide nanoparticles are biocompatible and can be metabolized by 
the human body 50. Further to this, MNPs can be used to deliver drugs to desired sites with the help 
of an external magnetic force.   
 
Fig. 1.2. Schematic representation of targeted delivery of MNPs with the presence of an external magnetic 
field. 
The mechanism of targeted delivery of MNPs under a magnetic field is shown in Fig. 1.2. MNPs are 
used in targeted delivery of drugs to cancer cells, the anti-cancer drugs are encapsulated in the 
carrier or coated on its surface 51. MNPs can pass through the gaps between endothelial cells in the 
blood vessels in tumour tissue to reach the cancer cells via the EPR effect 51-52. External magnetic 
fields can be used to facilitate their extravasation from blood vessels and accumulation at the 
desired tumour sites 51-52. Once accumulated, drugs are either released from the carriers or 
internalized by cancer cells along with the carriers 51. Therefore, targeted delivery and located 
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accumulation of drugs can be achieved, helping to reduce the undesired accumulation of drugs 
within healthy tissue and enhancing the therapeutic effect against cancer cells. The effect of MNP 
accumulation depends on the intensity of the magnetic field, rate of blood flow, surface 
characteristics of magnetic carriers and the location of tumour tissue 51. For tumours located deep 
inside the human body, magnetic targeting more difficult to achieve due to the magnetic force being 
dependent on the inverse square of the MNP-magnet distance 53. In order to counter this problem  
a magnet would need to be implanted near the tumour tissue 53.  
Drug delivery via magnetic carriers includes several advantages such as (1): the targeting process 
can be visualized by MRI; (2): external magnetic fields can provide additional means for directed  
accumulation at tumour sites, thus possessing a higher specificity against cancer cells; (3) in an 
alternating magnetic field, MNPs can be employed as mediators for magnetic hyperthermia 48, 52. 
Due to their outstanding properties, MNPs are believed to be very promising as drug carriers and 
research has been conducted to explore their applications in the field of drug delivery 48.  
The application of magnetic carriers for drug delivery was first conducted in the year 1978 by 
Widder et al., who reported the targeted delivery of DOX by magnetic albumin microspheres in 
animal models 54. This concept was then further developed in 1980s when several groups reported 
the employment of magnetic microspheres for drug delivery 55-57. However, these carriers used in 
early research were micro-sized. As discussed in Section 1.1.2.1, large particles are more likely to 
be eliminated by the RES and may not pass through the gaps in tumour blood vessels via the EPR 
effect, therefore, nano-sized magnetic carriers are desirable. The first usage of nano-sized 
magnetic carriers in animal models was reported by Lübbe et al. in 1996, who employed epirubicin 
loaded MNPs in first phase I clinical trials 58. From then onwards, various strategies have been used 
to prepare MNPs with improved properties and their application in the field of biomedical 
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engineering was expanded 48. For example, Tian et al. prepared the silk fibroin coated MNPs 
containing DOX for the targeted delivery of DOX in mice 59. Their results indicated that a 
significantly higher amount of DOX accumulated at the tumour sites when magnetic carriers were 
used (with an external magnetic field provided) in comparison to nonmagnetic carriers. 
However, despite various advantages of MNPs as mentioned above, there are drawbacks limiting 
their applications. One of the major drawbacks is their instability in aqueous solution 60. Fe3O4 
MNPs are more active than their bulk materials due to their high surface to volume ratio, thus are 
more likely react in aqueous solution 60. After injection into the human body, reactive oxygen 
species (ROS) may be generated from the surface of MNP by enzymatic degradation 50. Once ROS 
accumulates in the human body, consequences such as damage to cellular proteins, enzymes, 
lipids, and nucleic acids can occur, leading to apoptosis of healthy cells 50. Therefore, it is essential 
to coat the magnetic cores in order to avoid the leaching of toxic components 60. Apart from 
providing a shell to protect the magnetic cores from corrosion, surface coating made from e.g. 
polymers can be used to provide the MNPs with different applications. Coating of silk fibroin can 
provide a polymer matrix for enhanced drug loading and controllable drug release 28, 59. Coating 
polyethyleneimine onto Fe3O4 MNPs surfaces enables the magnetofection of DNA 61. Another 
example is the coating of alginate / chitosan polymers onto the surface of Fe3O4 MNPs, enabling 
enzyme immobilization 62.    
In this thesis, the three naturally occurring polymers (silk fibroin, alginate and chitosan) are used for 
the surface coating of Fe3O4 MNPs for controlled release of curcumin. They were chosen due to 
their excellent properties such as low toxicity, good biocompatibility and biodegradability. 
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1.1.4. Properties of polymers investigated in this project 
1.1.4.1. Silk fibroin 
In recent years, silk fibroin obtained from the silkworm bombyx mori has been widely studied to 
develop various biomaterials such as micro / nanoparticles, mats, films, scaffolds and gels for 
applications such as drug delivery and tissue engineering due to its excellent properties such as 
high biocompatibility, tuneable biodegradability, robust mechanical performance and ease of 
process 63-66. 
 
Fig. 1.3. Schematic representation of the structure of silk. 
The structure of silk is shown in Fig. 1.3. Naturally produced silk fibres consist of two parallel silk 
fibroins are surrounded by sericin 63. There is approximately 75% silk fibroin (SF) which is a fibrous 
protein and 25% sericin which is an amorphous protein 64, 67. The semi-crystalline structure of SF 
provides silk with stiffness and strength while sericin plays the role of a linker to keep the integrity of 
fibres 64, 66. Through a process known as degumming, sericin can be removed from SF and 
dissolved in boiling Na2CO3 solution 64. SF is composed of a light (L) chain (26 kDa) and a heavy (H) 
chain (390 kDa), which are linked by a single disulphide bond between Cys-c20 of the H chain and 
Cys-172 of the L chain 64, 67. P25, which is a glycoprotein (25 kDa), also acts as a linker to 
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non-covalently link the H and L chains 64. The ratio of H chain, L chain and P25 is 6:6:1 in SF 64. The 
amino acids in SF from bombyx mori mainly consist of alanine (Ala) (30%), glycine (Gly) (43%) and 
serine (Ser) (12%) 68. The hydrophobic domains of the H chain consist of repetitive hexapeptides of 
Gly-Ala-Gly-Ala-Gly-Ser and dipeptides of Gly-Ala, Gly-Ser and Gly-Tyr (tyrosine), which form 
stable anti-parallel β-sheet crystallites 63. On the other hand, the amino acid sequences in L chains 
are not repetitive, which makes the L chain less hydrophobic and more elastic 63. The crystal 
structures of SF including mainly random coil rich silk I and β-sheet rich silk II 63. Moreover, another 
crystal structure of SF (silk III) with a hexagonal packing of silk molecules in a left handed threefold 
helical chain conformation was also observed in films of the air / water interface of SF solutions 69. 
 
Fig. 1.4. Schematic representation of silk I structure converted to silk II. 
As shown in Fig. 1.4, silk I structure is metastable, soluble in water as random coils and α-helixes. 
On the other hand, silk II structure is rich in β-sheet, stable and insoluble in water 70. Silk I structure 
can be easily converted to silk II structure by adding methanol or potassium phosphate 63-64, 71. The 
strong hydrogen bonds between adjacent segments of the anti-parallel β-sheet structure in silk II 
makes it insoluble in water and thus provides a favourable materials for the fabrication of SF 
biomaterials 63.   
Kundu et al. investigated the drug release profile of vascular endothelial growth factor (VEGF) 
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loaded SF nanoparticles (150-170 nm) and found that sustained release of VEGF lasted over three 
weeks 72. Bessa et al. prepared the Bone morphogenetic proteins (BMPs) encapsulated SF 
microparticles (from 500 nm to 3 μm) and reported that sustained release of BMPs for two weeks 
was observed 73. Further to this, Chen et al. fabricated paclitaxel loaded SF nanoparticles 270-520 
nm in diameter and reported a sustained release of the drug for 2 weeks 74. Wen et al. successfully 
loaded enhanced green fluorescent protein (EGFP) in SF microspheres (30-60 μm) at a high 
encapsulation efficiency of 95% and achieved a burst release free and sustained release for 50 
days. All these researches indicate that SF is a promising material for the fabrication of drug carriers 
75.  
As previously discussed in Section 1.1.2.1, the size of drug carriers needs to be carefully 
engineered to improve circulation half-life and BD of loaded drug. Therefore, various methods have 
been developed for the fabrication of SF particles with appropriate size ranges. Cao et al. fabricated 
SF particles with sizes ranging from 200 nm to 1.5 µ m by adding predefined amounts of ethanol 
into SF solutions and incubation of the mixtures in a freezer (at temperatures between -5 to -40℃) 
76. The size of particles could be controlled by altering the concentration of SF, amount of ethanol 
used and the temperature of the freezer 76. A major advantage of this method is the simple 
production process coupled by ease of particle size control. However, the organic solvent residue in 
resultant particles may bring potential risk in their drug delivery applications due to toxicity 28.    
Imsombut et al. fabricated SF microspheres by adding SF solution dropwise into ethyl acetate under 
continuous stirring to create a W / O emulsion system in which the silk solution acted as the water 
phase and ethyl acetate as oil phase 77. The SF microspheres could be fabricated in the emulsion 
system and collected by centrifugation, washing with ethyl acetate and drying in a vacuum oven at 
room temperature for 4 h 77. This method possesses the advantage of fabricating smooth and 
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completely spherical shaped particles but its major drawbacks are difficulty to process and to 
remove the emulsion agent.   
An aqueous based method has been reported by Wang et al. to fabricate silk nano / microspheres 
(300 nm-2 µm) 78. Firstly, SF solution and polyvinyl alcohol (PVA) were blended and air-dried to 
produce silk / PVA blend films. These films were then dissolved in water and centrifuged to remove 
PVA 78. The PVA network enables the fabrication of regular and smooth SF particles but the process 
is slow and complicated 63.   
In contrast, the fabrication of SF particles via a salting-out method is significantly simpler 63. Lammel 
et al. fabricated SF particles by adding SF solution into potassium phosphate solution followed by 
incubation in a freezer at -20 ℃ for 2 h 79. the size of resulting SF particles ranged between 500 nm 
to 2 μm depending on the SF concentration and the ionic strength of the potassium phosphate 
solution 79. Apart from being a simple process, this method possesses several other advantages 
including the absence of organic solvents, low cost and safe operation. However, the size of SF 
particles (500 nm - 2μm) prepared by this method is far from the optimum size range (50 - 200 nm) 
of nanocarriers for drug delivery applications 38.   
1.1.4.2. Chitosan 
Chitosan (CHI) is a polysaccharide which is normally prepared by the deacetylation of chitin which 
is a naturally derived, nontoxic, biocompatible and low-cost polysaccharide 80. Chitin can be easily 
obtained from the environment because it wildly exists in shells of crabs or shrimps and can be 
used as a biomaterial to fabricate artificial fibres for wound dressing or coupled with chitosan to 
make tablets for drug delivery 81. However, the applications of chitin are limited compared with 
chitosan mainly because chitin is a hydrophobic polysaccharide which is insoluble in aqueous 
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solution 81.  
Unlike chitin, CHI is soluble in acidic solutions such as acetic acid and formic acid, which makes it 
easier to process CHI for the fabrication of many biomaterials 81. The different solubility of chitin and 
CHI results from their differences in structure. As shown in Fig. 1.5, CHI is composed of 
N-acetyl-D-glucosamine and D glucosamine in which the primary amino groups of CHI result from 
the deacetylation of chitin 81-82.     
 
 
Fig. 1.5. Chemical structure of chitin and chitosan.  
The primary amino groups of CHI are responsible for the solubility of CHI. Under acidic conditions, 
amino groups of CHI interact with protons, which leads to the protonation of the CHI structure 80. 
Therefore, the CHI chains will carry cationic charges which will increase the electrostatic repulsion 
between CHI chains and keep them stable and soluble in water. This is the reason why CHI is 
usually dissolved in 1% (v/v) acetic solution 80.   
In neutral and alkaline solutions, the protons associated with CHI amino groups tend to dissociate 
from amino groups, which lead to the neutralization of CHI chains and the reduction of the cationic 
charges and the electrostatic repulsion between CHI chains 32. In this case, the electrostatic 
repulsion will be insufficient to keep CHI chains from interacting with each other and thus resulting 
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in the reduced solubility of CHI 32. This mechanism has been confirmed by many previous reports 32, 
83-84. For instance, López et al. fabricated CHI coated iron oxide nanoparticles and investigated their 
stability and zeta potential at different pH conditions 83. They found at a pH value lower than 3, the 
zeta potential of particles was larger than +40 mV, suggesting protonation of CHI. With increasing 
pH, the zeta potential decreased, indicating that CHI chains were undergoing deprotonation. At pH 
11 the surface charge of particles reached ~0 mV and a large amount of precipitate could be 
observed.  
The pH-dependent zeta potential of CHI makes it a unique material among natural derived polymers 
85. The positive charge of CHI provides advantages for many applications including wound dressing, 
tissue engineering, gene delivery and drug delivery 85. For instance, by utilizing the pH dependent 
solubility property of CHI, particles for drug delivery can be made 80.  
Particles can be fabricated by adding acidic CHI solution into alkali solution such as sodium 
hydroxide or sodium hydroxide / methanol with an air nozzle to induce precipitations 80. The size of 
the particles can be controlled by altering the nozzle diameter or the air pressure 80. The drawback 
of this method is the introduction of hash environment from high concentration of alkaline solutions.  
Another way to make CHI particles is an emulsion cross-linking method 80. In this method, 
cross-linking agents are used to react with CHI. The amino groups in CHI can interact with aldehyde 
groups from cross-linking agents to form a cross-linked network. The reaction generally occurs in a 
water / oil emulsion system in which CHI is dissolved in the aqueous phase surrounded by oil phase 
86. With this method, the CHI particles size can be controlled by altering the aqueous droplet size 80. 
However, this method possesses a few drawbacks e.g. difficulty to process and the requirement of 
introduction of cross-linking agents 80.   
Using an ionic gelation method these problems can be overcome 87. Advantages of this method are 
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easy fabrication and avoiding the use of toxic cross-linking agents, this therefore can avoid the risk 
of organic solvents interacting with active drugs and allows the loading of sensitive molecules 80, 88. 
Fabrication of CHI particles with this method depends on the interaction between positive amino 
groups from CHI and negative phosphate ions from tripolyphosphate (TPP) which is a polyanion 88. 
In this method, CHI is first dissolved in acidic solution where its amino groups are protonated to 
possess positive charges. Next, the CHI solution is added dropwise to TPP solution with consistent 
stirring. In the mixed solution, cationic amino groups will interact with the anionic phosphates, which 
lead to the ionic gelation of CHI and the formation of CHI particles 80. Although this method 
possesses many advantages, there is one drawback associated with CHI particles fabricated with 
this method, which is the poor mechanic strength of these particles 80.  
The previously mentioned characteristics together with low toxicity, good biodegradability and 
biocompatibility make CHI a promising material for the fabrication of drug carriers 80. It has been 
reported that the LD50 of CHI in laboratory mice is 16 g/kg, which is close to sugar or salt 80. When 
in living tissues, CHI does not cause allergic reactions and can be degraded to non-toxic amino 
sugars that can be absorbed by the human body 80. Moreover, CHI possess antimicrobial properties 
and can absorb toxic metals such as mercury and cadmium 80.  
Moreover, CHI particles possess a few advantages as drug carriers such as controlled release 
property, mucoadhesive character, transfection enhancing property and permeation enhancing 
property 80, 85. These advantages are associated with the cationic amino group property of CHI. For 
example, CHI based carriers are excellent choices for the sustained release of anionic drugs 85. 
Normally, sustained release of drug depend on electrostatic interactions mediated retardation is a 
frequently used strategy for drug delivery if the desired release profile cannot be obtained by simple 
dissolution, diffusion, erosion or membrane control 85. Thus CHI particles can be used  for the 
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release of anionic drugs such as naproxen 89 and curcumin 29, 32, 90 to achieve prolonged drug 
release. Apart from this, coupled with anionic polymers such as alginate or carrageenan, CHI can 
be used to produce stable complexes from which encapsulated drugs can be sustained released via 
a diffusion or erosion process 91. The mucoadhesive character of CHI particles, which is achieved 
via the electrostatic interactions between positive amino groups from CHI and the negative 
substructures in the mucus gel layers, can help to increase their residual time at the site of 
absorption 80,85. Moreover, the transfection enhancing property, which can improve the uptake of 
DNA based drugs and the permeation enhancing property of CHI based carriers are also based on 
the positive charges of CHI 85. 
1.1.4.3. Alginate 
Alginate is a naturally obtained anionic polysaccharide extracted from brown seaweed 92-94. 
Hydrogels of alginate can be fabricated in different ways and they possess structures similar to the 
extracellular environment of living tissues 93. In addition to this, alginate possesses a few desirable 
properties such as good biocompatibility, low cost, low cytotoxicity and a mild synthesis process 
during gelation 92-94. Thus, alginate is a promising material for various applications including wound 
dressing, delivery of drugs and tissue engineering 92-94. As wound dressings, alginate matrixes can 
help to maintain a physiologically moist environment and minimize the microbial infection of the 
wound, which contributes positively to wound healing 93-94. As drug carriers, the release rate of 
active materials such as small molecular drugs or macromolecular proteins from alginate hydrogels 
can be controlled by altering the cross-linking methods and cross-linking agents 93, 95-97. As tissue 
engineering materials, alginate hydrogels can be used for the delivery of cells to the wounded sites, 
providing a space for new tissue to form and giving control over the structure and function of the 
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engineered tissue 93, 98.    
Alginate consists of two monomeric units: (1-4)-linked β - D-mannuronate (M) and α -L-guluronate 
(G) residues 93. As shown in Fig. 1.6, the structure of alginate is made up of the blocks of 
consecutive G residues, M residues and alternating M-G residues 93. Alginate originating from 
different sources possess different percentages of M and G residues and their sequences 93.  
 
Fig. 1.6. Chemical structures of G block, M block and alternating G-M block in alginate.   
M and G residues have different properties. For example, only G blocks in alginate are believed to 
be capable of cross-linking with divalent cations such as Ca2+ and Ba2+ to generate hydrogels 93. 
The process of fabricating alginate hydrogels with divalent cations is the most common method 93. 
When the divalent cations (e.g. Ca2+) are introduced to an alginate solution, they are believed to 
bind to the G blocks in alginate chains via the electrostatic interactions between carboxyl groups 
and cations 93. Therefore two G blocks on two adjacent alginate chains bind to cations and form a 
‘diamond shaped hole’ consisting of a hydrophilic cavity that binds the cations by multicoordination 
92. As shown in Fig. 1.7, this process leads to formation of the alginate network in the shape of an 
‘egg-box’ 92. The physical properties of the resulted hydrogels can be affected by the ratio of G and 
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M residues, their sequences, G block length and molecular weight 93. Normally, the longer the G 
block length and the higher the molecular weight, the stronger the mechanical properties for 
alginate hydrogels are 93. In addition, alginate hydrogels with higher amount of G residues exhibit a 
higher structural strength compared to the hydrogels with lower G residue content 94.   
 
Fig. 1.7. Preparation of alginate hydrogel via Ca2+ cross-linking resulting in the ‘egg-box’ shaped network. 
Apart from ionic cross-linking, alginate hydrogels can also be fabricated via altering the pH of the 
alginate solution 92. The disassociation constants (pKa) of M and G residues are 3.38 and 3.65 
respectively 92. Therefore alginate is soluble in water at neutral environment due to the 
deprotonation of carboxyl groups on alginate chains and exhibit negative charge across a wide 
range of pH 92, 99. The solubility of alginate solution decreases with decreasing pH and becomes 
insoluble around pH 3-3.5 as carboxyl groups of alginate chains are protonated and form hydrogen 
bonds which results in the formation of alginate acid hydrogels 93. The rate at which the pH changes 
can be used to form different types of alginate acid hydrogels 100. When the pH is rapidly decreased, 
alginate polymers tend to precipitate and form aggregates 100. On the other hand, if the pH is 
reduced slowly and steady, continuous alginate acid bulk gels can be prepared 100. Similar to ionic 
cross-linked hydrogels, the mechanical strength of alginate acid hydrogels is improved with 
increasing G block content in the alginate chains 101.    
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1.2. Gene delivery systems 
1.2.1. Gene therapy 
The mutation or deletion of human genes can result in disorders in metabolic pathways, receptor 
functions or protein structure and function, which will result in various diseases including cancer 102. 
Researchers found that by transferring a corrected or completed copy of the mutant or deleted gene 
into human cells, the gene-related diseases can be controlled or cured 103. By delivering genomic 
materials into certain cells to correct the disordered cell behaviour or provide the cells with desired 
functions, many diseases can be cured, this process is known as gene therapy 104. The concept of 
gene therapy was first investigated in the early 1970s 105 and the first gene transfer in humans was 
conducted in 1989 on tumour-infiltrating lymphocytes 106. In 1990, the first gene therapy was 
conducted to treat patients with severe combined immunodeficiency defects 107. During the last two 
decades, it has been used to treat many inherited and acquired diseases such as cancer, 
Parkinson’s disease, AIDS, cardiovascular diseases and cystic fibrosis 67, 108. Therefore, gene 
therapy is believed to be a promising technique for treating many human diseases caused by 
genetic problems 67, 109.     
However, the efficient application of gene therapy for curing diseases is still limited due to several 
biological barriers that must be overcome 108. For example, (1) the negatively charged phosphate 
backbone of DNA repels it from negatively charged cell surfaces, due to the electrostatic repulsion 
110; (2) the length of a DNA strand can be 105 times the length of a cell, which makes it very difficult 
to enter cells without being packed into a highly condensed structure 110-112; (3) naked DNA can  
easily be degraded by extra-cellar nucleases 110. What is more, the transgenes must be targeted 
delivered to the nucleus of cells for the correct gene expression, which is difficult for the gene itself 
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108. Therefore, in order to deliver the transgenes into the cell nucleus and to avoid gene degradation, 
sophisticated gene delivery systems are necessary 113-114.   
Apart from ensuring the delivery of transgenes to desired site of cells, a perfect gene delivery 
system is expected to possess several features: (1) it will not interact with vascular endothelial cells 
and blood components 115; (2) it will not be taken up by RES 116; (3) the size of the vector should be 
small enough to pass through the cell membrane for the final approaching of the cell nucleus 117.  
Various gene delivery systems have been developed for efficient gene delivery within the last three 
decades 118. Viral vectors are one of the most widely used vectors in gene therapy due to their high 
efficiency in delivering genes and ability in ensuring long term expression 119. However, the 
application of a viral delivery system is limited by its inherent drawbacks such as high toxicity, the 
risk of causing an immune response, high cost, difficulty to prepare and limited capacity for genes 
108. Therefore, non-viral gene delivery systems that possess advantages of low cost and lower 
toxicities have been developed as an alternative choice 108. Both viral and non-viral vectors are 
reviewed in following sections. 
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1.2.2. Viral gene delivery systems 
Viral vectors refer to vectors prepared from viruses. Viruses are capable of passing through cell 
membranes and delivering their own genetic materials to the nucleus of the host cells 120. After 
entering the host cell, viruses can use the cellular machinery of the host cells to replicate and 
express their own genetic materials before they spread to other cells 120. In order to be used as a 
gene delivery vector, the pathogenic part of the genetic materials of a virus must be removed and 
replaced by the desired gene 121. Meanwhile, the nonpathogenic structures of the virus must be 
retained to ensure its ability of infecting the cells 120. The prepared virus without pathogenic genes is 
called a viral vector 121. So far, viral vectors are one of the most used vectors for the transfection of 
genes due to their high transfection efficiency in vivo 122. Although as a successful gene delivery 
system, viral vectors possess several serious drawbacks that cannot be ignored: (1) viral vectors 
may cause serious immune responses in the human body 122; (2) it is very difficult and expensive to 
prepare viral vectors in large quantities 123; (3) the size of gene that can be carried by viral victors is 
limited 123. Some of most frequently used viral vectors including retrovirus vectors, adenovirus 
vectors and adeno-associated vectors are listed in following sections.   
1.2.2.1. Retrovirus vectors 
Retroviruses possess the genome of 7-10 kb which consists of four gene regions known as gag, pro, 
pol and env 124. These four gene regions are in charge of capsid proteins, viral protease, integrase 
and viral reverse transcriptase respectively 124. The life cycle of retrovirus is shown in Fig. 1.8. Once 
bound to the host cell receptor, the conformation of the glycoprotein of retrovirus will be changed, 
which causes the fusion of their retroviral envelope with the membrane of the host cell 124. 
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Meanwhile, the single stranded RNA of the retrovirus will be released into the cytoplasm and will be 
reverse transcribed to a double stranded DNA proviral genome 124. The DNA will then interact with 
the virial integrase to form a pre-integration complex which will be delivered to reach the nuclear 
membrane 124. When mitosis occurs, the nuclear membrane becomes disrupted and enables the 
internalization of complex to nucleus 124. After entering nucleus, the proviral genome will be 
integrated randomly to the host chromosomal genome by the viral integrase and the viral genes will 
be expressed by the host cellular machinery 124.  
 
Fig. 1.8. Schematic representation of the retrovirus life cycle.  
To prepare the retroviruses as gene delivery vectors, all the retroviral genes must be deleted and 
replaced with therapeutic genes or other desired genes 124. After the retroviral gene deletion, the 
infected host cells will not express viral proteins but will be capable of expressing the therapeutic 
genes 124.  
As one of the most frequently used viral vectors, retrovirus possess several advantages such as the 
inability to express any viral proteins, which can avoid immune responses, capability of stably 
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transduce dividing cells and capable of long term transgenes expression for over two years 125. On 
the other hand, the disadvantages of retrovirus vectors include their low capacity for therapeutic 
genes, the random insertion into the host genome, which may result in the activation of oncogenes 
or the inactivation of tumour suppressor genes, low efficiency in vivo and the inability to transduce 
non-dividing cells 124.  
1.2.2.2. Adenovirus vectors 
 
Fig. 1.9 Schematic representation of the adenovirus life cycle.   
Adenoviruses are double stranded DNA viruses and can cause several mild human infections such 
as respiratory tract infections and gastroenteritis 124. Adenoviruses are capable of efficiently 
infecting many cell types including dividing and non-dividing cells, which makes the adenovirus 
developed vectors capable of transferring both cell types 118, 124. The length of adenovirus genome is 
36 kb which makes it possible to pack large therapeutic genes after the deletion of its own DNA 124, 
126. As shown in Fig. 1.9, the infection of adenoviruses to a host cell is started from the interactions 
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between the virus fibre knob protein and the adenovirus receptor on surface of the cell 124. After the 
initial attachment, the adenovirus virion will be internalized by the host cell through endocytosis and 
then packed in the endosome 124. In the acidic environment of endosome, the conformation of 
adenoviruses virion capsid proteins tend to change which results in the release of the capsid into 
cytoplasm from where the capsid is delivered to the cell nucleus 124. After entering the cell nucleus 
the adenovirus genome will be released and start the process of replication and transcription 
without integrating into the host cell genome 118, 124.  
Adenovirus vectors can be prepared by the deletion of the E1 region and the replacement of E1 
region with therapeutic genes 124. The adenovirus vectors possess several advantages including: (1) 
the ability to infect various cell types including dividing and non-dividing cells 127; (2) a large 
transgene capacity 124; (3) a high gene transfer efficiency 124; (4) and the DNA of adenoviruses not 
integrating into the genome of host cells, therefore reducing the risk on activation of oncogenes or 
the inactivation of tumour suppressor genes 124. Despite these advantages, there are some 
disadvantages that restrict the applications of adenovirus vectors 118. For example, the gene 
expression time of adenovirus vectors is very short 118, 124. Another main drawback of adenovirus 
vectors is that they have a high risk of causing an immune response and some other bad side 
effects in humans 118, 124.   
1.2.2.3. Adeno-associated vectors  
Adeno-associated vectors are similar to adenovirus vectors in some respects but possess lower 
risks to human health, because they do not cause any human diseases 128. Adeno-associated 
viruses possess a short single stranded DNA which can integrate to a specific location on human 
chromosome 19 118. The life cycle of the adeno-associated virus is shown in Fig. 1.10. Unlike 
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retrovirus and adenovirus, the adeno-associated virus is incapable of replicating without the 
presence of a helper virus such as an adenovirus or herpes simplex virus 124. This feature makes 
the preparation of recombinant adeno-associated vectors become relatively complex. To replicate 
the vectors, helper viruses are needed for the infection, which result in the contamination of helper 
viruses in the resulting adeno-associated vector solution 124. In order to prepare purified vectors, a 
purification step is required during the production process 124.  
 
 
Fig. 1.10. Schematic representation of the adeno-associated virus life cycle.  
Apart from the difficulty in vector production, another main drawback of adeno-associated vectors is 
their limited gene capacity (4.7 kb) 124. Despite their drawbacks, adeno-associated vectors possess 
some advantages that cannot be ignored. Firstly, as all the viral genes are deleted from 
adeno-associated viruses, the resulting vectors are believed to be substantially safer to other 
vectors and are therefore not likely to cause any disease or immune response 124. Further to this, 
due to the integration of the vectors to the specific site of human chromosome 19, long-term 
transgene expression can be obtained 118, 124.  
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1.2.3. Non-viral gene delivery systems 
As reviewed above (Section 1.2.2), though viral vectors are widely used for gene delivery owning to 
their high efficiency and long term transgene express, their drawbacks such as the risk of causing 
serious immune responses, high toxicity and foreign gene insertion, which may cause mutations, 
have raised concerns for their usage in humans 114. Further to this, viral vectors are difficult to 
prepare, expensive and have limited transgenes capacity 114. All these drawbacks have brought 
various challenges to the application of viral vectors. Therefore, different non-viral vectors have 
been developed as alternatives 114. Synthetic or natural materials are used to design and fabricate 
non-viral vectors. Therefore, non-viral vectors usually possess reduced toxicity and immune 
response risks compared to viral vectors 129. What is more, chemical based non-viral vectors can be 
designed to enable transfection in specific cells and tissue 129. Although the lower transfection 
efficiency and relatively short term transgene expression remains challenging for the application of 
non-viral gene delivery methods, they are expected to have a strong future 129.  
1.2.3.1. Cationic Lipid vectors 
It was first reported in 1987 that N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride is 
capable of transferring DNA into cells. Since then, various cationic lipid vectors have been 
developed 114. The structure of lipid vectors can be divided into three sections: (1) a positively 
charged hydrophilic head, which is in charge of the interaction with nucleic acids; (2) a hydrophobic 
tail and (3) a linker group that connects the head and tail groups (see Fig. 1.11) 130.  
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Fig. 1.11. Schematic representation of cationic lipid vectors. 
In the early generations the most commonly used hydrophilic heads are primary, secondary and 
tertiary amines but new cationic lipid vectors have been developed using guanidino, imidazole, 
pyridinium and phosphorus for head groups 129-130. The hydrophobic tail groups are usually made of 
aliphatic chains and cholesterol linked to the hydrophilic head group by ether, ester or amide bonds 
114.  
As shown in Fig. 1.12, the transfection of DNA by lipid vectors is a complex process which involves: 
(1) the preparation of DNA-lipid complexes; (2) internalization by cells through endocytosis and 
encapsulation by endosome; (3) escape from endosome and enter cytoplasm; (4) DNA imported 
into nucleus 131. DNA-lipid complexes can be spontaneously formed by mixing DNA with lipids. 
When mixed with DNA, the positively charged head group of lipid victors will interact with negatively 
charged DNA through electrostatic attractions and the DNA will be condensed to form small 
particles. In the following process of lipid rearrangement, DNA is covered by lipids and DNA-lipid 
complexes are formed, known as lipoplexes 114. Since the negatively charged DNA is covered by 
positively charged lipids, lipoplexes are able to interact with the negatively charged cell membranes 
129. After approaching the cell membranes, lipoplexes are readily taken up by cells through 
endocytosis 131. 
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Fig. 1.12. Schematic representation of the cationic lipidmediated DNA transfection. 
It was initially believed that the fusion between lipoplexes and cell membranes was the main means 
for the internalization of lipoplexes, but new evidence may suggest that it is a proteoglycan 
mediated interaction process 131. After the initial internalization, DNA must escape the endosome to 
avoid being degraded by lysosomes and to reach cell nucleus, where the transgenes can be 
expressed 114. Therefore, cationic lipid mediated endosome escape is a crucial process in 
lipid-based transfection. The process of releasing DNA from the endosome into the cytoplasm 
based on the destabilization of endosome membrane by the cationic lipids 131. As shown in Fig. 1.13 
four steps are involved in endosome escaping 132. (1) Lipoplexes internalized by cells via 
endocytosis and encapsulated in an endosome 132. (2) A flip-flop that faces the cytoplasm is then 
created as a result of the electrostatic attractions between cationic lipids from lipoplexes and anionic 
lipids from the endosome membrane 132. (3) The anionic lipids then diffuse into the complex and 
form charge-neutralized ion pairs with the cationic lipids 132. (4) The complex is collapsed and the 
DNA is released into the cytoplasm 132. DNA that has been released from the endosomes needs to 
be imported into the nucleus for its expression. However, the detailed process of the internalization 
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of DNA into nucleus is currently not clear. It has been suggested that mitosis is required for DNA to 
enter the cell nucleus 131.  
 
 
Fig. 1.13. Schematic representation of lipid mediated DNA escaping from endosome.   
Good transfection efficiencies can be achieved by cationic-lipids-mediated transfections in cell 
culture, in the absence of serum. However, their performances are usually not satisfactory when 
transfection is conducted in cell cultures and in vivo with serum present 133. This phenomenon is 
associated with the positive charge of lipoplexes. When used in vivo, lipoplexes will interact with 
negative serum components in blood which results in the formation of large aggregates. These 
aggregates may accumulate to block microvasculatures and can be rapidly eliminated, which lead 
to the short circulation half-life of cationic lipoplexes 129. The rapid clearance of lipoplexes in blood 
tends to reduce their transfection efficiency and limit their applications in vivo 129. In addition, 
another negative side effect associated with the electrostatic interaction between positively charged 
lipoplexes and negatively charged serum molecules is the toxicity in transfection 114. Upon cationic 
lipids mediated transfection in vivo, negative serum proteins tend to adsorb on the surface of 
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lipoplexes and act as opsonins to trigger the uptake of the aggregates by RES, leading to toxic 
responses 114. 
To overcome these problems, various strategies have been used 129. For example, hydrophilic, 
neutral polymers such as PEG have been used to cover the surfaces of lipoplexes. Once coated 
with PEG, the excess positive charge of lipoplexes is reduced, which tends to decrease the 
electrostatic attraction between the lipoplexes and the negative components in blood 129. As a result, 
circulation time of lipoplexes is prolonged and the risk of causing serious immune response is 
reduced 129. Although increased circulation time is expected to increase the amount of lipoplexes 
that can interact with targeted cells which in turn increase the transfection efficiency, it is worth to 
note that the PEG coating can, on the other hand, lead to a dose dependent inhibition on the overall 
transfection efficiency since it can block the intimate interactions between cell membranes and 
lipoplexes 114. Therefore, PEG-lipid complexes with different hydrocarbon lengths haven been 
developed to adjust the time of PEG-lipid association with lipoplexes 114.   
Helper lipids such as dioleoylphosphatidylethanolamine (DOPE) and cholesterol can also be 
employed to reduce lipoplexes toxicity and increase transfection efficiency. Application of DOPE in 
cationic lipid systems has been reported to be capable of facilitating the escape of transgenes from 
endosomes by the means of promoting the membrane fusion between lipoplexes and the 
endosomal membrane 114. As a result, the cationic lipid mediated transfection efficiency can be 
promoted. Moreover, with promoted endosomal escape provided by DOPE the lipid / DNA charge 
ratio required to reach the maximal transfection efficiency is reduced, which in turn reduces the 
toxicity of lipoplexes 129. Although proven to be an effective helper lipid for transfection in vitro 
without the presence of serum, DOPE shows adverse effects on transfection. This is because 
DOPE lipoplexes tend to fall apart in presence of blood components 134. Cholesterol, on the other 
 34 
 
hand, has been reported to be a better helper lipid in the presence of serum. Cholesterol can 
stabilize the lipoplexes in blood against the serum components and provide better transfection 
efficiency 129. 
In summary, cationic lipids possess advantages such as simple preparation and can be cheaply 
engineered for targeted transfection. On the other hand, their disadvantages are their high toxicities 
and low transfection efficiency 129. 
1.2.3.2. Cationic polymer vectors 
Cationic polymers, synthesized or naturally derived, have been widely used as gene carriers 129. 
After mixing with DNA, cationic polymers tend to condense DNA molecules to form nano-sized 
complexes which are called polyplexes 129. One of the major advantages of polyplexes is their 
higher stability compared to lipoplexes 129. Poly-L-lysine is one of the first synthetic polymers that 
has been employed as a gene transfection carrier since 1987 135. Since then, various cationic 
polymers have been developed for gene delivery both in vitro and in vivo 129. Among them, 
polyethyleneimine is one of the most frequently used and most effective cationic polymers for gene 
transfection due to its high density of primary, secondary, and tertiary amine groups 129. The process 
of PEI mediated gene transfection is shown in Fig. 1.14. 
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Fig. 1.14. Schematic representation of PEI mediated gene transfection. 
 
PEI is capable of complexing with DNA to form polyplexes due to its high cationic charge density at 
physiological pH 42. The resulting PEI / DNA polyplexes are then concentrated at the cell surface via 
the electrostatic attractions between the positive polyplexes and negative cell membranes 61. The 
polyplexes are then internalized by cells through endocytosis and encapsulated in endosomes 61. 
After being encapsulated in endosomes, macromolecules normally will be transported into 
lysosomes where they will be degraded 129. In order to prevent the degradation of DNA in lysosomes, 
the endosome-lysosome process must be intercepted 129. PEI is known to be capable of protecting 
DNA from been degraded in lysosomes through the ‘proton sponge effect’ 61. The majority of the 
amine groups in PEI are non-protonated at physiological pH 61. In endosomes, these 
non-protonated amine groups will absorb protons at the low pH environment, which results in the 
protonation of these amine groups and the accumulation of protons in endosomes 61. Chloride ions, 
as counterions, are also internalized by endosomes and cause increased osmotic pressure, which 
in turn leads to the disruption of endosomes and the release of polyplexes to cytoplasm 61. 
Moreover, the protonated amine groups in endosomes will buffer the endosome pH, slowing down 
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the acidification process which is essential for endosome-lysosome transition 114. Therefore, PEI 
can protect the DNA from being degraded in lysosomes. Eventually, DNA is transported to cell 
nucleus for expression.  
Despite the promising functions of PEI during gene transfection, its applications are continuously 
limited by its persistent problems such as strong cytotoxicity and relatively low in vitro and in vivo 
transfection efficiency 42. The cytotoxicity and transfection efficiency of PEI is reported to be 
structure and molecular weight dependent 114. There are two types of structures observed for PEIs: 
branched and linear 114. The structures of branched PEI (BPEI) and linear PEI (LPEI) are shown in 
Fig. 1.15. Both BPEI and LPEI have shown good gene transfection capabilities in vitro but moderate 
transfection efficiency in vivo 114. Both PEIs possess molecular weight dependent transfection 
efficiency and cytotoxicity 114. The optimal molecular weight for transfection is 25 KDa for BPEI and 
22 KDa for LPEI 114. Higher molecular weight is associated with higher transfection efficiency but 
also greater cytotoxicity 114. PEI with a molecular weight of 2 KDa or less is nontoxic however it 
shows no effect for transfection 114. When the molecular weight is higher than 25 K, PEI is still active 
for transfection but exhibits a much higher cytotoxicity 114. Upon adding to cell cultures, LPEI 
polyplexes exhibit higher gene expression to cells than BPEI polyplexes 114. This phenomenon is 
most likely because LPEI polyplexes are not as condensed as BPEI polyplexes and more readily 
release DNA into the cells 114. It has also been reported that LPEI polyplexes tend to enter the cell 
nucleus more rapidly 114. Moreover, LPEI is reported to be less toxic to cells compared to BPEI 114.  
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Fig. 1.15. Schematic representation of the chemical structures of BPEI (a) and LPEI (b). 
Although BPEI exhibits higher toxicity and a lower transfection efficiency than LPEI, it is capable of 
condensing DNA more tightly and forming smaller and more stable nanoparticles 129. Normally, 
when mixed with DNA, BPEI can form particles with the size of a few hundred nanometers, while 
LPEI tends to form much larger particles with sizes at the micrometer scale 41.  
A hypothesis on the mechanism of the cytotoxicity of PEI is that it results from the high cationic 
charge density of PEI 45, 136-138. Free PEI molecules can interact with negative substances in blood 
such as serum proteins or red blood cells, forming aggregates which can adhere to tissue surfaces 
and cause significant cell damages 136. PEI can also interact with proteins inside the cell to interfere 
critical intracellular processes which can lead to serious toxic effects 44. Therefore, reduction of PEI 
surface charge is expected to be capable of reducing the cytotoxicity of PEI mediated polyplexes. In 
fact, many researches aimed at reducing the cationic charges of PEI have been done through 
conjugating nontoxic polymers or proteins on PEI or directly coating the polyplexes with nontoxic 
materials 114. The resulting PEI derivatives showed less cytotoxicity to cells 114. For example, in the 
research of Xue et al., hexadecylated polyethyleneimine polymers complexed with siRNA were 
encapsulated by negative lipids, the surface charge of encapsulated complex was decreased as 
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well as the cytotoxicity compared to un-encapsulated PEI complexes 139. Liu et al. designed ASF 
(Antheraea pernyi silk fibroin) / PEI / DNA ternary complexes by coating negatively charged ASF 
onto the surface of PEI / DNA complexes 140. The coating of ASF resulted in fewer surface charges 
for the complexes and higher viability for cells transfected with ASF / PEI / DNA ternary complexes 
compared with cells treated with PEI / DNA complexes. Ogris et al. compared the in vitro and in vivo 
properties of PEI / DNA polyplexes with PEGylated PEI / DNA polyplexes and indicated that 
PEGylation of the polyplexes significantly reduced the binding of serum protein, leading to a 
prolonged circulation of PEGylated polyplexes in blood 141.  
Although reduction of cationic charge of PEI based polyplexes can reduce their cytotoxicity effect to 
cells, it is worth to note that too much elimination of the positive charge can also lead to loss of 
transfection efficiencies 114. It is suggested that the coating / binding of PEI on the surface of 
nanoparticles may also modulate its cytotoxicity 136. For instance, after gold nanoparticles are 
coated with PEI, the resulting hybrid transfection carrier exhibited significantly lower cytotoxicity 
than PEI 136. Apart from gold nanoparticles, it is found that by coating PEI on surface of Fe3O4 
nanoparticles, magnetic nanoparticle-PEI (MNP-PEI) victors can be fabricated for efficient gene 
delivery through magnetofection 67. While applying magnetofection, an external magnetic field can 
be used to improve the transfection efficiencies via rapidly concentrates the magnetic vectors on the 
surface of cells 142. Moreover, it has been reported that the cytotoxicity of MNP-PEI victors are 
significantly lower than PEI 143.  
1.2.3.3. Magnetofection 
One of the major drawbacks of non-viral vectors including the most efficient transfection polymer 
(PEI) is their relatively low in vitro and in vivo transfection efficiency compared to viral vectors 144. 
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This drawback is mainly due to the fact that their delivery process is limited by the time that required 
for the gene loaded vectors to accumulate on cell surfaces, which is a diffusion dependent process 
144. Therefore, rapid accumulation of the vectors on the surface of cells or target tissue is desired for 
the improvement of the transfection efficiency 144 .    
Magnetic particles have therefore been developed to rapidly concentrate genes at the target sites 
under a magnetic field 145. The first practice of employing magnetic carriers to deliver nucleic acids 
was conducted in 1996, however with little experimental evidence 146. The first accounts in the 
scientific literature have been conference abstracts by Mah et al. 147 and Plank et al. 148 in 2000. The 
first full paper on concentrating vectors at desired sites was reported by Hughes et al. in 2001 149. 
Since then, various magnetic vectors were developed for the delivery of genes to target cells, this 
method is referred to as magnetofection 145.  
 
Fig. 1.16. Schematic representation of the principle of magnetofection. 144.  
The principle of magnetofection is shown in Fig. 1.16. Firstly, magnetic vectors are fabricated by 
coating MNPs with cationic materials e.g. PEI. The resulting magnetic vectors are then mixed with 
naked DNA to form magnetic vector-DNA complexes via electrostatic attraction between DNA and 
vectors. Next, the magnetic complexes are added to cell cultures and a magnetic plate is placed 
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under the cell culture plate to provide a downward magnetic force. With the help of this magnetic 
force, the magnetic complexes will rapidly concentrate on cell surfaces to overcome the diffusion 
barrier, which in turn will result in enhanced internalization of the magnetic complexes and improved 
transfection efficiency 144.  
Magnetofection exhibits advantages of much faster transfection than non-magnetofection method. 
For example, Mykhaylyk et al. have investigated the transfection performance of magnetic and 
non-magnetic complexes exposed to a magnetic field, their result indicated that the magnetic 
complexes can be rapidly focused onto the surface of target cells and the consequently transfection 
efficiencies can be 1,000-fold higher than the transfections conducted with non-magnetic vectors 150. 
Kro¨tz et al. have reported that magnetic particle-ODN complexes were transfected into 84% human 
umbilical vein endothelial cells within 15 min when exposed to a magnetic field, non-magnetofection 
methods, in contrast, required 24 h. 151. Also, it is worth to note that the mechanism of gene delivery 
from the cell surface into cells via magnetofection is the same as non-magnetofection 145. In another 
word, the external magnetic forces do not appear to draw the magnetic complexes into cells, 
instead, the improved gene transfection efficiency is due to the rapid sedimentation of complexes 
on the cell surface within a few minutes 145.  
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1.3. Thesis plan 
In summary, the above sections showed that nanocarriers can significantly facilitate the 
internalization of drugs and genes into cells. Materials used for the fabrication of nanocarriers must 
be carefully selected and generally nontoxic, biocompatible and biodegradable polymers are 
especially favoured so the resulting nanocarriers can avoid been rapidly cleared by the human 
immune system. In addition, the size and surface charge of the resulting nanocarriers can largely 
affect their half-life, biodistribution and internalization effect in a drug / gene delivery process. 
Further to this, the deployment of magnetic nanoparticles can provide nanocarriers with the ability to 
target desired sites under a magnetic field. Based on this information, my project aims at the design 
and preparation of nanocarriers with suitable size, surface charge, biocompatible coating materials 
and magnetic cores for the application of drug / gene delivery. 
The first experimental Chapter (Chapter 3) is focused on the fabrication of magnetic-silk core-shell 
nanoparticles via the salting-out method. In the conventional salting-out methods SF particles are 
prepared by potassium phosphate 152. However, the size of the resulting SF particles being around 
500-1200 nm is significantly larger than the optimum size range of 50-200 nm for cancer therapy 38. 
Therefore, a different salt (sodium phosphate) was selected for the preparation of SF particles. 
According to the ‘Hofmeister Series’： 
NH4+ > Cs+ > Rb+ > K+ > Na+ >Li+ > Ca2+ > Mg2+ 
the larger and less charged cations (cations to the left) are most effective at protein salting out, 
while the divalent cations (cations to the right) can lead to increased protein solubility 153. Thus, the 
employment of sodium phosphate is expected to be capable of preparing SF particles with smaller 
sizes compared to those prepared by potassium phosphate. Magnetic-silk core-shell nanoparticles 
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will be prepared using sodium phosphate, and the effect of the SF concentration, salt concentration 
and pH of the salt solution of the resulting particle size will be explored. 
In Chapter 4, instead of using only one polymer (e.g. SF) as the coating material, negatively 
charged sodium alginate and positively charged chitosan are layer-by-layer coated on MNPs to 
fabricate magnetic alginate/chitosan layer-by-layer nanoparticles for drug delivery. Alginate and 
chitosan are both commonly used polymers for drug delivery due to their excellent biocompatibility, 
biodegradability and nontoxicity 82. The electrostatic attraction between alginate and chitosan 
enables them to be layer-by-layer coated onto MNPs to construct particles with different amounts of 
coating layers. This method provides a simple way to control the size and surface charge of the 
resulting particles. The number of the coated layers and the outermost layer of polymers is 
expected to be capable of controlling the loading and release profile of drugs dependent on their 
electrostatic interactions with the drug.  
As mentioned in Section 1.2.3.2, PEI is one of the most frequently used and most effective cationic 
polymers for gene transfection due to its high density of amine groups 129. However, the application 
of PEI is limited by its strong cytotoxicity, which can lead to low in vitro and in vivo transfection 
efficiencies 42. The cytotoxicity of PEI is believed to be due to its high positive charge density 45, 
136-138. Free PEI molecules can interact with negatively charged substances such as serum proteins 
or even red blood cells to form aggregates, which can adhere to tissue surfaces and cause 
significant cell damage 136. Therefore, in Chapter 5, negatively charged, nontoxic, biocompatible SF 
is mixed with PEI to prepare SF-PEI nanoparticles and magnetic SF / PEI core-shell nanoparticles. 
It is expected that SF can reduce the overall surface charge of the resulting nanoparticles which can 
lead to the reduction of their cytotoxicity.  
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2. Materials and Methods 
2.1. Materials 
Bombyx mori silk was obtained from Jiangsu, P.R. China. Na2CO3 (11552) was purchased from Alfa 
Aesar. Curcumin (C8069) was purchased from LKT Laboratories. Paraformaldehyde (sc-253236A) 
was purchased from Chem Cruz®. K2HPO4 (BP363), KH2PO4 (BP362), CaCl2 (C1016), Na2HPO4 
(S7907), NaH2PO4 (S8282), ammonium hydroxide (221228) DMSO (Dimethyl sulfoxide, D5879), 
Rhodamine B isothiocyanate (R1755), Sodium alginate (w201502), Ca(OH)2 (21181), DMSO 
(Dimethyl sulfoxide, D5879) and Polyethyleneimine (branched, 408727) were purchased from 
SIGMA-ALDRICH. Roswell Park Memorial Institute (RPMI) 1640 Medium (BE 12-167F), PBS 
(Dulbecco's Phosphate Buffered Saline, BE17-512F), Penicillin 5.000 U/ml-Streptomycin 5.000 
U/ml (DE17-603E), L-Glutamine (17-605F) were purchased from Lonza®. NaHCO3 (A17005), 
Chitosan (349051000), Iron (II) chloride tetrahydrate (44939), Iron (III) chloride hexahydrate 
(44944), Foetal Bovine Serum (FBS,10500064), Texas Red®-X Phalloidin (T7471), Alexa Fluor® 
568 phalloidin (A12380), Oligofectamine (12252011), MTT (M6494) assay and DAPI (4′, 
6-Diamidino-2-phenylindole dihydrochloride, D1306) were purchased from Thermo Fisher Scientific. 
MDA-MB-231 cells (Human Caucasian Breast Adenocarcinoma cells) were purchased from 
ECACC. Ultra-High Quality (UHQ) water was prepared using PURELAB Classic (ELGA). HDF cells 
were provided by the Sheffield RNAi screening facility. Single-stranded human c-myc antisense 
oligodeoxynucleotides (5′-AAC-GTT-GAG-GGG-CAT-3′, with and without 5′-FAM 
(carboxyfluorescein- 5-succimidyl ester) labelled) were purchased from Eurogentec Ltd. (UK) and 
were HPLC purified. 
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2.2. Methods 
2.2.1. Particle preparation and drug release 
2.2.1.1. Preparation of silk fibroin (SF) solution 
Silk fibroin solutions were prepared based on the protocol previously reported 154. Silk fibres were 
boiled for 30 min in a solution of 0.02 M Na2CO3 and then rinsed 3 times with DI water to remove 
sericins. The resultant material was degummed silk fibroin. Then the degummed silk fibroin was 
dried overnight in a drying oven at 60°C before added into a ternary system (CaCl2 / Ethanol / water 
at molar ratio of 1: 2: 8) and heated to keep the system temperature at 75°C for 3 h. The solid silk 
fibroin was observed dissolved in the solution within 30 min. Next, the silk fibroin solution was 
dialysed in a cellulose dialysis tube (12 KDa cut off) against DI water for 3 days, during which DI 
water was replaced at least 5 times per day. The resulting solution was centrifuged twice at 10,000 
g to remove the impurities before stored in the refrigerator at 4 °C. 
2.2.1.2. Preparation of magnetic nanoparticles (MNPs) 
4 g iron (III) chloride hexahydrate and 4.5 g iron (II) chloride tetrahydrate were each dissolved in 
150 ml DI water and degassed with nitrogen for 30 min to remove the oxygen in the solutions. The 
solutions were then mixed in a 500 ml round-bottom flask and 15 ml of ammonium hydroxide was 
added under vigorous stirring in a nitrogen atmosphere at room temperature for 2 h. The magnetic 
nanoparticles (MNPs) were collected with strong Neodymium magnets and washed at least 5 times 
with DI water to remove any impurity. The particles were then washed with ethanol and dried over 
night at room temperature and stored for future usage.  
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2.2.1.3. Preparation of silk fibroin particles (SFPs) 
The fabrication of SF particles is based on the protocol reported by Lammel et al.79 and modified for 
the present experiments. Briefly, SF solutions with different concentrations (0.1-12 mg/ml) were 
added to potassium phosphate or sodium phosphate solutions (ionic strength: 1.25 M, pH 8) in a 
volume ratio of 1:5 followed by storing the as-prepared mixtures in the refrigerator for 2 h at -20 °C. 
The resulting particles were unfrozen and centrifuged at 20,000 g for 15 min before being 
re-dispersed and washed three times in UHQ water. To investigate the effect of phosphate ionic 
strength on SF particle size, sodium / potassium phosphate solutions with ionic strength from 0.6 to 
2 M were mixed with SF solutions (5 mg/ml). The effect of sodium phosphate pH on the secondary 
structure of SF particles was also studied by producing SFPs with sodium phosphate solutions at 
pH 4, 7 and 9. Secondary structures of SFPs were investigated with Fourier transform infrared 
(FTIR) spectroscopy.  
2.2.1.4. Preparation of magnetic silk fibroin particles (MSPs)  
MNPs were dispersed in sodium phosphate (1.25 M, pH 8) solution to reach the concentration of 
0.1 mg/ml. The MNP-salt mixture was then blended with SF (0.5 - 10 mg/ml) solutions to produce 
particles according to the process mentioned in Section 2.2.1.3 and the resulting MSPs were 
collected using Neodymium magnets. Sodium phosphate solutions with different pH values were 
also mixed with SF solution (5 mg/ml) to investigate the effect of pH on MSP size. 
2.2.1.5. Preparation of curcumin loaded magnetic silk fibroin particles (CMSPs) 
Curcumin (CUR) was dissolved in DMSO with a concentration of 100 mg/ml CUR DMSO solution. 1 
mg MNPs and different amount of CRU DMSO solutions (with CUR weight equal to 10%, 30%, 60% 
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and 90% of total SF used) were added to 10 ml sodium phosphate (1.25 M, pH 8) solution. To 
investigate the effect of pH on CMSP size, zeta potential and CUR release rate, sodium phosphate 
solutions with pH value 4, 7, 8 and 9 were used (while the CUR usage was 10 %). The prepared 
mixture was then blended with 2 ml SF solution (5 mg/ml) and stored at -20 °C for 2h. The CMSPs 
were then unfrozen and the supernatant was analysed to determine residual CUR concentration 
using UV-Vis spectrometry (JENWAY 6715, Bibby Scientific, UK). Standard calibration curves for 
CUR in sodium phosphate and PBS were used. Concentration of particles was determined by 
weighing dried particles from 1 ml solution. Encapsulation and loading efficiencies were determined 
by Eq. (2.1) and (2.2) below: 
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (𝑤 𝑤⁄ % ) =
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐶𝑈𝑅 𝑖𝑛 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 
𝐶𝑈𝑅 𝑖𝑛𝑖𝑡𝑖𝑎𝑙𝑙𝑦 𝑎𝑑𝑑𝑒𝑑
               (2.1) 
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (𝑤 𝑤⁄ % ) =
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐶𝑈𝑅 𝑖𝑛 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
                            (2.2) 
2.2.1.6. Preparation of magnetic alginate particles (MAPs) 
Magnetic alginate nanoparticles (MAPs) were prepared based on the procedure described by Liu et 
al. 62. 20 ml of ethanol and 10 ml of DI water was mixed into a beaker and 0.25 g of MNPs were 
suspended in the prepared mixture. Next 40 ml of sodium alginate (SA) solution (20 mg/ml) was 
added to the beaker upon which the mixture was sonicated for 10 min to allow full homogenous 
dispersion of MNPs in the suspension. The resultant mixture was vigorously stirred for 30 min at 
room temperature. Following, 128 ml of Ca(OH)2 solution (0.74 mg/ml) was added into the 
suspension and stirred for 1 h before 16 ml of NaHCO3 solution (10 mg/ml) was added. The 
suspension was then stirred for a further 12 h at room temperature and the resulting MAPs were 
collected with strong Neodymium magnets washing thoroughly with ethanol and water to remove 
excess salts. Finally, purified MAPs were suspended in DI water before been used for the 
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layer-by-layer process.  
2.2.1.7. Preparation of magnetic alginate / chitosan layer-by-layer particles (MACPs) 
The preparation of Magnetic alginate / chitosan layer-by-layer nanoparticles (MACPs) was based 
on the layer-by-layer self-assembly of sodium alginate (SA) and chitosan (CHI) on MAPs. Chitosan 
solution (10 mg/ml) was prepared in 1% (v/v) acetic acid aqueous solution. The first layer was 
deposited by adding 1 g of MAPs into 100 ml of the chitosan solution under vigorous stirring for 20 
min at room temperature. The resultant MA / CHI particles were collected with a Neodymium 
magnet and the excess CHI was removed by washing the particles several times with DI water. The 
next SA layer was deposited by adding the previously prepared MA / CHI particles into 100 ml of SA 
solution (10 mg/ml) under vigorous stirring for 20 min thus forming MA / CHI / SA particles. For each 
layer the previously described purification process was used. Particles with more layers were 
fabricated by alternatively coating positively charged CHI and negatively charged SA on MACPs 
until the desired number of layers was obtained.  
2.2.1.8. Preparation of curcumin loaded magnetic alginate / chitosan layer-by-layer 
particles (CMACPs) 
20 ml of CUR DMSO solution (7.5 mg/ml) was added into 30 ml of DI water to prepare the CUR 
mixture (3 mg/ml). Then 30 mg of MACPs were added into 20 ml of the CUR mixture and stirred for 
24 h. The resultant Curcumin loaded Magnetic alginate / chitosan layer-by-layer nanoparticles 
(CMACPs) were collected with a Neodymium magnet and washed three times with DI water. The 
supernatants were collected and analysed with a UV-Vis spectrometry (JENWAY 6715, Bibby 
Scientific, UK) to determine the concentration of residual CUR. The CMACPs were dispersed in 5 
ml of DI water and the concentration of these particles was determined by weighing dried particles 
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from 1 ml solution. Encapsulation and loading efficiencies were determined by Eq. (2.1), and Eq. 
(2.2). 
2.2.1.9. Preparation of silk fibroin-polyethyleneimine particles (SPPs) 
SF solution (5 mg/ml) and polyethyleneimine (PEI) solution (5 mg/ml) were mixed at different 
volume ratios (1:9, 1:3, 1:1, 3:1 and 9:1) to prepare SF/PEI mixtures. 2 ml of SF/PEI mixtures were 
then added to 10 ml of sodium phosphate solutions with an ionic strength of 1.25 M at pH 8. The 
prepared solutions were kept at room temperature (20 °C) for 6 h to allow the formation of particles. 
The resultant solution was then centrifuged at 20,000 g for 15 min to collect the SPPs. The particles 
were washed several times with DI water to remove excess salts before further characterizations. 
SF and PEI particles were prepared using the same method as controls. 
2.2.1.10. Preparation of magnetic silk fibroin / polyethyleneimine particles (MSPPs) 
5 mg of MNPs were dispersed in 50 ml of sodium phosphate solution to prepare a MNP-salt mixture. 
2 ml of SF/PEI mixtures (5 mg/ml) at different SF/PEI concentration ratios (1:9, 1:3, 1:1, 3:1 and 9:1) 
were then blended with 10 ml of MNP-salt mixtures and the resulting solutions were kept at room 
temperature (20 °C) for 6 h to allow the formation of MSPPs. The particles were then washed and 
collected with Neodymium magnets. Magnetic SF and magnetic PEI particles were prepared by the 
same method as controls. 
2.2.1.11. Preparation of magnetic-silk / polyethyleneimine nanoparticles-cmyc antisense 
oligodeoxynucleotide (MSPP-ODN) complexes 
MSPP-ODN complexes were prepared by mixing the MSPP solutions with cmyc antisense 
oligodeoxynucleotide (ODN) solutions. An ODN aqueous solution of 0.2 mg/ml was prepared. 
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MSPPs were dispersed in DI water to obtain MSPP solutions at different concentrations (0.2, 1.2, 
2.4, 5, 10, 20 mg/ml). 100 µl of prepared ODN solution was then added to 100 µl MSPP solutions 
and mixed under gentle shaking until a homogenous dispersion was achieved. Finally, the mixed 
solution was incubated for 30 min at room temperature. The ODN concentration in the mixed 
solution described above was fixed at 0.1 mg/ml and the MSPP concentrations were varied from 0.1 
to 10 mg/ml to achieve different MSPP/ODN mass ratios (1:1, 6:1, 12:1, 25:1, 50:1, 100:1). 
MSPP/ODN mixed solutions with higher concentrations of ODN (1 or 2 mg/ml) and MSPPs (12 or 
24 mg/ml) were also prepared with similar process. The prepared dispersions were diluted in PBS 
before added into cell cultures. 
2.2.1.12. Release of curcumin from curcumin loaded magnetic alginate / chitosan 
layer-by-layer nanoparticles  
5 mg of CMSPs or CMACPs were suspended in 5 ml PBS buffer (pH 7.4) in vials and incubated at 
37 °C under constant agitation (200 rpm). The particles were collected with strong Neodymium 
magnets at pre-determined time points and the supernatants were carefully removed before 
re-dispersing the particles in 5 ml fresh PBS. The CUR concentrations of the supernatants were 
analysed using UV-Vis-spectrometry and the percentage of cumulative CUR release was plotted as 
a function of incubation time. 
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2.2.2. Characterization 
2.2.2.1. Particle size and zeta potential analysis 
The particle size and zeta potential of SFPs, MSPs, CMSPs, SPPs and MSPPs were carried out by 
a Dynamic light scattering analyser (DLS) (NanoBrook 90 plus Pals Particle size Analyzer, 
Brookhaven Instrument, NY, USA). Particles were dispersed in DI water in a cuvette before placed 
in the sample cell. A diode laser with wavelength of 660 nm was used. All samples were washed 
several times and dispersed in DI water prior to measurements. Refractive indexes of 1.331 for 
water and 1.540 for particles were employed for the calculation of particle size. All experiments 
were conducted at a measurement temperature of 18 °C using a circulation bath. Three batches of 
samples were prepared and analysed.  
The particle size of MACPs and CMACPs were analysed by a nanoparticle tracking analysis (NTA, 
Nanosight LM10, UK). Particles were dispersed in sodium phosphate solution (10mM, pH7) and 
injected into the scattering cell of a NTA where their motion was analysed and average size was 
calculated. The zeta potential measurement of particles was carried out by a Dynamic light 
scattering analyser (DLS) (NanoBrook 90 plus Pals Particle size Analyzer, Brookhaven Instrument, 
NY, USA). Particles were washed several times and dispersed in DI water (pH adjusted to 7 with 
NaOH and HCl) or 10 mM sodium phosphate buffer (pH 7) prior to zeta potential measurements.  
2.2.2.2. Fourier transform infrared spectroscopy 
Fourier transform infrared spectroscopy (FTIR) analysis of SFPs was conducted with Fourier 
Transform Infrared Spectrophotometer (IR Prestige-21, Shimadzu, UK). SFPs were washed three 
times with UHQ water and allowed to air dry on the diamond attenuated total reflectance (ATR) 
 51 
 
attachment (ATR apparatus, Pike Technologies, USA) of the spectrophotometer. The range of wave 
numbers was set from 4000 to 400 cm-1 and the spectrum was read using the Happ-Genzel 
apodisation function over 64 scans with a resolution of 4 cm-1. The amide I region (1575 - 1750 cm-1) 
was investigated to determine the secondary structure of SF protein. The spectral processing was 
conducted with the software IR solution provided within the FTIR instrument. 
FTIR analysis of MAPs and MACPs was conducted with the Spectrum 100 spectrophotometer 
(PerkinElmer, USA). Particles were washed three times with DI water and dried in an oven at 60 °C 
for 24 hours before being placed on the diamond attenuated total reflectance (ATR) accessory and 
compressed. The wavenumber region was set from 4000 to 600 cm-1 with a resolution of 1 cm-1. 
The spectral processing was conducted with the software (IRPal 10) provided within the FTIR 
instrument.  
2.2.2.3. Atomic Force Microscopy analysis 
The size and morphology of particles was characterised using Atomic Force Microscopy (AFM) 
(Dimension Icon with ScanAsyst, Bruker Corporation, U.S.A). Particle suspensions were dropped 
on mica substrates and air dried before being placed on the sample stage. AFM measurements 
were conducted using SCANASYST-AIR tips and PeakForce Tapping mode. The data was 
analysed with NanoScope Analysis 1.5 software. 
2.2.2.4. Transmission electron microscopy analysis 
Particles were dispersed in DI water at the concentration of 0.1 mg/ml. The dispersions were then 
dropped onto TEM copper grids and incubated at room temperature for 30 s. Excess solution on 
grids was then removed with filter paper, by gently dapping the edge and allowing excess liquid to 
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be absorbed prior to TEM imaging (Tecnai G2 Spirit, FEI, USA). An acceleration voltage of 80 kV 
was used and images were recorded using a Gatan Orius SC1000B bottom mounted digital camera 
and analysed in Gatan Digital Micrograph software (version 3.9.1). 
2.2.2.5. In vitro cytotoxicity assay 
SFPs, MSPs, CMSPs: MDA-MB-231 cells were cultured in RPMI medium supplemented with 10 % 
Foetal Bovine Serum (FBS), 1 % Penicillin / Streptomycin and 1 % L-Glutamine at 37 °C and 5 % 
CO2. The cytotoxicity of SFPs, MSPs and CMSPs against MDA-MB-231 cells was investigated by 
the MTT assay. The cells were seeded in 96 - well plates at a density of 5 × 103 cells per well before 
incubation for 24 h to allow cells to attach to the plates. Cells were then incubated with SFPs, MSPs, 
CMSPs (30 % CUR usage) and free CUR (amount equal to the CUR content in CMSPs) at 
preselected concentrations respectively. After 3 days incubation, 50 μl of 3 mg/ml MTT was added 
to each well and incubated at 37 °C for 3 hours followed by removing the supernatants and adding 
200 μl DMSO. A plate reader (FLUOstar galaxy, BMG LABTECH, Germany) was used to measure 
the absorbance of each well including control wells containing only cells at 570 nm. The relative cell 
viability was determined by comparing the absorbance with control wells. 
MACPs and CMACPs: MDA-MB-231 or HDF cells were seeded into 96-well plates with 200 μl 
medium at a density of 5 × 103 cells per well and incubated overnight at 37 °C under 5% CO2 
atmosphere. Then the mediums were removed and replaced with 200 μl free CUR medium solution, 
MACPs or CMACPs dispersion (CUR content in the particles is equivalent to the dosage of free 
CUR) to reach the final CUR concentration of 0.5, 1.5, 5, 15, 30 μg/ml. After 48 h of incubation, 50 
μl of 3 mg/ml MTT was added to each well and incubated at 37 °C for 3 hours followed by removing 
the supernatants and adding 200 μl DMSO. The absorbance of each well was measured at 570 nm 
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with a plate reader (FLUOstar galaxy, BMG LABTECH, Germany). 
SPPs, MSPPs, SPP-ODN and MSPP-ODN: MDA-MB-231 or HDF cells were seeded into 96-well 
plates with 200 µl of complete RPMI medium (supplemented with 10% Foetal Bovine Serum (FBS) 
and 1% L-Glutamine) at a density of 5 × 103 cells per well and incubated overnight at 37 °C under 5% 
CO2 atmosphere. The medium was then removed, and the cells were washed twice with PBS buffer 
before being replaced with 180 µl serum-free medium. 20 µl of SPP-ODN or MSPP-ODN complex 
dispersions with different particle/ODN mass ratios were added into each well. SPP or MSPP 
solutions (20 µl) with equivalent amount of particles used for complexation with ODNs were added 
into wells. ODN solutions were also used as negative controls with dosages equivalent to the 
amount of ODNs used in complexes. Cells were incubated for 4 h initially being exposed to a 
magnetic field for 20 min. The serum-free medium was then removed and replaced with 200 µl 
complete medium and cells were cultured to a final duration of 3 days. Then 50 µl of MTT reagent (3 
mg/ml) was added into each well and cells were cultured for another 3 h until the purple precipitate 
was visible. The medium was then removed and 200 µl of DMSO was added into each well before 
placing plates on a shaker until purple precipitates in wells were fully dissolved. The absorbance of 
each well was measured at 570 nm with a plate reader (FLUOstar galaxy, BMG LABTECH, 
Germany). 
2.2.2.6. Cellular uptake assays 
SFPs, MSPs and CMSPs: SF was labelled with Rhodamine B isothiocyanate (Ex 543 nm, Em 580 
nm) before used for the fabrication of SFPs, MSPs and CMSPs fabrication. MDA-MB-231 cells were 
seeded in 6-well plates with 3 × 105 cells per well and incubated overnight at 37 °C under 5% CO2 
atmosphere before incubation with Rhodamine B labelled SFPs, MSPs and CMSPs (30% CUR 
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usage) at particle concentrations in medium from 3 -100 μg/ml. After 24 h, the cells were harvested 
with trypsin and washed twice with PBS to remove free particles. The intracellular fluorescence of 
Rhodamine B and CUR was determined using a flow cytometer (FACS Calibur, BD Biosciences, 
USA) to investigate the particle and CUR uptake. 
CMACPs: CUR medium solutions were prepared by adding CUR dissolved in DMSO (50 mg/ml) 
dropwise into medium to obtain different final CUR concentrations (0.5, 1.5, 5, 15, 30 μg/ml). 
CMACPs were dispersed in medium to reach the final CUR concentrations equivalent to those of 
CUR medium solutions. MDA-MB-231 and HDF cells were seeded in 6-well plates at a density of 3 
× 105 cells per well and incubated overnight at 37 °C and 5% CO2. Then the mediums were 
removed and replaced with 2 ml CUR medium solutions or CMACPs medium solutions and 
incubated for a further 24 h. After this, the cells were harvested with trypsin and washed twice with 
PBS to remove any free CUR or CMACPs. The resultant cells were collected and analysed with the 
BD™ LSR II flow cytometer (BD Biosciences, USA) to investigate the cells CUR uptake. 
SPP-ODN and MSPP-ODN complexes: MDA-MB-231 and HDF cells were seeded in 6-well plates 
at a density of 5 ×105 cells per well with complete medium and incubated overnight at 37 °C and 5% 
CO2. The cell culture mediums were removed, and cells were washed twice with PBS before 
incubation with serum-free medium. SPP-ODN or MSPP-ODN complexes were added into different 
wells and incubated for 5, 20 min or 1, 4, 24 h with and without initial exposure to a magnetic field 
for 5 or 20 min (the maximum exposure time is 20 min). ODNs were added as a negative control. 
Oligofectamine-ODN was used as a positive control with a standard incubation time for 4 h in 
serum-free medium. After incubation, cells were washed twice with PBS buffer before further 
incubation in the complete medium to a final duration of 24 h (the total incubation time is fixed at 24 
h). The resulting cells were harvested with trypsin and analysed with the BD™ LSR II flow 
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cytometer (BD Biosciences, USA) to investigate the ODN uptake.  
2.2.2.7. Fluorescence microscopic images and magnetically targeted delivery assay  
CMSPs: To obtain fluorescence microscopic images of cellular uptake, MDA-MB-231 cells were 
incubated on the cover slips in 12-well plates at a concentration of 1× 105 cells per well and 
incubated with CMSPs (30% CUR usage) at 37 °C and 5 % CO2 for 3 h. Cells were washed three 
times with PBS to remove non-specifically adsorbed particles or CUR before fixation with 4 % 
paraformaldehyde at room temperature for 30 min. The fixed cells were stained with 3 μl 1% Texas 
Red®-X Phalloidin (Ex 591 nm, Em 608 nm) for 1 h and washed twice with PBS followed by staining 
with DAPI (Ex 358 nm, Em 461 nm) for 30 min. Finally, cells washed twice with PBS ready for 
fluorescent microscope (AF6000, Leica, Germany). Fluorescence images of DAPI, Texas Red and 
CUR (Ex 340 nm, Em 530 nm 155) stained cells were captured using different channels. All images 
were captured and analyzed with LAS AF Lite software (Leica, version 2.6.3). 
CMACPs: MDA-MB-231 cells were seeded in glass bottom dishes (Nunc™, Thermo Scientific, 
diameter 35 mm) at a density of 3×105 cells per dish and incubated for overnight to allow the 
settlement. Free CUR and CMACPs were added into cell cultures to reach a final CUR 
concentration of 5 μg/ml and incubated for 4 h. Magnetically targeted delivery was conducted by 
initially placing a Neodymium magnet under one edge of the dish for the first 15 min during 
incubation. Cells were then washed twice with PBS buffer and fixed with 4 % paraformaldehyde. 
The fixed cells were stained with Alexa Fluor 568 Phalloidin and DAPI for 1 h. The confocal 
fluorescence images of cellular uptake of CUR were observed with an Inverted Zeiss LSM 510 NLO 
microscope (Zeiss, Germany) and analysed with LSM Image Browser software version 4.2.0.121. 
SPP-ODN and MSPP-ODN: MDA-MB-231 cells were seeded into 6-well plates (with 2 coverslips in 
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each well) at a density of 3×105 cells per well with complete medium. After 24 h, cells were washed 
twice with PBS buffer before incubation in serum-free medium. Cells were incubated with naked 
ODNs, Oligofectamine-ODN, SPP-ODN and MSPP-ODN complexes for 4 h. The magnetically 
targeted delivery was conducted by placing a circular neodymium magnet under one of the 
coverslips in each well for 20 min at the start of incubation. After initial incubation, cells were 
washed twice with PBS buffer to remove free ODNs and transfection complexes followed by a 
further incubation in complete medium to a total incubation time of 24 h. The cells were then 
washed twice with PBS and fixed with 4% paraformaldehyde. The fixed cells were stained with 
Alexa Fluor 568 Phalloidin and DAPI for 1 h. The confocal fluorescence images of cellular uptake of 
ODNs were observed with an Inverted Zeiss LSM 510 NLO microscope (Zeiss, Germany) and 
analysed with LSM Image Browser software (version 4.2.0.121). 
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2.3. Techniques 
2.3.1. Dynamic light scattering 
Dynamic light scattering (DLS) is used to investigate the size and zeta potential of particles.  
2.3.1.1. Particle size analyzation   
DLS is a powerful technique commonly used to determine particle size and distribution in 
suspensions 156. The measurement is based on the detection of the Brownian motion of particles. 
When particles are dispersed in a solution, they undergo a constant random movement known as 
Brownian motion 156. The Brownian motion rates of these particles are related to their sizes and 
larger particles move slower in solution. DLS can detect and analyse the motion performance of 
these particles and calculate their size. The schematic representation of a DLS apparatus is shown 
in Fig. 2.1. 
 
Fig. 2.1. Schematic diagram of DLS analysing particle size.  
 
As shown in Fig. 2.1, a laser is focused on the sample and strikes the particles in the suspension, 
leading to scattered light in all directions. The scattered light is then collected by the photomultiplier 
tube (PMT) and the output of the PMT is digitized and sent to the autocorrelator 156. If all the 
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particles stay stationary in the solution, the intensity of scattered light will remain stationary as well 
156. However, as mentioned above, particles are undergoing constant Brownian motion which will 
cause either constructive or destructive interference of the scattered light 156. Therefore, the 
intensity of scattered light fluctuates and can be detected by DLS to determine the time 
autocorrelation function Gt: 
1 + 𝛾(𝐺𝑡)
2 =
<𝐼𝑡><𝐼0>
<𝐼0><𝐼0>
                             (2.3) 
where γ is a constant determined by experimental setup and I0, It is the scatter light intensity at the 
start of experiment and at time t. It can be expected that It is related to the position of particles which 
can be related to the rate of their Brownian motion 156. Therefore, Gt can be used to calculate the 
particle size. For dilute and monodispersed suspensions of nanoparticles, Gt is determined by the 
self-diffusion coefficient (Dt) of particles and the length of the scattering vector q shown as:   
 
𝐺𝑡 = exp(−𝑞
2𝐷𝑡)                             (2.4) 
 
In Eq. (2.4), q depends on the scattering angle θ and the wavelength λ of the light in the scattering 
medium shown as: 
 
𝑞 = (
4π
λ
) sin(𝜃/2)                    (2.5) 
 
Since Gt is given by DLS, from Eq. (2.4) and (2.5), the self-diffusion coefficient Dt can be obtained. 
For spherical particles in a dilute dispersion, Dt is related the particle radius R shown as:  
 
𝐷𝑡 = 𝑘B𝑇/6𝜋𝜂𝑅                             (2.6) 
 
where kB is Boltzmann’s constant, T is the thermodynamic temperature and η is the suspension 
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medium viscosity 156. Combining all the equations above the radius of spherical particles can be 
obtained. It is important to note that the solvation layer is also included in the calculated radius.  
For non-spherical particles the radius calculated from the equations above is called the 
hydrodynamic radius which is not equal to the geometrical radius of the particles, size of solvent 
molecules or other molecules moving with the particles are included in the hydrodynamic radius. 
The shape of the particles can also affect the hydrodynamic radius. In most measurements, 
particles are not monodispersed, and they therefore have different diffusion coefficients Dt, thus the 
autocorrelation function is given as:   
 
𝐺𝑡 = ∑ 𝐴𝑖𝑖  𝑒𝑥𝑝 (−𝑞
2𝐷𝑖𝑡)                           (2.7) 
 
“Where Ai is a weighting factor of a certain fraction of particles in the solution and is proportional to 
the scattered light intensity 156.” Dit is the diffusion coefficient for each faction of particles. Therefore, 
the autocorrelation function has become a sum of exponentials contributed by particles with 
different Dit that size related to different particle sizes. Cumulant method can be used to solve this 
equation and calculate the size distribution of the particles 156.   
2.3.1.2. Zeta potential measurements  
The zeta potential (ZP) of particles is measured by the electrophoretic light scattering in conjunction 
with DLS 157. The ZP is the difference in potential between the electric double layer of a particle and 
the dispersant around them 157. If particles possess net charges on their surfaces are dispersed in a 
solvent. The ions with opposite charges to the particle surface charge will be attracted to the surface 
of the particles and form an ion layer called ‘Stern layer’ 157. Outside the Stern layer, the electrostatic 
effects caused by the particle surface charges decreases as the increase of the distance of a point 
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from the Stern layer 157. Therefore both same and opposite charged ions are grow beyond the Stern 
layer 157. These ions and the ions in Stern layer together form the electric double layer (EDL) as 
shown in Fig. 2.2 157. When placed in an electric field, the particles move toward the opposite 
electrode 157. Part of the diffuse layer moves with the particle, therefore a hypothetical plane, called 
slipping plane, is determined and acts as the interface between the moving particles and dispersant 
around it during electrophoresis. The ZP of the particles is the potential at the slipping plane 157. 
 
Fig. 2.2. Schematic representation of the EDL on the surface of a negatively charged particle. Ions with 
opposite charges are attracted to the surface of the particle and a strongly adhered layer (Stern layer) is 
formed. A diffuse layer consisting of both positive and negative ions is developed outside of the Stern layer. 
During electrophoresis the particle and its EDL moves towards the electrode of opposite charge. The slipping 
plane becomes the interface between the particle and dispersant.  
To determine the ZP, a technique called electrophoretic light scattering is used as shown in Fig. 2.3. 
A laser is focused on the sample and once it hits the particles, scattered light is generated which 
possess light frequency different from that of the original laser 157. The shift of frequency is 
proportional to the velocity of particles moving toward the electrodes 157. Fig. 2.3 illustrates that the 
laser beam is divided into two beams in which one is used to strike the sample and the other is used 
as the reference beam. The scattered light from the sample is collected and combined with the 
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reference beam to determine the shift of light frequency 157. Thus the velocity of particles can be 
determined from the frequency shift and in turn determine the ZP 157.  
 
 
Fig. 2.3. Schematic representation of the instrumentation of ZP measurement by electrophoretic light 
scattering 157. 
2.3.2. Nanoparticle tracking analysis 
2.3.2.1. Working principle of nanoparticle tracking analysis  
Nanoparticle tracking analysis (NTA) was another method to analyse the size of particles. Similar to 
DLS, the analysis of particle size by NTA is also based on determining the Brownian motion of 
particles. However, a different strategy is used to do this. Fig. 2.4 shows the principle of analysing 
particle size with an NTA instrument. As shown in Fig. 2.4, a laser is guided to a glass prism through 
which it is introduced into the sample (dilute suspensions of particles in liquid). After passing 
through the glass prism, the laser is refracted at a low angle and then enters the sample, which 
results in the illumination of the particles in the sample 158. Scattered light is generated when the 
laser hits the particles. The scattered light from particles in the sample can be collected by a 
microscope fixed with a video camera. In this way, the particles can be visualized and a video 
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recording the motion of the particles is taken, which is then analysed by the NTA software 158. In the 
video, the particles are detected and their Brownian motion is tracked on a frame-by-frame basis 
and used to obtain particle sizes by Eq. (2.8) 
 
< 𝑥, 𝑦 >2=
𝑇𝑡𝑘𝑏
3π𝜂𝑑ℎ
                               (2.8) 
 
where <x,y>2 is the mean squared displacement of particles, kb is Boltzmann's constant, T is the 
thermodynamic temperature of the solvent, η is the suspension medium viscosity, t is the sampling 
time and dh is the hydrodynamic diameter 158. 
 
 
Fig. 2.4. Schematic representation of an NTA instrument configuration.  
 
2.3.2.2. Comparing NTA with DLS  
DLS is a powerful technique for particle sizing and it has the advantage of rapid analysis and ease 
of operation. However, a drawback of DLS is that it tends to bias larger particles. In DLS the particle 
size is determined by analysing the fluctuations of total scattered light from all the particles in 
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sample 159. However, the total scattered light is not equally contributed by each particle 159. In fact, 
larger particles will provide higher light intensities because the intensity of the scattered light is 
proportional to the sixth power of the diameter of particles 159. Therefore, DLS is more sensitive to 
the larger particles in samples and results in a bias to larger particles. On the other hand, NTA 
determines the particle size by tracking the movement of individual particles visualized on the 
screen, which allows better resolution of particle sizes and there is no intensity bias towards larger 
particles 159.  
 
2.3.3. Atomic force microscopy 
In this thesis atomic force microscopy (AFM) was used to investigate the size, shape and surface 
topography of particles. An AFM can scan samples in x, y and z directions therefore capable of 
providing 3D representations of the surface of the samples.  
2.3.3.1. Principle of AFM 
The principle of an AFM is shown in Fig. 2.5, a very sharp probe tip is mounted on a cantilever 
which scans over the sample 160. When the tip is moved to a position close enough to the sample 
surface, the force between the tip and the surface of the sample will cause the deflection of the 
cantilever 160. A laser is reflected off the top of the cantilever and detected by a position sensitive 
photodetector. Therefore, the deflection profile of the cantilever can be obtained by analysing the 
movement of laser position 160.   
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Fig. 2.5. Schematic representation of the basic principle of AFM. A sharp probing tip is mounted on a 
cantilever. The cantilever deflected by the force between tip and the sample. The deflections can be 
monitored by a photodetector and the feedback loop is used to keep the deflection constant. 
The deflection of the cantilever is related to the force between the probe tip and the sample surface, 
while the force is related to the distance between tip and sample following Hook’s Law: 
 
𝐹 = −𝑘𝑥                                  (2.9) 
 
where F is the force between sample and probe tip, k is the spring constant of the cantilever and x is 
the deflection of the cantilever 160.  
There are two basic modes for the scanning of samples in AFM, known as the contact mode and 
tapping mode 161. In contact mode, the probe tip is close enough to the sample surface to generate 
a repulsive force between the tip and surface of sample. Then the tip is dragged over the sample 
surface and the deflection or the position of laser hit on the photodetector is kept constant by 
adjusting the height of sample with the XYZ-piezo scanner and the feedback loop 161. Thus, the 
height information of the sample surface can be obtained. However, since the probe tip is very close 
to the sample surface, contact mode has a drawback that cantilever is easily attracted to the sample 
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surface, due to the capillary condensation 161. To overcome this problem, tapping mode was 
developed. 
In the tapping mode, the cantilever is oscillated at a fixed frequency and the tip is made to contact 
the surface of the sample on each oscillation 161. The frequency and amplitude of the cantilever 
oscillation is constant if there is no interaction between the probe tip and the sample surface. 
However, when the tip moves close to the sample surface, a force is generated from the interaction 
between tip and sample surface 161. This causes the amplitude of the cantilever to change, which is 
detected by the photodetector. Via the feedback loop the height of cantilever is altered to keep the 
cantilever amplitude constant 161.  
2.3.3.2. Factors to note in AFM  
AFM artefacts in its images that do not indicate the actual surface information of the sample and 
can be generated due to intrinsic limitations of AFM. Therefore, it is important to recognize and 
avoid the artefacts during AFM operation. For example, Fig. 2.6 shows artefacts that can be caused 
by tips.  
 
Fig. 2.6. Three types of situations, when tips scan sample surfaces. a) The objects on sample surface are 
significantly larger than the tip. b) The size of tip is comparable to the size of objects. c) Objects are 
significantly smaller than the tip 162. 
A probe tip should be significantly smaller than the objects on sample surface to be able to 
determine accurate morphology of the sample 162. Blunt tips or tips attached with materials from 
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sample can lead to poor AFM images. As shown in Fig. 2.6a, the radius of the tip is significantly 
smaller than the objects and there are no objects on sample surface can touch the side walls of the 
tip 162. Therefore, accurate information of the sample surface can be obtained. When the size of the 
tip is comparable to the sample objects as shown in Fig. 2.6b, the tip cannot scan every place in the 
‘well’, thus the resulting image shows the sidewalls of the tip instead of the accurate shape of the 
objects 162. In an extreme case, as shown in Fig. 2.6c, the radius of the tip is significantly larger than 
the size of objects on the sample surface. Thus, the resulting image can only show the shape of the 
tip. The tip-related artefacts may result from the selection of wrong tips or the tips are contaminated 
by sample materials attached on them 162. In this case, a fresh tip is required 162.   
2.3.4. Transmission electron microscopy 
Transmission electron microscopy (TEM) was used to analyse the size, shape and inner structure 
of Fe3O4 / Polymer (silk fibroin, alginate or chitosan) core-shell nanoparticles. TEM is a powerful 
technique to investigate the details of small samples such as subcellular structures. The principle of 
TEM is similar to optical microscopes but instead of using photons to detect samples, electrons are 
used in TEM 163-164. Since the wavelength of electrons is much smaller than the wavelength of light, 
much higher magnifications can be obtained by TEM than optical microscopes 163. Therefore, 
significantly more detailed information, even small as a single atom, can be obtained by TEM 163. 
The working principle of a TEM instrument is illustrated in Fig. 2.7. Firstly, an electron beam is 
created by the electron source and then reaches the condenser lenses where it is focused to a 
small, thin coherent beam. The final size range of the electrons strikes the sample can be controlled 
by adjusting the condenser lenses. After passing through the condenser lenses, the electron beam 
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passes through a condenser aperture where it is restricted and the high angle electrons are 
removed 163. Next, the restricted electron beam from condenser aperture strikes the specimen 
where the electrons interact with the sample and are divided into three electron types: (1) 
transmitted electrons, (2) elastically scattered electrons and (3) inelastically scattered electrons 163. 
The amount of transmitted electrons is dependent on the properties of materials such as thickness, 
density, electron transparency and composition 163. Normally, more electrons will be allowed to pass 
through a low-density or thin materials compared to thick and dense materials 163. After passing 
through the specimen, the transmitted electrons strike the objective lens and are then focused into 
an image on the fluorescent screen. The objective aperture can block out high-angle diffracted 
electrons to enhance the contrast. The projector lens can be used to enlarge the electron beam 
onto the fluorescent (phosphor) screen where light is generated 163-164.  
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Fig. 2.7. Schematic representation of the working principle of TEM (a). TEM images of SF-PEI (polymer) 
nanoparticles (b) and Fe3O4 – SF / PEI core-shell nanoparticles(c).  
 
Therefore, the electron signal is converted to a light image that can be used to analyse the detailed 
structure of the sample. The darker areas of the image represent areas where fewer electrons have 
been transmitted, those areas are denser than the lighter areas. For example, Fig. 2.7 shows the 
TEM image of SF-PEI polymer nanoparticles. The darker area in the middle of the image represents 
the thick polymer material of SF-PEI where less electrons have been transmitted, while the lighter 
areas around represent arears where more electrons have passed through. The detailed structure 
of a nonuniform material can also be determined by TEM. As shown in Fig. 2.7c, the darker areas in 
the image represent the presence of Fe3O4 particles and the surrounding lighter areas represent the 
presence of less dense polymers of SF-PEI nanoparticles.  
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Since electrons can only transmit through very thin materials, the specimen must be carefully 
prepared to provide a thin film, which allows the transmission of sufficient electrons 163. In this 
project, the specimens of particles are prepared by dropping particle dispersion onto the grid with 
incubation at room temperature for 30 s. Excess solution on grids was then removed with filter 
paper, by gently dapping the edge and allowing excess liquid to be absorbed prior to transmission 
electron microscope (TEM) imaging. It is very important in the process to keep the particle 
dispersion at low concentrations to avoid excess thicknesses. On the other hand, if the particle 
concentration was too low, it is difficult to find enough particles for analysis.  
 
2.3.5. MTT assay 
In this thesis, the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay was 
used to measure the viability of cells after treatment with free drugs, drug loaded nanoparticles or 
blank particles. Thus, the cytotoxicity of different materials toward cancer or normal cells could be 
determined.  
2.3.5.1. Principle of MTT 
The principle of the MTT assay is based on the fact that MTT can be reduced to insoluble purple 
formazan crystals by mitochondrial succinate dehydrogenase. Since the mitochondrial activity is 
constant for most viable cells, the increase or decrease of viable cell numbers is linearly related to 
the mitochondrial activity 165. The activity of mitochondria can be estimated by the level of MTT 
converted into formazan, which is soluble in DMSO and the optical density (OD) of formazan / 
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DMSO solution, which is related to its concentration, can then be measured by a plate reader 165. 
Therefore, the difference on the number of viable cells in each well can be determined by 
measuring their OD values. In an application of measuring the cytotoxicity of a drug towards the 
cells, the decreased OD value represents the decreased mitochondrial activity that reflects the 
decreased number of viable cells 165. Therefore, the inhibition of a drug to cells can be determined 
by comparing the OD values of wells with the drug treated cells and those with the untreated cells. 
 
2.3.5.2. Procedure of MTT 
Plate setup: cells are generally plated in a 96-well plate with culture medium and are incubated for 
overnight to allow the settlement of cells. In the plate, blank wells (without cells and drugs), control 
wells (with cells but without drugs) and experimental wells (with cells and drugs) must be contained 
165.  
 
Fig. 2.8. Schematic representation of Part of a 96-well plate after formazan crystalsare fully dissolved. (a) 
Blank control wells. (b) Untreated control wells. (c) Drug treated experimental wells. 
An example of blank control wells, untreated control wells and drug treated experimental wells is 
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shown in Fig. 2.8, in which blank control wells contain only medium; untreated control wells contain 
same amount of cells as experimental wells but are not exposed to drugs; experimental wells 
contain cells and medium and treated with drug at different concentrations 165. If a drug shows 
absorbance at the wavelength that can affect the OD value of formazan, the additional control wells 
(without cells) that contain the drug are required. The outer wells surround the plate cannot be used 
for the experiment because they can evaporate more rapidly than the inner wells. Normally, PBS is 
used to fill the outer wells to minimize the evaporation of the plate.  
Drug incubation: Drugs of desired concentrations are added to the experimental wells. Equivalent 
amounts of solvent of drug solutions is added to the untreated control wells. The cells are then 
incubated for certain periods (normally 1-4 days) to determine the optimum effect of drugs to the 
cells 165.  
MTT incubation: after the appropriate incubation time, MTT solutions are added to the 96-well 
plate followed with an incubation for 3-6 h at 37°C in a CO2 incubator 165.   
Formazan dissolution & viability calculation: the supernatant in each well is carefully removed 
and DMSO is added. The plate is then placed on a shake bed where it undergoes a mild agitation to 
allow the full dissolution of formazan. The OD value of each well can then be measured by a plate 
reader. In order to determine the viability of each well, the average OD value of blank control wells is 
subtracted from that of untreated control wells and experimental wells. The viability of cells in an 
experimental well is calculated by (mean OD of experimental wells - mean OD of blank control wells) 
/ (mean OD of untreated control wells - mean OD of blank wells) 165.  
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2.3.6. Flow cytometry 
Flow cytometry is a powerful technique that can be used to simultaneously obtain multiple physical 
characteristics of a single cell such as size and granularity (internal complexity) in a short period of 
time 166. Therefore, this technique is widely employed for manly applications such as 
immunophenotyping of peripheral blood cells, analysis of apoptosis and detection of cytokines 166. 
2.3.6.1. Principle of flow cytometry 
The successful process of analysing cells by a flow cytometry is based on focusing the cell 
suspension into a tiny stream allowing the analyzation of one cell at a time. This process is 
conducted by the device shown in Fig. 2.9 a. When the cell suspension is injected into the flow 
chamber, it is focused by the surrounding sheath fluid to form a tiny stream located in the core of 
sheath fluid. 
 
 
Fig. 2.9. Schematic representation of the working principle of a flow cytometer (a) and light scattering (b).  
The pressure of the cell suspension stream is always greater than the pressure of sheath fluid, thus 
making the cells align in a single file fashion through the laser beam 166. The flow rate of cell 
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suspension to the laser beam can be controlled by altering its pressure for different purpose of 
analysis 166.  
When the laser beam strikes a cell, lights is scattered. There are two kinds of light scattering called 
forward scatter (FSC) and side scatter, as shown in Fig. 2.9b. The FSC is measured along the path 
of the laser beam and the SSC is measured perpendicular to the laser beam. The light scattering 
can be affected by the cell membrane, size, shape, surface morphology and internal complexity 166. 
For FSC, it is proportional to the surface and size of cells and suitable for the application of 
immunophenotyping 166. On the other hand, SSC is proportional to the granularity (internal 
complexity) of cells such as nucleus, mitochondria and particles internalized by cells 166. 
Fluorescent light generated from antibodies or dyes can be measured at the same angle as SSC. 
By combining FSC and SSC, information of cell types and populations can be obtained 166. The 
fluorochromes in cells can be excited by the laser beam and the emission light is collected by a 
series of lenses, and a series of optical mirrors and filters are used to separate the collected light 
and direct those with specified wavelength to suitable optical detectors 166.   
The scattered light is collected and then transformed to voltages by photodetectors 166. There are 
two types of photodetectors: photodiodes (PDs) and photomultiplier tubes (PMTs). as shown in Fig. 
2.10, PDs detect the stronger light signals, which is generated from FSC. PMTs can be used to 
detect the weaker signals generated by SSC due to higher sensitivity of PMTs compared to PDs 166. 
The light signals detected by PDs and PMTs are converted to a proportional number of electrons to 
generate an electrical current which then travels to the amplifiers and converted to voltage pulse 
(see Fig. 2.10) 166.  
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Fig. 2.10. Schematic representation of the signal detectionand processing by a flow cytometer.  
When a cell strikes the center of the laser beam, the maximum amount of scatter or fluorescence is 
generated. After the cell leaves the laser beam, the voltage pulse decreases to the baseline 166. 
Therefore, the information of each cell can be obtained in the form of voltage pulse which needs to 
be converted into a digital data that can be displayed as plots for analysis 166.  
 
2.3.7. Fluorescence microscopy 
Fluorescence microscope is used to visually determine the uptake of drugs or genes by the cancer 
cells and their location within the cells. The principles of conventional fluorescence microscopy and 
confocal fluorescence microscopy are reviewed in the following sections.  
2.3.7.1. Conventional fluorescence microscopy 
The principle of confocal fluorescence microscopes is developed based on conventional 
fluorescence microscopes 167. Thus it is helpful to understand the mechanism of the conventional 
 75 
 
fluorescence microscopes for the study of the confocal fluorescence microscope 168. Fig. 2.11 
shows the schematic representation of a fluorescence microscope. Multiple excitation lights are 
generated from the light source and only the excitation light with selected wavelength can pass 
through the excitation filter to reach the dichroic mirror. The dichroic mirrors possess the unique 
property of reflecting light with wavelength shorter than a certain value but passing those with 
wavelength longer than that 167. Therefore, the selected excitation light that possess short 
wavelength (with higher energy) is reflected to the objective from where it is focused onto the 
sample.  
 
Fig. 2.11. Schematic diagram of a fluorescence microscopy. Emission light is emitted by the excitation light 
focused on the sample and then focused to the detector by the objective. 
 
Upon reaching the sample, some molecules in the sample can absorb the energy from photons 
from excitation light at the right wavelength and become unstable. Part of the absorbed energy can 
be lost by these molecules and photons with less energy is emitted. The emission light is then 
guided to the dichroic mirror by the objective. An additional emission filter is employed to prevent 
the light with unselected wavelength from reaching the detector 169.   
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2.3.7.2. Confocal fluorescence microscopy 
In conventional fluorescence microscopy, the whole region of the sample is illuminated and all the 
emission light (from focal point or not) is collected by detector, thereby obscuring the image of the 
point we want to see 167. Confocal microscopy is developed to reduce this effect. The principle of 
confocal fluorescence microscopy is shown in Fig. 2.12. A laser is reflected by the dichroic mirror to 
the objective where it is focused onto the sample. The sample is excited and fluorescent light is 
generated and guided by the objective to pass though the dichroic mirror. The light (blue lines in Fig. 
2.12) from the focal point (the point we want to see) on the focal plane will be focused to another 
focal point on the other side of the objective system. The yellow lines in Fig. 2.12 represent the light 
from another point in the sample which is away from the focal point and it is not focused to the focal 
point to the left side of objective system. Unlike in conventional fluorescent microscopes, in a 
confocal fluorescent microscope, all the light from the sample must go through a pinhole before it 
can finally reach the detector. The pinhole is placed at the same point as the focal point. As a result, 
the light (blue) form the focal point in the sample and focused to the other focal point at the other 
side of the objective and pass through the pinhole to be detected. On the other hand, the light 
(yellow) form another point on the sample is out of focus, thus most of the light (yellow) is blocked 
and the image of yellow point is significantly attenuated compared to the image of blue point (focal 
point) 167. In this way, the background haze is significantly reduced by confocal microscopy. Since 
the objective lens forms an image at the focal point where the pinhole is placed, those two points 
are celled conjugate points and the pinhole is called confocal pinhole 167. 
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Fig. 2.12. Schematic representation of the principle of confocal microscopy. The light from the focal point on 
the focal plane is allowed to pass through the pinhole while most of the light from other point is blocked.  
 
However, in confocal microscopy, only one point is imaged at one time. In order to obtain the whole 
image, a point-by-point illumination of the sample is required. The setup is shown in Fig. 2.13. 
Excitation light is provided by the laser and reflected by the dichroic mirror to a serial of scanning 
mirrors which can be rotated to scan the laser across the sample 167. The emission light generated 
from the sample is then guided by the same mirrors and focused by objectives to pass through the 
pinhole and finally reach the detector 167. Since the image of the sample is obtained via the 
point-by-point illumination, the complete image can only be obtained by building up the image one 
pixel at a time 167. 
 
Fig. 2.13. Schematic representation of the basic setup of a confocal microscope.  
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2.3.8. Fourier-transform infrared spectroscopy 
Fourier-transform infrared spectroscopy (FTIR) is used to investigate the structure and composition 
of particles. FTIR is a powerful technique to obtain infrared spectrum of solid, liquid or gas 
materials. 
2.3.8.1. Principle of FTIR   
When infrared radiation come into contact with a sample, some molecules can selectively absorb 
the radiation with a specific wavelength, which leads to a change in the dipole moment of these 
molecules. The vibration energy of the sample molecules is then increased from ground state to an 
excited state. The frequency and intensity of the absorption peaks is related to the unique vibration 
properties of the molecules 170-171. Therefore, the structural information of these molecules can be 
obtained by analysing their infrared spectrum 170. It is important to note that homo-nuclear diatomic 
molecules such as N2 and O2 are not appropriate for infrared spectroscopy because their vibration 
and rotation cannot cause dipole changes 171. Apart from those molecules Infrared absorption 
spectroscopy is suitable for most molecules and is capable of analysing gases, solids and liquid 
samples. If there is only one species to be analysed, a conventional species-specific spectrometer 
can be used, in which the radiation with a narrow wavelength is employed.171 For samples 
containing different components, FTIR which employ infrared radiation with large range of 
wavelength need to be used 171.   
For FTIR, the radiation beam generated by the source strikes the interferometer where it is divided 
to two radiation beams. These beams travel through different path and re-combined before 
reaching the detector. The radiation signal is then converted to a digital signal by a computer.   
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Fig. 2.14. Schematic representation of the principle of a Michelson interferometer.  
The key component in FTIR is Michelson interferometer which serves the purpose of providing the 
interference beam that possesses path distance dependent intensity. The principle of a Michelson 
interferometer is shown in Fig. 2.14. The infrared radiation emitted from radiation source strike onto 
the beam splitter from which half of the radiation is transmitted to a movable mirror that moves 
between two extreme positions at constant speed 171. The other half of the original radiation is 
reflected to a fixed mirror and goes back to the beam splitter along with the transmitted radiation 
that also reflected back from the movable mirror 171. These two beams then recombine at the beam 
splitter where interference between beams occurs 171.    
Assuming the distance between the beam splitter and the fixed mirror is x and the distance between 
the beam splitter and movable mirror is y, the optical path difference (retardation δ) of these two 
beams is 2(x-y). If x=y, then the optical path difference equates 2(x-y) =0. Therefore, these two 
beams are perfectly in phase and will interfere constructively in the beam splitter. As a result, all 
radiation from the radiation source will reach the detector 171. On the other hand, if the movable 
mirror is moved forward for a distance equivalent to quarter of the wavelength ( 
1
4
λ) of the original 
beam, then the optical path difference is 
1
2
λ which will result in a destructive interference and no 
light will reach the detector 171. If the movable mirror is moved forward for a distance of 
1
2
λ, the 
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optical path difference will be λ which means another constructive interference pattern is obtained. 
Therefore, when the movable mirror is constantly moved, a cosine curve (interferogram) of light 
intensity as a function of optical path difference can be obtained 171.   
The frequency of the cosine wave is related to the frequency of wavelength of the line source and 
the amplitude is related to the intensity of line source 171. If another line source is added and both 
reach the interferometer at the same time, the resultant interferogram will be the sum of two 
individual line sources. In a similar way, if a broad band source is used, the resultant interferogram 
will be the sum of curves generated by different radiation with identical frequency and intensity. By 
converting the optical path difference to wavenumber and the relative light intensity to absorbance 
or transmittance, a FTIR spectrum can be obtained which illustrates the absorbance of an 
unidentified sample at different wavenumbers and this information can be used to determine the 
component of the sample.   
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3. Magnetic-Silk Core-Shell Nanoparticles as Potential 
Carriers for Targeted Delivery of Curcumin into Human 
Breast Cancer Cells 
 
Abstract 
Curcumin is a promising anti-cancer drug but its applications in cancer therapy are limited due to its 
poor solubility, short half-life and low bioavailability. In this Chapter, a curcumin loaded magnetic silk 
fibroin core-shell nanoparticle system is presented for sustained release of curcumin into breast 
cancer cells. Curcumin loaded magnetic silk fibroin core-shell nanoparticles were fabricated by a 
simple salting-out method using sodium phosphate with magnetic nanoparticles. The size, zeta 
potential, encapsulation / loading efficiency and curcumin release rate were controlled and 
optimised by regulating silk fibroin concentration, pH value of the phosphate solution and curcumin 
usage. Curcumin loaded magnetic silk fibroin core-shell nanoparticles showed enhanced 
cytotoxicity and higher cellular uptake in the human Caucasian breast adenocarcinoma cell line 
(MDA-MB-231cells) evidenced by MTT and cellular uptake assays. In addition, silk fibroin 
nanoparticles and magnetic silk fibroin nanoparticles without CUR loaded were used as controls. 
The particles prepared using sodium phosphate showed significantly smaller diameter (90-350 nm) 
compared with those prepared using potassium phosphate, which possess a diameter range of 
500-1200 nm. These smaller particles are superior for biomedical applications since smaller 
particles (50-200 nm) are desired for cell internalization. In addition, the magnetic cores inside the 
particles provide possibility of using an external magnet for cancer targeting. 
Keywords: Silk, Magnetic nanoparticles, Drug delivery, Cancer, Curcumin 
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Abbreviations: 
SF: silk fibroin; CUR: curcumin; MNPs: magnetic nanoparticles;  
SFPs: Silk fibroin nanoparticles;  
MSPs: Magnetic silk fibroin core-shell nanoparticles 
CMSPs: CUR loaded magnetic silk fibroin core-shell nanoparticles  
 
3.1. Introduction 
Curcumin (CUR) is the main component of turmeric which is extracted from the root of Curcuma 
longa native to Southeast Asia 172. It is considered a pharmacologically safe drug 173 and has been 
widely used in medicine due to its anti-oxidant 4-6, anti-inflammatory 7-9, wound healing 10-11 and 
anti-bacterial 12-13 properties. Also, CUR has been widely used to fight against cisplatin-resistant 
cancer cells and decrease its unwanted side effects 14. Moreover, it has also been found that CUR 
may modulate markers of High-density lipoprotein (HDL) function and subsequently improve 
conditions in which HDL is dysfunctional 174. Recent research revealed that CUR also possess 
anti-cancer properties on multiple cell lines via its effects on the regulation of cellular growth and 
apoptosis 15-17 which makes it a promising drug for cancer therapy. However, due to its poor 
solubility in aqueous solution 18-19, short half-life in the body and low bioavailability after oral 
administration 175-177, the accumulation and uptake of CUR at the disease area by itself is very poor. 
Therefore, the applications of CUR as an anti-cancer drug have been significantly limited 19, 175-176, 
178. To overcome these obstacles, various strategies including the development of liposome 23, 
phospholipid 21, adjuvants 179 and nanoparticle carriers 22 for  CUR delivery have been conducted. 
However, most of these drug delivery systems lack the ability of tumour targeting, which makes the 
accumulation of drugs at tumour sites limited. Thus, a drug delivery system which is capable of not 
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only improving the availability, cell uptake and half-life of CUR, but can also deliver it to disease 
sites is desired. In this report, we present the fabrication of CUR loaded magnetic silk fibroin 
core-shell nanoparticles (CMSPs) for the delivery of CUR into breast cancer cells. 
Silk fibroin (SF) protein from cocoons of Bombyx mori is an FDA approved, natural derived material 
and has been widely used to form various biomaterials including SF gels, sponges and films for 
different medical applications 64. It has also been demonstrated that SF is an extremely promising 
material for drug delivery systems due to its excellent biocompatibility 180, tuneable biodegradability 
181 and easy processing 64. An increasing number of strategies including capillary-microdot 
technique 182, desolvation method 72-74, 183, supercritical fluid technologies 184 and salting-out method 
79 have been developed to fabricate SF based nanoparticles that can load and release model drugs. 
For example, Gupta et al. have fabricated  CUR loaded SF nanoparticles (<100 nm) with the 
capillary-microdot technique 182. However, preparation of SF nanoparticles (SFPs) with this method 
is difficult to process and the yield is relatively low. Kundu et al. have prepared  SFPs (150 - 170 
nm) with the desolvation method by adding SF solutions into dimethyl sulfoxide (DMSO) 72. 
Nevertheless, the organic solvent residue in these SFPs is still difficult to avoid. Zhao et al. have 
prepared smaller  SFPs (~ 50 nm) using solution-enhanced dispersion by CO2184. However, the 
processing of this method is complicated and the cost is high. Lammel et al. have developed a 
salting-out method for the preparation of SFPs (500 - 1200 nm) by adding SF solution into 
potassium phosphate solutions 79. This method possesses several advantages such as low cost, 
simplicity and safe operation, avoiding the use of toxic solvents and easy to maintain protein 
activities. However, the size of SF particles prepared with this approach is relatively large, which 
means their circulation time in blood will be shorter and are more likely to be entrapped within the 
liver and spleen 35.  
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Targeted drug delivery using magnetic carriers and an external magnetic field focused on the 
tumour areas has been reported as a promising strategy, which possesses advantages such as 
visualize the targeting process, rapid targeting and potential of being heated in a magnetic field to 
promote drug release as well as avoiding complicated chemical modification of targeting ligands on 
the surface of nanocarriers 48. Therefore, the combination of magnetic nanoparticles (MNPs) and 
SF become a promising strategy for targeted drug delivery. Recently, Tian and co-workers 
successfully prepared Doxorubicin (DOX) loaded magnetic silk fibroin nanoparticles (DMSPs) using 
the potassium phosphate salting-out method. The as-prepared DMSPs were proved capable of 
delivering the drug to the tumour site with the help of an external magnetic field 59. Nevertheless, 
targeted delivery of CUR using magnetic silk fibroin particles (MSPs), and the use of sodium 
phosphate to make smaller SFPs, to the best of our knowledge, has not yet been reported. It has 
been observed in our result that SFPs fabricated using sodium phosphate possess much smaller 
particle sizes (90 – 300 nm) compared with those fabricated with potassium phosphate, which 
normally possess the size over 500 nm. Since the particle size and performance of SFPs produced 
using sodium phosphate is significantly different from those fabricated using potassium phosphate 
and the properties of these particles have not yet been studied. It is important to investigate the size, 
zeta potential, secondary structure, CUR loading / release efficiency of SFPs and CMSPs prepared 
using sodium phosphate. On the other hand, it is expected that CUR will easily be encapsulated or 
adsorbed on the water-insoluble SFPs or CMSPs due to the strong hydrophobic interaction 
between hydrophobic CUR and the water-insoluble silk-II structure formed during the salting-out 
process. High encapsulation and loading efficiency of CUR in SFPs and CMSPs are also 
expectable, which is desired for a drug delivery system. Therefore, in this experiment, CMSPs were 
prepared with the salting-out method using sodium phosphate instead of potassium phosphate to 
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prepare smaller SFPs. The particle properties including size, zeta potential and CUR loading / 
release efficiency were investigated. In addition, how processing parameters such as pH value of 
sodium phosphate solution affect those properties were also studied. The cytotoxicity and cellular 
uptake performance of CMSPs was investigated using MDA-MB-231 (human breast 
adenocarcinoma) cells. 
3.2. Results and discussion 
3.2.1. Controlling the size and secondary structures of silk fibroin nanoparticles 
Desolvation and salting-out are two common methods for the fabrication of SF particles 185. While 
the desolvation method 186 is capable of making relatively smaller SFPs (< 200 nm), toxic organic 
solvents such as ethanol, methanol or acetone have to be introduced in the process, which may 
increase the toxicity to cells. On the other hand, SF particles can be prepared by the salting-out 
method without organic solvents involved. In the process of salting-out, SF protein chains will first 
form micellar-like structures in a salt solution due to the enhancement of hydrophobic interactions. 
The particulate globules will then be formed with the micelles by further hydrophobic interactions 79. 
In this paper, the salting-out method was used for the fabrication of SF particles. To investigate the 
effect of SF concentration and different salts on the size of SF nanoparticle, SF solutions with 
various concentrations (0.1-12 mg/ml) were added to 1.25 M sodium or potassium phosphate 
solutions (pH 8) and kept at - 20 °C for 2 h. The as-prepared particles were measured with dynamic 
light scattering (DLS). As shown in Fig. 3.1a, when using potassium phosphate, increasing SF 
concentrations from 0.1 to 12 mg/ml, resulted in the change of particle mean diameter from 0.62 to 
2.12 μm which is very similar to the result reported by Lammel and co-workers 79. However, the 
sizes of the particles are bigger than the desired size for drug delivery. For example, it has been 
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reported that nanoparticles in the range of 100 - 200 nm can extravasate through vascular 
fenestrations of tumours and escape filtration by liver and spleen 35.   
 
Fig. 3.1. Effects of SF concentration, salt, ionic strength and solution pH to the particle size and protein 
secondary structure. Particle diameter as a function of SF concentration when adding SF (concentration from 
0.1-12 mg/ml) solutions to sodium phosphate (Na-P) and potassium phosphate (K-P) solutions (both at ionic 
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strength 1.25 M, pH 8) at the volume ratio of 1:5 (a). Diameter of SFPs fabricated with K-P or Na-P as a 
function of their ionic strength (b). (The SF concentration was fixed at 5 mg/ml). AFM images of particles 
fabricated by adding silk fibroin solution (12 mg/ml) in to Na-P (c) and K-P (d) both solutions are at ionic 
strength 1.25 M and pH 8. Diameter of SFPs fabricated with Na-P as a function of the pH of Na-P solutions 
(e). The SF concentration was fixed at 5 mg/ml. FTIR spectra of particles produced by salting out by 1.25 M 
Na-P at different pH values (f). The results are shown in mean ± SD, n ≥ 3. It was found from the above 
results that the use of Na-P, lower ionic strength and higher pH of solution provides smaller SFPs.  
Nanoparticles with diameter ~100 nm are long-lasting in circulation, as the size increased to 150 nm 
and larger, more and more nanoparticles become entrapped in the liver and spleen 35. Therefore, it 
is likely that lots of these SF nanoparticles with diameters over 600 nm will be filtered by the liver 
and spleen instead of reaching the tumour site once injected into human body. In contrast, those 
fabricated with sodium phosphate showed much smaller sizes (90 - 300 nm) and narrower size 
distributions (Fig. 3.1a). Therefore, it provides a method to prepare SFPs with more appropriate 
sizes for drug delivery without involving organic solvent.    
To explain the difference in nanoparticle size crated using sodium phosphate and potassium 
phosphate, we need to first determine the reason why SF polypeptides are stable in aqueous 
solution. Since the isoelectric point (pI) of SF is 4.53 and its surface charge becomes more and 
more negative by increasing the pH above the pI 79. SF is negatively charged in aqueous solution 
(pH 7). The net charge on the surface of SF thus prevents them from aggregating via electrostatic 
repulsion 187. Therefore, to eliminate the polypeptide-polypeptide repulsion of SF for their 
aggregation, counterions must be introduced. Here, the counterions are sodium and potassium ions. 
When SF solutions are mixed with sodium or potassium phosphate solutions, the cations can 
adsorb onto the negatively charged SF surface which results in the decrease of the overall SF net 
charge, resulting in aggregation. The difference in the adsorption behaviour of sodium and 
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potassium ions is expected to be responsible for the different aggregation results of SF. When 
added to water, the negative side of water molecule (oxygen) will be attracted to the cations (sodium 
and potassium ions) and the positive side of water (hydrogen) to negatively charged phosphate ions 
188. As a result, ion-water shell structures are created with ions surrounded by shells of water 
molecules, which are celled hydrated ions. Since sodium and potassium ions possess the same 
charge while the ion radius of sodium is smaller than potassium, sodium ions have a higher charge 
density compared to potassium ions. Therefore, sodium ions exhibit a stronger affinity towards 
water compared to potassium ions, which also results in a larger radius of hydrated sodium ions 
(see Fig. 3.2a) 189.  
 
Fig. 3.2. Schematic representation of the ion radius and hydrated ion radius of sodium and potassium ions (a). 
the adsorption of hydrated sodium (b) and potassium (c) ions onto hydrophobic SF surfaces.  
 
According to the law of matching water affinities (LMWA), cations tend to contact and form stable 
ion pairs with anions with the same affinity to water 190. Which means, strongly hydrated cations are 
more likely to contact with strongly hydrated anions instead of weakly hydrated anions. Therefore, 
sodium ions may more readily be adsorbed to the strongly hydrated groups such as COO- from SF 
polypeptide than potassium ions do, while potassium ion are more readily to adsorb to the negative 
sides of backbones such as C=O. It can be assumed that sodium ions are more hydrophilic than 
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potassium ions and tend to stay closer to the bulk of water molecules while potassium ions tend to 
stay closer to SF backbones. Therefore, during the process of salting out, sodium ions are more 
readily adsorbed to more hydrophilic and strongly hydrated sites of SF than potassium ions. 
However, when it comes to more hydrophilic and less hydrated sites, potassium ions are more 
readily to be adsorbed. Then it can be assumed that there are more weakly hydrated sites in SF 
than the strongly hydrated ones and the salting out property of SF is dominated by the weakly 
hydrated and less hydrophilic parts. In this case, potassium ions can be more effectively adsorbed 
onto SF to reduce its overall net charge and induce aggregation.  
It might be easier to explain the above process by assuming the SF polypeptides are small, uniform 
and hydrophobic (more hydrophobic than water) particles with negatively charged surfaces (as 
shown in Fig. 3.2b&c). Then the salting out process is to eliminate their surface charges by 
adsorption of counterions (sodium / potassium) to their surface. In this case, strongly hydrated 
sodium ions prefer to stay close to the bulk of water due to their higher infinity with water, while 
weakly hydrated potassium ions prefer to stay close to hydrophobic SF surface and away from the 
bulk. Therefore, potassium ions can more effectively bind to SF surfaces and reduce their surface 
charge to facilitate aggregation. 
Apart from the different adsorption behaviours of sodium and potassium ions, their different 
hydration behaviour may also responsible for their difference in aggregation. As shown in Fig. 
3.2b&c, once hydrated cations are adsorbed on SF surfaces, water molecules from hydrated 
cations are also located surround SF surfaces. As a result, a layer of tightly bound water molecules 
is produced on SF surfaces which may provide protection against direct contacting between SF 
polypeptides. Since the hydrated sodium ions possess more water molecules than hydrated 
potassium ions, SF that has hydrated sodium ions adsorbed is expected to possess a thicker water 
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bound layer (Fig. 3.2b) than SF adsorbed with hydrated potassium ions (Fig. 3.2c) 191. Therefore, 
more hydrated sodium ions exhibit a lower salting out efficiency compared to less hydrated 
potassium ions, in this case resulting in smaller SF particles fabricated using sodium phosphate to 
potassium phosphate. 
The effect of ionic strength on the size of the particles has also been investigated. Fig. 3.1b 
illustrates the diameter of SFPs fabricated with sodium or potassium phosphate as a function of the 
ionic strength of the salts. Below 0.6 M ionic strength, particles in both salt solutions can hardly be 
detected. Therefore, the lowest ionic strength to form particles is assumed to be 0.6 M. This finding 
is consistent with the previous literature 79. Increased ionic strength resulted in larger particles for 
both cases, which is assumed to be a result of enhanced denaturation of silk fibroin and 
aggregation of smaller SF nanoparticles. It is also clear that at the same ionic strength, particles 
fabricated with potassium phosphate are much larger than those fabricated with sodium phosphate. 
AFM images of SF nanoparticles fabricated by adding SF solution (12 mg/ml) into sodium or 
potassium phosphate solution (1.25 M, pH 8) are shown in Fig. 3.1c&d. Particles formed using 
sodium phosphate are much smaller (380 nm) and smoother, while particles formed by potassium 
phosphate are larger (1800 nm) in size and have a rough surface that may result from the 
aggregation of smaller particles. Therefore, by using different phosphate solutions or adjusting their 
ionic strength, SFPs with a large range of diameters (90 nm - 2.2 μm) can be prepared, which 
provides more options on designing SFPs for different applications.  
The solution pH can also affect particle size. Fig. 3.1e shows the diameter of SFPs fabricated with 
sodium phosphate as a function of pH, the ionic strength of solutions was fixed at 1.25 M. From pH 
4 to 9, the size of particles decreased gradually. The isoelectric point (pI) of silk fibroin is 4.53 79, at 
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which pH the net charge of SF is close to 0 and thus tend to aggregate due to the increased 
inter-molecular interaction 79. At pH higher than the pI, the net charges of SF are negative and the 
charge density tends to increase as pH increases. As a result, the increased repulsion resulted in 
smaller SF nanoparticles and prevented further aggregation.  
To investigate the effect of pH values on SF secondary structures, FTIR analysis was carried out 
and the results are shown in Fig. 3.1f. Absorption band in the frequency range of 1616 - 1637 cm-1 
represents the β-sheet rich silk-II form while those in the frequency range from 1636 - 1655 cm-1 
represent the random coil and α-helix rich silk I form 192. In an α-helix structure, hydrogen bonds are 
formed between the N-H groups and C=O groups within the same strand. On the other hand, in a 
β-sheet structure, hydrogen bonds are formed between adjacent peptide strands, which can bring 
strands to interact with each other to form insoluble aggregates 63. Therefore, the silk II structure is 
more hydrophobic than the silk I structure. As revealed in Fig. 3.1f, the secondary structure of SFPs 
contains more silk II structure, and is more hydrophobic, at pH 4 compared to a less hydrophobic 
silk I-rich structure at pH 9. These results explain the change on SF nanoparticle size at different pH 
values, more hydrophobic particles have larger tendency to gather and form bigger aggregates. 
Furthermore, this phenomenon is very useful in manipulating drug loading, for example, increasing 
the loading efficiency of hydrophobic drugs on particles by using more hydrophobic particles.  
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3.2.2. Controlling the size and Zeta potential of magnetic silk fibroin nanoparticles 
and curcumin loaded magnetic silk fibroin core-shell nanoparticles 
Magnetic Fe3O4 nanoparticles (MNPs) with diameter 10 - 30 nm were introduced to SFPs by adding 
MNPs into sodium phosphate solutions (1.25 M, pH 8) before mixed with SF solutions. As shown in 
Fig. 3.3, as-prepared magnetic-SF core-shell particles (MSPs) can be rapidly collected with the help 
of an external magnetic force from a Neodymium magnet, which can be potentially used for the 
targeted delivery of particles to desired tissue sites under external magnetic forces 59. 
 
 
 
 
 
 
Fig. 3.3. MSPs can be rapidly collected with a Neodymium magnet (pull force 25 Kg, 25.4 mm Diameter x 
30 mm thick) within 3 min. 
The size of as-prepared MSPs can be manipulated by changing SF concentration or pH values of 
sodium phosphate used. Fig. 3.4a illustrated the diameter of MSPs as a function of SF 
concentrations. The addition of MNPs did not change the particle size of SFPs. Instead, the 
particles size remained within the range of 100 - 250 nm. This result is in agreement with the work 
of Tian et al. who have reported that, when using potassium phosphate, the addition of MNPs can 
dramatically decrease the particle size of SFPs from 1.4 µm to 130 - 210 nm 59. Fig. 3.4b showed 
15 s 30 s 3 min 0 s 
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the effect of sodium phosphate pH on MSP diameter. It is clear that both SF concentration and 
sodium phosphate pH affect MSP size similarly as they affect SF particle size (Fig. 3.1a&e), which 
suggests the property of MSPs is dominated by the SF structures coated on the MNPs. It can be 
assumed that when the MSPs were prepared in a pH 9 solution, the SF coating became more 
negatively charged and less hydrophobic, which tend to increase the repulsion and decrease the 
hydrophobic interaction among MSPs and eventually fabricate smaller particles. Therefore, the size 
of MSPs can be controlled by altering the pH value of salt solution used in the process. 
CMSPs were fabricated by adding CUR and MNPs into sodium phosphate solution (1.25 M, pH 8) 
followed by adding SF solution (5 mg/ml) into the mixture. As shown in Fig. 3.4c, increasing the 
amount of CUR (with weight equivalent to the percentages of the weight of SF used) resulted in the 
increased diameter of CMSPs, indicating the drug loading into the particles. The Zeta potential of 
the CMSPs with different CUR loading was measured. As shown in Fig. 3.4e, higher CUR usages 
resulted in less charge densities, which lead to weaker repulsive interactions and therefore, larger 
particles. The same reason can also be used to explain the effect of pH value on CMSP size. As 
shown in Fig. 3.4d, CMSP diameter decreases with the increase of sodium phosphate pH value. 
Meanwhile, Fig. 3.4f illustrated that higher pH values correspond to higher charge densities. Thus, 
we may conclude that the property of CMSPs is also dominated by its SF content, therefore, higher 
pH value correspond to higher charge densities and smaller particles. 
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Fig. 3.4.The effects of SF concentration, solution pH, and CUR amount to the particle size and zeta potential 
of MSPs and CMSPs. The effect of SF concentrations to the diameter of MSPs fabricated by sodium 
phosphate solutions (a) (ionic strength: 1.25 M, pH 8). The effect of sodium phosphate solution pH to the 
diameter of MSPs (b) (SF concentration: 5 mg/ml, sodium phosphate ionic strength: 1.25M). The effect of 
CUR amount to the diameter (c) and Zeta potential (e) of CMSPs, which were fabricated by adding different 
amounts of CUR (with weight equivalent to the percentages of SF used) to sodium phosphate solutions 
before SF solutions (5 mg/ml) and MNPs were added to the mixed solution. The effect of sodium phosphate 
solution pH to the diameter (d) and Zeta potential (f) of CMSPs (SF concentration: 5 mg/ml, CUR amount: 
10% of SF used). The results are shown in mean ± SD, n ≥ 4. It was found that the size and Zeta potential of 
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MSPs and CMSPs can be controlled by altering the SF concentration, solution pH and the amount of CUR 
used in the fabrication process. 
Pure CUR is negatively charged as shown in Fig. 3.4e, the surface charge property of CUR is 
attributed its chemical structure. The IUPAC nomenclature of CUR is 
(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione and its chemical structure is 
shown in Fig. 3.5. CUR is composed of two aromatic rings that are connected by a seven carbon 
linker (α,β-unsaturated β-diketone moiety) 193. A methoxy and a phenolic hydroxyl group are 
contained in each aromatic ring at the ortho position. A keto-enol tautomerism exists in diketones 
group, leading to two different forms of CUR (enol form and keto form). The enol form is more stable 
than the keto form in solution phase and gas phase because the structure is composed of three 
planar groups inter connected via two double bonds. Since the carbon atoms in the aromatic ring 
are sp2-hybridized and left their π electrons to delocalized in the molecular orbitals extend all over 
the ring, the atoms in the aromatic ring are on the same plane and the ring is conjugated. Apart from 
the aromatic group, the seven-carbon linker in a CUR molecule (enol form) consists of double 
bonds separated by single bonds, therefore, the linker is also conjugated. Combining the linker and 
two aromatic rings, the conjugation is extended and the π electron cloud is all along the CUR 
molecule 193-194. Because of the conjugated structure of CUR, the hydroxyl groups (one enolic 
hydroxyl group and two phenolic hydroxyl groups) in CUR possess protons that can be ionized. A 
long pair on the oxygen atom can overlap with the delocalized π electrons on the CUR molecule, 
which leads to the extension of the delocalization of π electrons to the oxygen atom. Once a proton 
is lost, the negative charge from the oxygen atom will delocalize around the π system and the 
resulting anion is stabilized. Therefore, CUR molecules exhibit weak acidity in aqueous solution and 
the resulted CUR ions are negatively charged. 
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There are three different pKa values for the three hydroxyl groups in CUR. The identification of pKa 
is shown in Eq. (3.3) - (3.5): 
𝐻𝐴 ⇋ 𝐻+ + 𝐴−                                                           (3.3) 
𝐾𝑎 =
[𝐻+][𝐴−] 
[𝐻𝐴]
                                                           (3.4) 
𝑝𝐾𝑎 =  −𝑙𝑜𝑔10(𝐾𝑎)                                                    (3.5) 
Where HA represents an acid, H+ represents a hydrogen ion, Ka is the acid dissociation constant, 
pKa is the negative base 10 logarithm of Ka 195. The smaller the pKa value, the higher the hydrogen 
ion concentration is in solution and therefore the stronger the acid is 195. The enolic proton has been 
reported as the most acidic one among the three protons in CUR and it has a pKa1 value of 7.8, as 
shown in Fig. 3.5. The phenolic protons are slightly weaker in acidity and have pKa2 and pKa3 of 8.5 
and 9.0 respectively 196. 
 
Fig. 3.5. Chemical structure of CUR and the ionization of CUR (Enol form). 
To reveal the morphology of the particles before and after the CUR loading, AFM and TEM 
experiments have been carried out. AFM images of MSPs and CMSPs are shown in Fig. 3.6a&b 
respectively. Spherical particles with a smooth surface were observed for MSPs, very similar to the 
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morphology of the SFPs (Fig. 3.1c). The diameter of the particles is around 250 nm, consistent with 
the data measured by DLS in Fig. 3.4a. In contrast, the surface of CMSPs appears to be rougher, 
indicating the loading of CUR into the particles. Presumably, the loading of CUR into the particles 
makes the particles more hydrophobic; therefore, the particles were dehydrated. Fig. 3.6c&d 
showed the TEM images of MSPs and CMSPs respectively. These images indicate clearly that both 
MSPs and CMSPs are formed by multiple magnetic cores covered by SF or SF / CUR shells, which 
is in agreement with the work by Tian et al 59. The insets in Fig. 3.6c&d are the enlarged images 
from the red boxes. It can be seen from the enlarged images that the black magnetic cores are 
surrounded by SF shells. A number of smaller core-shell particles (~ 30 nm) aggregate to form a 
bigger particle (~ 250 nm). 
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Fig. 3.6. AFM and TEM images of the MSPs and CMSPs. AFM (a) and TEM (b) images of MSPs (SF: 5 
mg/ml, ionic strength of sodium phosphate: 1.25 M, pH 8). AFM (b) and TEM (d) images of CMSPs (SF: 5 
mg/ml, ionic strength of sodium phosphate: 1.25 M, pH 8, CUR amount: 10% of SF used). Inserts are the 
enlarged images of from the red boxes. 
 
 
 
 
 
 
 
 
 
 
 
 
b. a. 
c. d. 
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3.2.3. Controlling loading and release of curcumin  
To investigate the loading and release property of CMSPs, diverse amounts of CUR were loaded 
into CMSPs and the effect of sodium phosphate pH values was also investigated. Fig. 3.7a 
illustrated the effect of CUR amount on encapsulation of CUR. The pH of sodium phosphate 
solution was fixed at 8 in this experiment. It can be seen that more than 97% of CUR has been 
encapsulated regardless of the amount of CUR used. Loading efficiency of CUR into these particles 
increased from ~ 10% to ~ 80% with the increasing amount of CUR used as shown in Fig. 3.7c. The 
encapsulation and loading efficiency of CUR in CMSPs is remarkably high given the fact that the 
typical loading efficiency for hydrophobic compound loading in protein nanoparticles is around 5% 
197-201. This phenomenon could owe to the strong hydrophobic interaction between hydrophobic 
CUR and the water-insoluble silk-II structure formed during the salting-out process. The results has 
shown significant improvement in loading efficiency (up to 80%) compared with 6% found for 
curcumin-loading into silk fibroin (SF) / poly(L-lactic acid-co-e-caprolactone) (P(LLA-CL)) 
nanofibrous scaffolds 202, 12% for the silk / curcumin nanoparticles fabricated in supercritical CO2 27, 
15% for the SF nanoparticles reported by Li et al. 203, 30% for the silk / curcumin nanoparticles 
produced by desolvation method 204, as well as 10% loading efficiency for the paclitaxel loaded silk 
fibroin nanoparticles 205. The lower loading efficiency in SF nanoparticles via desolvation method 
was due to the fact that CUR tend to dissolve in organic solvent instead of adsorb on SF 
nanoparticles. However, for loading via slating-out method, the hydrophobic CUR was either 
encapsulated in or adsorbed on the water-insoluble SF nanoparticles instead of suspend in the 
aqueous solution. Therefore, the loading of CUR in SF nanoparticles via salting-out method is more 
suitable for the fabrication of high CUR-loading efficiency SF nanoparticles, which is desired for the 
drug delivery systems.  
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Another desired capability of a drug carrier is to be able to control the release of drug and normally 
a longer releasing period is desired. To investigate the release profile of the CMSPs with different 
encapsulation and loading efficiencies, 5 mg of each type of particles were dispersed in 5 ml PBS 
(pH 7.4) and incubated at 37 °C with shaking (200 rpm). The CUR concentrations in solution were 
measured at different time scales and the cumulative CUR release curves are shown in Fig. 3.7e. 
Although CMSPs with 10% CUR loading released more in terms of percentage (12.4% drug 
released in 20 days) of loaded CUR than others during the releasing period, the total amount of 
released CUR is still less than other (30%, 60% and 90% CUR loaded) particles. The drug release 
rate for CMSPs with 10% CUR loading stays at a higher slope for the first 14 days and gradually 
level off, while for other particles, the release rates are still at steady slopes. The higher 
accumulative release rate was due to the low CUR loading 206.  
During the whole period of CUR releasing, the release was progressive without obvious burst 
release, which indicates that the CUR was homogeneously dispersed in the CMSPs. This release 
profile was also in agreement with the work by Xie et al. that the inconspicuous burst release was 
due to the poor water-solubility of CUR 27. The release profile of CUR from SF matrix can be 
described as a three-step process; firstly, the initial diffusion resulted from desorption of CUR from 
the particle surface, then water penetrates into the matrix and the inner drugs are released. Finally, 
the degradation of SF releases the remaining encapsulated drug 207. Since the burst release of CUR 
is limited by its poor solubility, the CUR release can be assumed that depend on the solubility, 
diffusion and biodegradation of the SF matrix. It has been reported that the change of SF structure 
can lead to a different release profile of CUR 208. Xie et al. found that silk I structure of SF 
nanofibrous become more water-insoluble when exposed to ethanol vapour, and the ethanol vapour 
treated SF carriers showed a lower CUR release rate than the no-treated ones 27. Li et al. have 
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prepared CUR loaded SF nanoparticles by desolvation method, the resulted SF carriers have 
released only ~ 5% of loaded CUR and nearly stopped releasing after around 3 days 203. This low 
CUR release amount and short release period can be explained by the fact that water-insoluble 
β-sheet structures were formed after the SF have been treated with ethanol 186, thus the 
hydrophobic CUR tend to remain in hydrophobic SF matrix, weakening the CUR diffusion. It should 
be noted that our release profile last 20 days with up to 12% release of the CUR which is significant 
better than the literature which normally last only one week 27, 203-204.   
Because the structure of SF particles can be controlled by using salt solution with different pH 
values, we have observed the loading / release profiles of CMSPs prepared at different pH values. 
Fig. 3.7b&d illustrated the encapsulation and loading efficiencies of CUR in MSPs fabricated using 
sodium phosphate solutions with different pH values. It can be seen that MSPs fabricated by 
sodium phosphate solutions with pH 4 - 8 have similar CUR encapsulation (over 97%) and loading 
(over 10.5%) efficiencies, however, those using pH 9 solution showed noticeably less encapsulation 
(76%) and loading (8.4%) efficiencies than others. Considering the results shown in Fig. 3.1f that 
SFPs fabricated with pH 9 sodium phosphate solutions have more silk-I content than those 
fabricated in lower pH values, it is suspected that the secondary structure of SF significantly affects 
the ability of MSPs in absorbing CUR and the less hydrophobic silk-I content is less capable of 
capturing CUR. Therefore, the CUR loading efficiency of CMSPs via salting-out method can be 
controlled by altering the pH of salt solution. Fig. 3.7f showed the cumulative CUR release of 
CMSPs fabricated using sodium phosphate with different pH values. CMSPs fabricated in pH 4 
have released more CUR than those fabricated at higher pH values. This is because the CUR 
loading was carried out at pH 4 while SF was more hydrophobic and the release was carried out at 
pH 7.4, at which pH the SF become less hydrophobic therefore facilitate the release of the 
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hydrophobic CUR. Therefore, the release of CUR depends on the charge and structure of SF which 
can be controlled during the salting-out process. These results suggest that CMSPs possess many 
desired properties such as high encapsulation / loading efficiency and controllable release profile, 
which makes it a promising system for drug delivery. 
 
Fig. 3.7. Drug leading and release profiles of the CMSPs. Encapsulation efficiency of CMSPs fabricated with 
various CUR amounts in terms of the amount of SF used (a) (pH 8) and various pH (b) (CUR amount: 10%). 
Loading efficiency of CMSPs fabricated with various CUR usage (c) (pH 8) and various pH (d) (CUR 
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amount: 10%). Cumulative release of CUR from CMSPs fabricated with different CUR usage (e) (pH 8) and 
different pH (f) (CUR amount: 10%). For each experiment, SF concentration was fixed at 5 mg/ml, ionic 
strength of sodium phosphate solution was fixed at 1.25 M. The results are shown in mean ± SD, n ≥ 3. The 
statistical significance is expressed as ***p < 0.001, **p < 0.01, *p <0.05. 
 
3.2.4. In vitro cytotoxicity assay 
MTT assay was conducted to investigate the ability of CMSPs to inhibit growth of MDA-MB-231 
cells. SFPs and MSPs were used as controls. SFPs, MSPs and CMSPs with 30% CUR were 
incubated with MDA-MB-231 cells for 3 days before determining the relative cell viabilities. Free 
CURs with amount equal to that encapsulated by CMSPs were also incubated and the viabilities 
were compared with that from CMSPs. As illustrated in Fig. 3.8, cell growth was significantly 
inhibited by either CMSPs or free CUR at higher CUR concentrations. Within the dose range from 3 
to100 μg/ml, CMSPs were significantly more cytotoxic to MDA-MB-231 cells than free CUR at 
equivalent CUR dosage. For instance, the cell viability of MDA-MB-231 cells treated with 60 μg/ml 
CMSPs for 3 days was 12.2 ± 6.3% and when treated with equivalent CUR, the viability was 46.3 ± 
5.2 %, which suggests the inhibition of cancer cell growth was enhanced by CMSPs. The enhanced 
cytotoxicity of CMSPs could be the result of enhanced uptake of CMSPs by cells and the 
encapsulated CUR was released via diffusion or the degradation 27 of SF matrix inside the cells, 
which in turn increased the up take efficiency of CUR, thus decreased the cell viability. SF 
nanoparticles and MSPs, on the other hand, had very little effect on cell toxicity at lower 
concentration and relatively low cytotoxicity at higher concentrations, indicating that SF 
nanoparticles and MSP are non-toxic nanoparticles. Similar studies have been reported and 
indicated that SF particles also showed no cytotoxicity to many other cell lines 59, 182, 205, 208. For 
example, Xie et al. have compared the in vitro anti-cancer effect of CUR and CUR loaded SF 
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nanoparticles against HCT-116 cancer cells 208. It was found that the curcumin-silk fibroin 
nanofibrous matrix had equivalent anti-cancer effect to the DMSO dissolved CUR.  
 
Fig. 3.8. In vitro cytotoxicity studies for MDA-MB-231 cells treated with SFPs, MSPs, CMSPs (CUR usage: 
30%) and free CUR (amount equivalent to the CUR loaded in CMSPs) for 3 days. Added inhibitions of free 
CUR and MSPs equivalent to the amount of CUR and MSPs in CMSPs were also compared (CUR + MSPs). 
The results are shown in mean ± SD, n = 8. The statistical significance is expressed as ***p < 0.001, **p < 
0.01, *p <0.05. 
To investigate whether the higher cytotoxicity of CMSPs on MDA-MB-231 cells is a simple addition 
of CUR and MSPs cytotoxicity or enhanced CUR delivery by the nanoparticles, the growth inhibition 
result of CMSPs is compared with the added inhibition of corresponding free CUR and MSPs with 
amounts equal to the amounts of CUR and MSP content in CMSPs. The results are also shown in 
Fig. 3.8 demonstrated that CMSPs have higher cytotoxicity than the added toxicities of free CUR 
and MSPs (except the data at 100 μg/ml). Therefore, the enhanced cytotoxicity of CMSPs against 
MDA-MB 231 cells is expected as a result of enhanced cell internalization of the CUR loaded 
particles. 
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3.2.5. Cellular uptake assays 
To investigate the internalization and intracellular drug release behaviours of CMSPs, MDA-MB-231 
cells were treated with different concentrations of CMSPs (with 30% CUR loaded) and free CUR. 
The amount of free CUR was equal to the CUR content in CMSPs. The percentage of cell uptake of 
CUR is determined by flow cytometry and the results are shown in Fig. 3.9a. The uptake efficiency 
of CUR for cells treated with CMSPs is significantly higher than those treated with free CUR at all 
concentrations and the difference is especially large at lower concentration. This result suggests 
that the enhanced growth inhibition effect of CMSPs, as illustrated in Section 3.2.4, is a result from 
higher CMSPs uptake. Since CUR is a highly hydrophobic drug, its dispersion and diffusion in 
aqueous solution is significantly poor. However, when loaded in CMSPs, CUR was encapsulated 
within CMSPs and can cross the cell membrane for cell uptake. The results are consistent with the 
reports that SF particles can be taken up rapidly by cells 72, 182. To investigate whether the uptake 
efficiency of CMSPs is significantly affected by the CUR content, MDA-MB-231 cells were incubated 
with SFPs, MSPs and CMSPs (30% CUR loaded) for 24 h. The SF content of these particles was 
labelled with Rhodamine B which can be detected by flow cytometry to determine the uptake of 
these particles. These results are shown in Fig. 3.9b. All three kind of particles displayed similar 
cellular uptake efficiency and uptake increased with the increasing particle concentration. 
Considerably high uptake efficiency (nearly 70%) can be reached at lower concentration (e.g.10 
μg/ml) which is beneficial to drug delivery.  
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Fig. 3.9. Cellular uptake assays of the different particles. CUR uptake in MDA-MB-231 cells after treated 
with CMSPs (with 30% CUR loaded) and equivalent amount of free CUR for 24 h (a). Particle uptake 
efficiency of SFPs, MSPs and CMSPs in MDA-MB-231 cells after incubation for 24 h (b). SF content in 
these particles was labelled with Rhodamine B and the uptake efficiencies were determined by measuring the 
cell population containing Rhodamine B fluorescence with flow cytometry. The results are shown in mean ± 
SD, n = 3. The statistical significance is expressed as ***p < 0.001, **p < 0.01, *p <0.05. It was found that 
cells treated with CMSPs had significantly higher uptake efficiency of CUR than those treated with free 
CUR. 
Fig. 3.10 shows the fluorescent microscopic images of CUR uptake by MDA-MB-231 cells after 
incubation with free CUR (Fig. 3.10a&b) or CMSPs (Fig. 3.10c&d). CUR molecule is 
auto-fluorescent (Ex 340 nm, Em 530 nm 155) and was observed with GFP channel. The nucleus 
and cytoskeleton were stained with DAPI and Texas Red®-X Phalloidin. The enhanced CUR up 
take effect of CMSPs is confirmed by these images. As shown in Fig. 3.10a&b, the green 
fluorescence in cells that have been treated the free CUR, is very weak which suggests the uptake 
efficiency of free CUR is low, consistent with uptake efficiency shown in Fig. 3.9a. In contrast, Fig. 
3.10c&d shows that over 90% of the cells incubated with CMSPs have displayed much brighter 
green fluorescence which appears to be quite uniformly distributed within the cytosol. The 
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dramatically increased fluorescence intensity suggests that CMSPs can significantly enhance the 
uptake of CUR for MDA-MB-231 cells. The yellow fluorescence in the merged images indicates the 
co-localization of the Texas red and CUR fluorescence. 
 
Fig. 3.10. Representative microscopic images of MDA-MB-231 cells incubated with free CUR (a&b), CUR 
amount (10 μg/ml) equivalent to the CUR loaded in CMSPs (30%) and CMSPs (c&d, 30 μg/ml) for 4 h. Cell 
nucleus and cytoskeleton were stained with DAPI (blue) and Texas red (red); all images were taken with 
AF6000 microscope (Leica). Comparing the images in a&b to c&d, it can be seen that CMSPs significantly 
improve the cellular uptake of the CUR. 
To demonstrate the uptake of the nanoparticles, Fig. 3.11 shows the fluorescent microscopic 
images of FITC-labelled SFPs (Fig. 3.11a&b) and MSPs (Fig. 3.11c&d) uptake by MDA-MB-231 
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cells. It can be seen from Fig. 3.11a&c that over 90% of the cells have green fluorescence, 
consistent with uptake efficiency shown in Fig. 3.9b. Fig. 3.11b&d shows the uptake by single cells.  
 
Fig. 3.11. Representative microscopic images of MDA-MB-231 cells incubated with FITC-labelled SFPs 
(a&b, 30 μg/ml) or FITC labelled MSPs (c&d, 30 μg/ml). Cell nucleus and cytoskeleton were stained with 
DAPI (blue) and Texas red (red); all images were taken with AF6000 microscope (Leica).  
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3.3. Conclusions 
Smaller particles as drug carriers are desired for drug delivery systems. However, SF particles 
fabricated using potassium phosphate are relatively larger (500 -1200 nm). In this Chapter, a 
method to fabricate SFPs using sodium phosphate was developed and the results indicated that 
SFPs fabricated with sodium phosphate possess significantly smaller size than those fabricated 
using potassium phosphate. This new method provides a simple process allowing the fabrication of 
smaller SFPs without using any organic solvent. Size and secondary structure of SFPs was 
controlled by changing SF concentration, the pH and ionic strength of sodium phosphate solutions. 
The size, zeta potential and drug loading / releasing efficiency of CMSPs was controlled by using 
different SF concentrations, CUR amounts and pH values of sodium phosphate solutions. 
Sustained release of CUR from CMSPs was observed for 20 days and CMSPs fabricated at lower 
pH values showed higher CUR release rate. Enhanced growth inhibition of CMSPs against 
MDA-MB-231 cells was observed by MTT assay and CUR uptake efficiency was also significantly 
enhanced due to the better internalization of CMSPs. The effect of particle concentration on cellular 
uptake efficiency was investigated and the results indicate that uptake efficiency can be increased 
by increasing particle concentration. In addition, these particles displayed similar uptake efficiency, 
which suggests the CUR content in CMSPs did not affect the uptake efficiency of particles. 
Therefore, CMSPs can be used as potential drug delivery system for cancer therapy.  
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4. Preparation of Magnetic Alginate / Chitosan Layer-by-Layer 
Nanoparticles as Potential Carriers for Targeted Delivery of 
Curcumin into Human Breast Cancer Cells 
Abstract 
Curcumin is a promising anti-cancer drug but its applications in cancer therapy are limited due to its 
poor solubility, short half-life and low bioavailability. In this study, curcumin loaded magnetic alginate 
/ chitosan nanoparticles were fabricated to improve the bioavailability, uptake efficiency and 
cytotoxicity of curcumin to MDA-MB-231 breast cancer cells. Alginate and chitosan were deposited 
on Fe3O4 magnetic nanoparticles based on their electrostatic properties. The sizes of the 
nanoparticles were within the optimum size range (50 - 200 nm) for drug delivery. Sustained 
curcumin release was obtained use the nanoparticles with the ability to control the curcumin release 
rate by altering the number of chitosan and alginate layers. In addition, the final polymer layer was 
found strongly affected the drug release. Confocal fluorescence microscopy results showed that 
targeted delivery of curcumin to desired sites with the aid of an external magnetic field was 
achieved. The Fluorescence-activated cell sorting (FACS) assay indicated that MDA-MB-231 breast 
cancer cells treated with curcumin loaded magnetic alginate / chitosan nanoparticles had a 3-6-fold 
uptake efficiency to those treated with free curcumin. MDA-MB-231 breast cancer cells exhibited 
significantly higher curcumin uptake efficiency in contrast to normal HDF cells after both been 
treated with curcumin loaded nanoparticles. The MTT assay indicated that the curcumin loaded 
nanoparticles exhibited significantly higher cytotoxicity towards MDA-MB-231 cancer cells than 
HDF cells, which is desired for anticancer drug delivery. The sustained release profiles, enhanced 
uptake efficiency and cytotoxicity to cancer cells as well as the potential of targeted delivery make 
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MACPs a promising candidate for targeted anti-cancer drug delivery.  
Keywords: Alginate, Chitosan, Layer-by-layer, Magnetic nanoparticles, Drug delivery, Cancer, 
Curcumin 
Abbreviations: CUR: curcumin; CHI: chitosan; SA: sodium alginate; MNPs: magnetic 
nanoparticles; MAPs: Magnetic alginate nanoparticles; MACPs: magnetic alginate / CHI 
layer-by-layer nanoparticles; CMACPs: Curcumin loaded magnetic alginate / chitosan 
layer-by-layer nanoparticles; CMACPs 1&4: Curcumin loaded magnetic alginate / chitosan 
layer-by-layer nanoparticles with 1 and 4 layers of polymer coating; HDF: Human Dermal 
Fibroblasts 
4.1. Introduction   
Curcumin (CUR) is a yellow, hydrophobic, polyphenolic compound of turmeric that is extracted from 
the rhizomes of Curcuma longa, which are widely cultivated in Asian countries such as India and 
China and have been historically used as a spice 3, 172. CUR is ‘Generally Recognized as Safe 
(GRAS)’ by the Food and Drug Administration (FDA) 3 and has been widely used in medicine due to 
its anti-oxidant 4-6, anti-inflammatory 7-9, wound-healing 10-11 and anti-bacterial 12-13 properties. 
Recent research has demonstrated that CUR has the ability to inhibit carcinogenesis in various cell 
lines including breast, colon and gastric cancer cells, which has resulted in increased interest as a 
promising anticancer drug 14-17. However, CUR exhibits poor solubility in aqueous solution, limiting 
its applications for cancer therapy 18-20.   
It has been reported that after an oral administration of 2 g/kg of CUR in humans, an extremely low 
serum concentration (0.006 ± 0.005 μg/ml) of CUR was observed after 1 h 209. As a result, the 
bioavailability and anti-cancer efficiency of CUR is limited by its low solubility 18-20. In order to 
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improve the bioavailability, various nanocarriers have been used, including lipid based 
nanoparticles 21-25, polymer nanoparticles 26-32 and inorganic nanoparticles 33. The main advantages 
of the CUR loaded nanocarriers are their small size and large surface area, which enable them to 
pass through the cell membranes with an enhanced uptake efficiency 3, 30. Research has 
increasingly focused on the fabrication of biopolymer nanoparticles for CUR delivery due to 
advantages of low cytotoxicity, excellent biocompatibility and biodegradability 30. Two of the most 
commonly used biopolymers in medical applications are alginate and chitosan (CHI). Alginate is an 
anionic polysaccharide composed of (1-4)-linked β-D-mannuronate (M) and α -L-guluronate (G) 
residues while CHI is a cationic polysaccharide composed of N-acetyl-D-glucosamine and D 
glucosamine 82, 93 and is positively charged below neutral pH, due to the protonation of amino 
groups 80. Both alginate and chitosan (CHI) are naturally obtained biopolymers that possess 
desirable properties such as biocompatibility, biodegradability and are not toxic 82. Moreover, 
alginate based nanoparticles can be fabricated by simple processes such as Ca2+ cross-linking or 
altering of pH 92. CHI based nanoparticles can be prepared by providing polyanion of 
tripolyphosphate (TPP) without introducing harsh cross-linking agents or organic solvents 88. 
Electrostatic interactions between positive CHI chains and negative drugs such as CUR enable the 
retention of the drugs in CHI based nanoparticles, providing a prolonged drug release profile 85. 
These advantages of alginate and CHI make them promising candidates as nanocarriers for drug 
delivery 82. Various alginate or CHI based nanoparticles have been developed for the delivery of 
CUR 32, 90, 210-212. For example, Anitha et al. prepared CUR loaded dextran sulphate–chitosan 
nanoparticles and reported that a controlled and pH dependent CUR release over a period of one 
week was achieved 90. Maghsoudi et al. prepared CUR loaded alginate nanoparticles and reported 
that the CUR loaded nanoparticles exhibited enhanced solubility in aqueous solution comparing 
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with free CUR 211.  
Exploiting the electrostatic properties of alginate and CHI, a layer-by-layer coating method can be 
employed to prepare multilayer alginate / CHI polyelectrolyte nanoparticles, this method allows 
simple engineering of desired surface features for specific applications 213. By altering the number of 
layers deposited it is possible to control the drug release rate 214-216. In addition, the use of a 
noncovalent route for multilayer formation provides a low-cost simple fabrication method 217. Due to 
these promising advantages of the layer-by-layer method, it has been widely used to fabricate 
nanoparticles for drug delivery 213-216, 218. Apart from engineering the size and surface properties of 
nanocarriers, incorporation of magnetic nanoparticles (MNPs) enables the targeted delivery of the 
drug carriers to tumour sites with the help of an external magnetic field 48. Targeted delivery by 
MNPs has been reported as a promising strategy for cancer therapy, which possesses the 
advantages including visualize the targeting process, rapid targeting and accumulation of drug 
carriers at the tumour sites by magnetic forces, the MNPs can be heated in a magnetic field to 
promote the drug release and avoid complex chemical modifications of targeting ligands on the 
surface of nanoparticles 48. The toxicity of MNPs has been reported very low and can be well 
tolerated in the human body 219. The small size and large surface area of MNPs makes them 
suitable for polyelectrolyte layer-by-layer deposition. Therefore, deposition of alginate / CHI 
multilayers onto MNPs will enable targeted delivery and controlled released of drugs. In this paper, 
magnetic alginate / CHI layer-by-layer nanoparticles (MACPs) were fabricated for the delivery of 
CUR into MDA-MB-231 breast cancer cells and HDF (Human dermal fibroblasts).   
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4.2. Results and discussion 
4.2.1. Characterization of magnetic alginate / chitosan layer-by-layer 
nanoparticles and curcumin loaded magnetic alginate / chitosan 
nanoparticles  
4.2.1.1. Zeta potential, size and FTIR spectra  
As shown in Fig. 4.1, magnetic alginate particles (MAPs) were prepared via the self-assembly of 
alginate on the surface of MNPs in Ca2+ solution (Stage 1). Following this the formation of MACPs 
(Stage 2) was done by coating MAPs with CHI. Stage 3: Particles with 1 layer of alginate and CHI 
were then coated with sodium alginate (SA) again. Stage 2 and 3 were then repeated consecutively 
for the desired number of layers.  
  
Fig. 4.1.Schematic illustration for the preparation of MAPs and MACPs. MAPs were fabricated by coating 
cross-linked alginate on MNPs using Ca2+ as the cross-linker. MACPs were prepared by alternatively 
depositing CHI and SA on MAPs based on the electrostatic interaction between the two biopolymers. The 
alternative coating was repeated until MACPs with desired number of layers were obtained (Stage 2 and 3). 
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MAPs and MACPs with different number of layers were dispersed in DI water (pH was adjusted to 7 
using HCl and NaOH) or sodium phosphate solution (pH 7) and their zeta potential was analysed 
using DLS. As shown in Fig. 4.2a, the zeta potential of MAPs in water was -21.4 mV which was 
similar to the results of Ca2+ crosslinked alginate particles reported in previous literature 220-221. The 
zeta potential of free SA in water has been reported as -50 mV 222. The reason for the increased 
zeta potential of MAPs is due to the crosslinking with Ca2+. The carboxyl groups contribute to the 
anionic charge of the alginate polymer 223. Upon gelation, the negatively charged carboxyl groups 
from the G blocks in the alginate chains interact with Ca2+ ions and form an ‘egg-box’-like structure, 
reducing the density of free carboxyl groups as well as the anionic charges 223. Therefore, an 
increase of zeta potential was observed for MAPs. After deposition of the first layer (CHI), zeta 
potential of particles become positive (+19.2 mV) followed by a reduction to -44.8 mV after the 
negatively charged alginate polymer was coated as the second layer. Positive charges ranging from 
+12.1 to +19.2 mV were observed when CHI was coated as the outermost layer and negative 
charges ranging from -43 to -48.5 mV were associated with alginate coatings as the outermost layer. 
An oscillation of zeta potential was observed with the alternative deposition of SA and CHI, 
indicating the successful coating of negative alginate and positive chitosan polymers.  
The zeta potential of particles in sodium phosphate solution (10 mM) is also shown in Fig. 4.2a and 
exhibited a similar oscillation behaviour between coatings. However, negative surface charges were 
observed for MACPs (layer number: 1, 3, 5, 7, 9) with CHI outermost layer. This phenomenon is due 
to the adsorption of the phosphate anions onto the surface of the chitosan polymers. Phosphates 
contain small multivalent anions and therefore, tend to interact or complex with cationic amino 
groups on CHI surfaces via electrostatic interactions 88. Therefore, the phosphate anions adsorbed 
onto CHI layers provided the negative charges on the particles. Similar phenomena have been 
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reported previously: for example, Swain et al. analysed the zeta potential of CHI in both 1 and 10 
mM NaCl and found that the zeta potential value decreased as the ionic strength of NaCl increased 
84. The authors suggested the reduced surface charge was attributed to the adsorption of anions 
onto the surface of CHI polymers 84. Further to this, Acevedo et al. analysed the zeta potential of 
CHI (5 mg/ml) in water and NaCl solution (0.2 M) and reported the zeta potential value of +72 mV in 
water and +33 mV in NaCl solution 224. It was suggested that this reduced absolute zeta potential 
value was governed by a compression of the electrical double layer due to the electrostatic 
interactions with Cl− in the solvent 224. As shown in Fig. 4.2a, the zeta potential of MACPs with 
alginate as the outermost layer analysed in phosphate solution exhibited similar values as they 
were in water, which is in agreement with previously reported data 222. On the other hand, MAPs 
exhibited a more negative zeta potential values in phosphate solution (-36 mV) compared to water 
(-21.4 mV). This is due to reaction between Ca2+ and phosphate ions to form insoluble calcium 
phosphate, which leads to the loss of Ca2+ and the increased density of free carboxyl groups thus 
resulting in an overall increased negative charge. The zeta potential behaviour of drug carriers can 
be utilized to control the drug loading and release processes. For example, cationic drug carriers 
such as CHI nanoparticles can be used to improve the loading of anionic drug molecules and 
prolong their release time based on electrostatic interactions between positive CHI and negative 
drug molecules 85. In the case of MACPs, different numbers of polymer layers with different zeta 
potentials can potentially be used to improve drug loading.  
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Fig. 4.2. Zeta potential (a) and average diameter (b) of MACPs and CMACPs as a function of the number of 
coated layers. Zeta potential of particles was analysed in water (pH 7) and phosphate solution (10 mM, pH 7). 
Particle size was analysed in phosphate solution. Oscillations of zeta potential and average diameter were 
observed with the alternate coating of SA and CHI. (c) FTIR spectra of MAPs and MACPs with the number 
of deposited polymer layers from 1 to 5. The results are shown in mean ± SD, n ≥ 3.  
The average diameter of MACPs was analysed by NTA as shown in Fig. 4.2b, where the diameter 
of MAPs was found to be 141 nm which increased to 167 nm after the coating of the first CHI layer. 
The size of particles increased gradually as the coating of SA / CHI bilayers and reached 187 nm for 
9 layers. The growth in particle size is attributed to the deposition of SA and CHI polymers. Size 
differences were observed depending on the outermost polymer of MACPs were also observed. For 
example, after coating with the second layer (SA), the average diameter of MACPs decreased from 
167 (3 layers) to 128 nm (4 layers) and then increased to 174 nm after the deposition of CHI as the 
fifth polymer layer. This leaves a mean size difference of ~40 nm between CHI and SA and is most 
likely due to the different surface charges of the particles. For MACPs with CHI as the outermost 
layer, the zeta potential ranged from -20 to -25.1 mV in phosphate buffer solutions while the zeta 
potential for alginate as the outermost layer ranged from -47 to -55.2 mV. Particles with absolute 
zeta potential values higher than 30 mV can be considered stable in solution 225. Therefore, MACPs 
with alginate outermost layers were very stable in solution due to their sufficient surface charges. 
On the other hand, particles with CHI as the outermost layer were less stable and more likely to 
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aggregate in aqueous solutions forming larger particles.  
The zeta potential of CMACPs in sodium phosphate solution at pH 7 is shown in Fig. 4.2a.  A 
significant change in surface charge was observed for particles after CUR loading. The zeta 
potential of free CUR sodium phosphate solution was -31.1 mV. In contrast, the zeta potentials of 
MAPs and MACPs with the outermost layer of alginate (layer number: 0, 2, 4, 6, 8, 10) was within 
the range from -36 to -55.5 mV (Fig. 4.2a) while the zeta potentials of the particles with CHI 
outermost layer (layer number: 1, 3, 5, 7, 9) were around -20 mV. After CUR loading, the zeta 
potentials of CMACPs were found between -28.7 and -34.2 mV suggesting the CUR was 
encapsulated in or adsorbed onto the particles, reducing the difference of the zeta potentials 
between MACPs with alginate and CHI outermost layers. Increased particle sizes (between 172 – 
199 nm) were observed for CMACPs (Fig. 4.2b) compared to MACPs (122 – 187 nm), which can be 
attributed to the loading of CUR. For CMACPs with the same outermost polymer (SA or CHI), the 
average diameter of particles increased as the number of layers increased due to the fact that larger 
polymer matrixes encapsulate more CUR molecules. Slightly larger particle size was observed for 
CMACPs with the outermost polymer of CHI compared to those with SA as the outermost layer. This 
is because CMACPs with SA outermost layers exhibited a higher absolute value of zeta potential 
than those with CHI. They possessed a greater electrostatic repulsion therefore maintained smaller 
aggregation sizes. It is worth to note that the size of CMACPs were also within the range of 50 - 200 
nm. For the efficient delivery of drug to the cancer sites, the optimum size range of drug carriers is 
generally accepted  to be about 50 - 200 nm 38. Particles with size less than 50 nm will easily 
extravasate through the discontinuous endothelium of live, spleen and bone marrow therefore are 
less likely to accumulated at the desired sites. On the other hand, particle with diameter larger than 
200 nm may not pass through the porous vasculature to reach the tumour site and will be eliminated 
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more easily by the immune system 38. Therefore, CMACPs are within the optimum size range for 
the delivery of drugs to the tumour sites. 
The chemical compositions and interactions between different polymer layers were analysed by 
FTIR as shown in Fig. 4.2c. For SA, the peaks at 1590 cm-1 and 1402 cm-1 were characteristic for 
the asymmetric stretching and symmetric stretching of -COOH groups respectively 226-227. In MAPs 
and MACPs with the number of layers (1, 2, 3, 4 and 5), these two peaks moved towards higher 
wavenumbers, indicating the formation of Ca2+-alginate ionic cross-linking 228. This is because of the 
changes in charge density, atom radius and atom weight of the cations 228-229. For CHI, the peak at 
1538 cm-1 was characteristic of -NH2 bonds 230. The presence of CHI in the MACPs was also 
confirmed by comparing the curves of MAPs (0 L) and MACPs (1 L - 5 L). The broad characteristic 
adsorption at 3329 cm-1 for -OH groups in MAPs shifted to a lower frequency for MACPs (1-5 L), 
demonstrating the superposition of amine N-H stretching in CHI and -OH groups of alginate and 
CHI 230-231. The peak at 1596 cm-1 in MAPs became broader, and moved to a lower frequency for 
MACPs, which can be attributed to  the overlapped -NH2 stretching from chitosan and -COOH 
stretching from alginate 232. These results confirmed that CHI and alginate chains were successfully 
incorporated into the MACPs.  
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4.2.1.2. Morphology characterization  
The morphology of MAPs and MACPs were also analysed by AFM and TEM (Fig. 4.3).  
 
Fig. 4.3. AFM and TEM images of MAPs (a and g) and MACPs with the layer number of 1 (b and h), 4 (c 
and i), 5 (d and j), 8 (e and k) and 9 (f and l). Smaller particles were observed for MACPs with SA as the 
outermost layer.  
a. b. c. 
d. e. f. 
g. i. 
j. k. l. 
h. 
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As shown in Fig. 4.3a, particles with diameters around 140 nm were observed and exhibited rough 
surfaces, which were attributed to the aggregation of small solid MAPs. This finding is consistent 
with the MAPs size analysed by NTA. After alternate coating with SA and CHI, the resultant MACPs 
(Fig. 4.3b-f) exhibited more spherical shapes and smooth surfaces, which further confirmed the 
successful coating of both polymers. For MACPs, inter-digitation among the adjacent CHI / SA 
layers were constructed due to the existence of surface charges 233. Therefore, after the removal of 
excess polymers, stable films were formed by soft polymers of CHI and SA leading to the smooth 
surface of MACPs.  
Moreover, AFM images showed that MACPs with SA as the outermost layer (Fig. 4.3c&e) exhibited 
smaller sizes, which is consistent with the NTA measurements and confirmed the result that MACPs 
with SA as the outermost layer are more stable due to their lower zeta potential values. 
Characterisation of MAPs and MACPs via TEM revealed magnetic cores (dark areas) surrounded 
by polymer shells, which were the chitosan and alginate layers as shown in Fig. 4.3g-l. The inset in 
Fig. 4.3l is an enlarged section of the image clearly showing magnetic core particles and the 
surrounding CHI / SA layers. 
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Fig. 4.4. AFM images of CUR loaded MAPs (a) and CUR loaded MACPs (CMACPs) with the layer number 
of 1 (b), 4 (c), 5 (d), 8 (e) and 9 (f).  
AFM was also used to investigate the morphology of CMACPs. As shown in Fig. 4.4a, the diameter 
of CUR loaded MAPs was ~150 nm and increased as the polymer layer increased, reaching a 
maximum of ~200 nm for 9 layers (Fig. 4.4f), which is in agreement with the average size analysed 
by NTA as shown in Fig. 4.2b. However, rougher surface morphology was observed for CMACPs 
compared to MACPs as shown in Fig. 4.3. CUR is known as a highly hydrophobic drug 234-236 and 
the loading of CUR into MACPs increased the hydrophobicity of the particles. This meant that the 
particles rapidly dehydrated during AFM analysis and exhibited rough surfaces, indicating the 
successful loading of CUR into MACPs. 
a. b. c. 
d. e. f. 
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4.2.2. Loading and release of curcumin 
CUR loaded MACPs were prepared by dispersing MACPs in CUR water / DMSO solution and 
incubated under stirring for 24 h. The addition of DMSO increases CUR solubility and its 
permeability into MACPs. The volume ratio of water : DMSO was 3:2, resulting in a homogeneous 
CUR solution (3 mg/ml) without sedimentation during the 24 h of incubation.237 Fig. 4.5a clearly 
demonstrates that the resulting CMACPs can be collected with a Neodymium magnet while CUR 
itself in the bulk solution was not affected by the magnetic field. Therefore, MACPs can be 
potentially used for targeted delivery of CUR via external magnetic fields.  
 
Fig. 4.5. CMACPs were prepared by suspending MACPs in CUR water / DMSO solution  and incubating 
for 24 h under stirring. The resulting CMACPs can be rapidly collected by a Neodymium magnet (pull force 
25 Kg, 25.4 mm diameter x 30 mm thick) within 1 min (a). The free CUR in solution on the other hand was 
not affected by the magnetic force (b).  
Encapsulation efficiency results reveal that 49.2% of CUR was loaded into CMAPs and the 
encapsulation efficiency increased to 67.5% with increasing number of layers of CHI and SA (see 
Fig. 4.6a). For particles with the same type of polymer (CHI or SA) on the outermost surface an 
increased trend of encapsulation efficiency was observed with the increase of the layer number. 
However, as illustrated in Fig. 4.6a, a higher encapsulation efficiency of CUR was observed for 
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CMACPs with CHI as the outermost layer (layer number: 1, 3, 5, 7 and 9) compared to that use SA 
as the outermost layer (layer number: 2, 4, 6, 8, 10). The most feasible explanation for this is the 
different surface charges between the particle outermost layers. As illustrated in Fig. 4.2a, CHI 
layers exhibited positive surface charges in water while SA layers exhibited negative surface 
charges. Therefore, the negatively charged CUR molecules are adsorbed on the surface of the CHI 
layer more readily, facilitating a more efficient and faster encapsulation into polymer matrix. On the 
other hand, SA layer was negatively charged in water, and thus CUR molecules were less readily to 
interact with the negatively charged particle surface and enter the polymer matrixes due to the 
electrostatic repulsion. Moreover, larger amount of CUR molecules was expected on the surface of 
CHI layer, which also led to a higher encapsulation efficiency. The same hypothesis can be used to 
explain the loading efficiency of CMAPs and CMACPs. As shown in Fig. 4.6b, a higher loading 
efficiency of CUR was observed for MACPs with CHI as the outermost layer to those that 
possessed SA as the outermost layer. Higher loading efficiencies from 54.8% to 64.9% were 
achieved for CMAPs and CMACPs compared to many previously reported CUR loaded CHI and 
alginate based particles 26, 29, 90 with loading efficiencies from 2.7 % to 48 %, suggesting CMAPs and 
CMACPs possess great potential loading CUR into nanoparticles for drug delivery applications. 
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Fig. 4.6. The drug loading and release profiles of the CMAPs and CMACPs  are affected by the type of 
outermost polymers and the number of layers. Encapsulation efficiency of CMAPs and CMACPs (a).  
Curcumin loading efficiency into CMAPs and CMACPs (b). Curcumin release profile of CMAPs and 
CMACPs with different layers (1, 4, 5, 8, 9) of deposited polymers (c). Curcumin release profile of CMAPs 
and CMACPs (layer number: 1&4) in PBS buffer at pH 7.4 and pH 5.6 (d). The results are shown in mean ± 
SD, n =3. 
In order to investigate the release profile of CMAPs and CMACPs, 5 mg of particles were dispersed 
in 5 ml PBS buffer at pH 7.4 and incubated at 37 °C under shaking (200 rpm). The particles were 
collected with strong Neodymium magnets at predetermined time intervals and the CUR 
concentration in supernatants were analysed to obtain the accumulative CUR release profile. As 
shown in Fig. 4.6c, for all particles, CUR was released more rapidly within the first two days and 
then released slower but at more sustained rates in PBS for up to 2 weeks. The faster release in the 
first two days is most likely due to the loss of weakly adsorbed CUR molecules on the surface of the 
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particles or in the polymer matrix close to particle surfaces. The sustained CUR release after the 
first two days was then dependent on the diffusion of CUR molecules through the polymer matrixes 
into the bulk PBS solution, thus exhibiting a slower and more sustained release pattern. No 
significant burst release was observed during the whole release process most likely due to the poor 
solubility of hydrophobic CUR into aqueous solution 27, 238. During drug release, CMACPs with CHI 
as the outermost layer exhibited a faster CUR release rate than CMAPs and CMACPs with SA as 
the outermost layer (CMACPs 4 and 8). As mentioned previously in Section 4.2.1.1, CHI is 
positively charged in water but negatively in phosphate solution due to the adsorption of negative 
phosphate ions 88, therefore more negatively charged CUR molecules are adsorbed onto the CHI 
layer surface when these particles were dispersed in CUR water / DMSO solution than on alginate, 
as illustrated in Fig. 4.6a&b. When CMACPs with layer numbers of 1, 5 and 9 were dispersed in 
PBS, phosphate ions competed with CUR molecules for the free amino groups on the CHI chains, 
which in turn facilitated the loss of CUR molecules from the surface of CHI and the diffusion of CUR 
from inner polymer matrix (where CUR concentration is higher) to the particle surface. Thus, faster 
CUR release rates were observed for CMACPs with layer numbers of 1, 5 and 9. On the other hand, 
CMAPs and CMACPs with layer numbers of 4 and 8, where alginate was deposited as the 
outermost layer, showed similar negative surface charges in water and phosphate solutions, less 
CUR molecules were adsorbed during the loading process and thus the drug release rate was not 
promoted in phosphate solutions. For particles with the same type of polymer, reduced release 
rates were observed as the number of layers increased (release rate: CMACPs 1 > CMACPs 5 > 
CMACPs 9, CMAPs > CMACPs 4 > CMACPs 8). By increasing the number of polymer layers, it 
was more difficult for the innermost CUR to permeate out. This is in agreement with previously 
reported data 214-216, where Chai et al. fabricated doxorubicin loaded poly (lactic-co-glycolic acid) 
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nanoparticles and layer-by-layer coated the particles with CHI and alginate 214. After comparing the 
drug release rates of uncoated and polymer coated particles, the authors found that with the CHI / 
SA coating the initial drug burst release was reduced from 55.1% to 5.8% and the overall drug 
release rate was also reduced. In another example, Haidar et al. prepared bovine serum albumin 
loaded liposomes and layer-by-layer coated them with CHI / SA 215. The polymer coated liposomes 
showed a reduced albumin release rate to the uncoated ones. Further to this, Zhou et al. developed 
polyethyleneimine coated PLGA nanoparticles and reported that the drug release rate reduced with 
increasing layers 216. 
In order to investigate the drug release profile of CMAPs and CMACPs at different pH, CMAPs, 
CMACPs with 1 and 4 layers were dispersed in PBS at pH 7.4 and pH 5.6. As illustrated in Fig. 4.6d, 
the release pattern of CUR from particles at pH 5.6 was similar to those at pH 7.4 but slightly slower. 
In 14 days, about 23%, 41% and 17% of CUR were released from CMAPs, CMACPs 1 and 
CMACPs 4 at pH 7.4 respectively while about 20%, 37% and 13% of CUR were released at pH 5.6. 
This data are in agreement with previously published work by Martins et al. who investigated the 
release profiles of CUR from N-trimethyl chitosan / alginate complexes at pH 7.4 and pH 1.2 and 
reported that 80% of CUR was released at pH 7.4 within the first hour while only 22% of CUR was 
released at pH 1.2 212. The pH dependent release pattern can be attributed to the altered surface 
charge and hydrophobicity of polymers at different pH values.  
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Fig. 4.7. Zeta potential of MAPs, MACPs 1 and MACPs 4 in sodium phosphate solution as a function of pH. 
Zeta potential of all the particles decreased as the increase of pH. MACPs 1 (with CHI outermost layer) 
exhibited higher zeta potential than MAPs and MACPs 4, which possess cross-linked or adsorbed SA as the 
outermost layer. MACPs 1&4 represent MACPs that possess 1&4 layers of polymers coated on MNPs 
respectively. The results are shown in mean ± SD, n = 3.  
The zeta potential of MAPs, MACPs 1 and MACPs 4 in sodium phosphate solution as a function of 
pH is shown in Fig. 4.7. MACP1 showed positive surface charge under acidic conditions, (at pH ~ 
4.3 and lower) this can be explained by the protonation of amino groups from the surface CHI on the 
particles 80. In neutral and alkaline conditions the surface charge of MACPs 1 turned negative and 
an increased negative zeta potential was observed with increasing pH, due to the loss of protons 
from the amino groups 32. Therefore, as the pH value of the solution decreased from pH 7.4 to 5.6, 
more amino groups were protonated and the consequential increased electrostatic interaction 
between CHI and CUR made the dissociation of CUR molecules more difficult. MAPs and MACPs 
with SA as the outermost layer showed negative surface charges from pH 3 to 9, however became 
less negative as the decrease of pH, which was due to the protonation of the carboxyl groups of 
alginate 224. Thus, the less negatively charged alginate surface also made the dissociation of CUR 
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molecules more difficult. Moreover, as the decrease in pH, more protonated carboxyl groups from 
the alginate surfaces formed hydrogen bonds with each other, reducing the solubility of alginate 
layers 93. Therefore, alginate surfaces became more hydrophobic with decreasing pH, which in turn 
restricted the release of CUR. 
4.2.3. Cellular uptake assays 
4.2.3.1. CUR uptake assay by flow cytometry 
 
Fig. 4.8. Cellular uptake analysis of CUR in MDA-MB-231 cells (a) and HDF cells (b)  after incubation 
with CMAPs, CMACPs 1&4 and free CUR for 24 h. The CUR uptake was analysed by flow cytometry. The 
dosages of CUR in particles were equivalent to the amounts of free CUR used. CMACPs 1&4 represent 
CMACPs that possess 1&4 layers of polymers coated on MNPs respectively. The results are shown in mean 
± SD, n = 3. The statistical significance is expressed as *** p < 0.001, ** p < 0.01, * p <0.05. 
To investigate the cellular uptake kinetics of CMAPs and CMACPs, MDA-MB-231 breast cancer 
cells and HDF cells were incubated with free CUR and particles containing equivalent amount of 
CUR for 24 h. The resulting cells were analysed by flow cytometry to determine the cellular uptake 
of CUR by different cells. As shown in Fig. 4.8a, it is evident that the percentage of MDA-MB-231 
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cells that have taken up CUR was CUR dose dependent. Significant higher uptake efficiency was 
observed for MDA-MB-231 cells treated with CMAPs and CMACPs than those treated with free 
CUR, indicating that the nanoparticles can facilitate the CUR uptake. This is in agreement with 
previously reported data3, 31, 239-241 that CUR uptake through nanoformulations is at least 2-3-fold 
greater than free CUR 3. Here, at a CUR concentration of 1.5 μg/ml, an uptake efficiency of 31.2%, 
39.6% and 24.2% was observed for MDA-MB-231 cells treated with CMAPs, CMACPs 1&4 
respectively, which is 3-6-fold higher than the uptake efficiency of cells treated with free CUR. The 
increased CUR uptake of CMAPs can be attributed to the fact that the CUR loaded nanoparticles 
were more easily taken up by cells via endocytosis due to their smaller size (172 - 199 nm), while 
highly hydrophobic CUR was insoluble in aqueous solution forming larger aggregates, which are 
more difficult to be internalized by cells 240, 242. The order of uptake efficiency of free CUR and CUR 
loaded particles was CMACPs 1 > CMAPs >CMACPs 4 > free CUR. Particles with CHI as the 
outermost layers exhibited the highest uptake efficiency (39.6 %). This result is in agreement with 
the work by  Zhou et al. who compared the uptake efficiency of CHI / alginate coated poly 
(lactide-co-glycolide) nanoparticles and observed the uptake efficiency of particles with CHI as the 
outermost layers was higher than those having alginate as the outermost layer 213. The promoted 
CUR uptake by the CHI surface is because of the protonated amino groups, which interact with the 
negatively charged cell surfaces and promote the accumulation of CMACPs 1 onto the surface of 
MDA-MB-231 cells. Fig. 4.8b shows the CUR uptake efficiency for HDF cells after being treated with 
free CUR and CUR loaded particles. HDF cells exhibited a similar uptake pattern but an overall 
much lower CUR uptake efficiency compared to MDA-MB-231 cells, suggesting CMAPs and 
CMACPs tend to target cancer cells rather than normal cells. This agrees with many previously 
published reports that the cancer cells normally exhibit higher uptake efficiencies of CUR and CUR 
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loaded nanoparticles than normal cells 29, 243-245. Cancer cells possess a higher metabolic activity to 
normal cells and their surfaces tend to overexpress various receptors which in turn increase the 
available binding sites promoting the uptake of particles and drugs 246-248.  
4.2.3.2. Magnetically targeted delivery assay 
To investigate the potential of CMAPs and CMACPs for magnetically targeted delivery of CUR, free 
CUR, CMAPs and CMACPs were incubated with MDA-MB-231 cells in glass bottom dishes. A 
Neodymium magnet was placed under the target area of the dish to allow for the accumulation of 
magnetic nanoparticles within the selected area. Taking advantage of the auto-fluorescent property 
of CUR, the confocal fluorescence images show the cellular uptake of CUR in and out of the target 
(magnet-affected) areas. The overall fluorescent intensity of MDA-MB-231 cells within the target 
areas that were treated with free CUR (Fig. 4.9a) was lower than cells treated with CUR loaded 
nanoparticles (Fig. 4.9c, e&g), suggesting CMAPs and CMACPs have enhanced the uptake of CUR. 
This result is consistent with the uptake efficiency shown in Fig. 4.8. No obvious difference on 
fluorescent intensities was observed between Fig. 4.9a and b, showing that the free CUR uptake is 
not affected by the presence of magnetic forces. 
In contrast, cells treated with CMAPs (Fig. 4.9c), CMACPs 1 (Fig. 4.9e) and CMACPs 4 (Fig. 4.9g) 
within the magnet-affected area showed a significant increase of fluorescent intensity compared to 
the cells treated with same particles but outside of the target areas (Fig. 4.9d, f&h). The enhanced 
CUR uptake in the target areas was attributed to the accumulation of CUR loaded magnetic 
nanoparticles to the target areas driven by the magnetic force. On the other hand, the local 
concentration of CUR loaded magnetic particles outside the target areas was significantly lower, 
thus showing much lower fluorescent intensities. This result clearly shows that CMAPs and 
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CMACPs have the potential for targeted drug delivery.  
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Fig. 4.9. Confocal fluorescence microscopy images of MDA-MB-231 cells incubated with free CUR (a&b), 
CMAPs (c&d), CMACPs 1 (e&f) and CMACPs 4 (g&h). CMACPs 1&4 represent CMACPs that possess 1 
& 4 layers of polymers coated on MNPs respectively. CUR loaded particles contained equivalent amount of 
drug as free CUR (5 μg/ml). Cell nucleus and cytoskeleton were stained with DAPI (blue) and Alexa Fluor 
568 Phalloidin (red). M+ denotes the images taken within the magnet affected target area and M- denotes the 
images taken outside of the magnet-affected area.  
4.2.4. In vitro cytotoxicity assay 
 
Fig. 4.10. The in vitro MTT assay suggested CMACPs exhibited significantly higher cytotoxicitytowards 
MDA-MB-231 breast cancer cells than HDF cells. MDA-MB-231 cells (a&b) and HDF cells (c&d) were 
treated with free CUR, CMACPs 1, CMACPs 4 and blank MACPs 1, MACPs 4 for 48 h. CMACPs 1&4 (or 
MACPs 1&4) represent CMACPs (or MACPs) that possess 1&4 layers of polymers, respectively. The 
amounts of CUR in CUR loaded nanoparticles were equivalent to the amounts of free CUR (0.5 - 30 μg/ml), 
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respectively. The results are shown in mean ± SD, n ≥ 3. The statistical significance is expressed as *** p < 
0.001, ** p < 0.01, * p <0.05. 
In order to investigate the cytotoxicity of CMACPs towards cancer and normal cells, MDA-MB-231 
breast cancer cells and HDF cells were incubated with free CUR, CMACPs 1, CMACPs 4 and blank 
MACPs for 48 h. The in vitro MTT assay results are shown in Fig. 4.10. It can be observed in Fig. 
4.10a&b that both free CUR and CMACPs exhibited increased cytotoxicity towards MDA-MB-231 
cells with increasing CUR concentration, which was in agreement with previously reported data that 
indicated CUR possesses dose dependent cytotoxicity towards cancer cells 3, 31, 239-241. Both 
CMACPs 1 and 4 showed enhanced cytotoxicity towards MDA-MB-231 cells compared to free CUR, 
which can be attributed to the enhanced uptake of CMACPs. As discussed in Section 4.2.3.1, the 
uptake efficiency of MDA-MB-231 cells treated with CMACPs was 3-6-fold greater than those 
treated with free CUR. It is expected that the sustained release of CUR from internalized CMACPs 
maintained a high CUR concentration within the MDA-MB-231 cells, thus leading to lower viability of 
cells. CMACPs 1 were observed to exhibit higher cytotoxicity towards MDA-MB-231 cells than 
CMACPs 4, which was due to their higher CUR release rate (Fig. 4.6c) and uptake efficiency (Fig. 
4.8a). As shown in Fig. 4.10c&d, the viability of HDF normal cells after treatment with free CUR and 
CMACPs was reduced at higher CUR concentrations (> 15 μg/ml) but significantly less affected at 
CUR concentrations less than 15 μg/ml compared to MDA-MB-231 cancer cells. This is in 
agreement with many previously studies, indicating CUR shows specific cytotoxicity towards cancer 
cells 29, 243-245. One of the major accepted theories is that cancer cells possess lower glutathione 
levels than normal cells due to their reprogrammed metabolic pathways 30. Depletion of glutathione, 
which is important for the sensitivity of cells to CUR can lead to the enhancement of CUR sensitivity 
of cancer cells 30, 243, 249. In addition, most cancer cells, but not normal cells, express constitutively 
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active NF-KB that mediates their survival. CUR can suppress NF-KB regulated gene products, thus 
suppressing the proliferation of cancer cells 243, 250. High viabilities were observed for both 
MDA-MB-231 cells and HDF cells after they were treated with blank MACPs, demonstrating that 
MACPs are non-toxic towards these cells. 
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4.3. Conclusions 
MACPs were prepared by a layer-by-layer coating of CHI and SA onto the surface of Fe3O4 
nanoparticles. The successful coating of CHI and SA was confirmed by the zeta potential and FTIR 
spectral measurements of the particles. Incorporation of CUR was confirmed by a change in surface 
charge and morphology of CMACPs. Meanwhile, the mean diameter of CMACPs was lower than 
200 nm and within the optimum size range for drug delivery applications. In vitro drug release 
profiles illustrated the sustained release of CUR from CMACPs and indicated that it was possible to 
control the release rate by altering the outermost polymer (CHI or SA) as well as by changing the 
number of layers. More polymer layers resulted in a slower CUR drug release profile, where CHI as 
the outermost layer showed a faster CUR release. Confocal fluorescence microscopic images 
confirmed the successful internalization of CUR into MDA-MB-231 breast cancer cells and indicated 
that rapid and targeted delivery of CUR could be achieved by CMACPs in the presence of an 
external magnetic field. FACS analysis indicated the CMACPs mediated uptake of CUR by 
MDA-MB-231 cells was 3-6-fold greater than that of free CUR. MDA-MB-231 cancer cells showed a 
significantly higher uptake efficiency of CUR than that of HDF normal cells after being treated with 
CMACPs. The MTT assay indicated that CMACPs exhibited a significantly higher cytotoxicity 
towards MDA-MB-231 cancer cells than towards HDF cells. In summary, the sustained release 
profiles, enhanced uptake efficiency and strong cytotoxicity to cancer cells as well as the potential 
for targeted delivery make MACPs a promising candidate for anti-cancer drug delivery. 
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5. Magnetic-Silk Fibroin / Polyethyleneimine Core-Shell 
Nanoparticles as Potential Carriers for Cell Transfection 
Abstract 
Gene therapy is a promising method for disease treatment. Despite the recent advances, the lack of 
efficient methods significantly hindered the applications. Polyethyleneimine (PEI) is one of the most 
efficient non-viral gene delivery agents due to its high cationic charge density and is capable of 
condensing DNA into nano-sized complexes. However, the high cytotoxicity and lack of targeting 
have limited its application. In this paper, silk fibroin (SF), a biocompatible and biodegradable 
protein, was selected to fabricate magnetic-silk / PEI core-shell nanoparticles (MSPPs) and silk-PEI 
nanoparticles (SPPs) for the delivery of c-myc antisense oligodeoxynucleotides (ODNs) into 
MDA-MB-231 breast cancer cells. The size and zeta potential of the particles can be controlled by 
altering the amount of silk fibroin in particle synthesis. Lower surface charges and reduced 
cytotoxicity were observed for MSPPs compared to PEI coated magnetic nanoparticles (MPPs). 
Both MSPPs and SPPs were capable of delivering the ODNs into MDA-MB-231 cells and 
significantly inhibiting the cell growth. With magnetofection, high ODN uptake efficiencies (over 70%) 
were achieved within 20 min using MSPPs as carriers, exhibiting a significantly enhanced uptake 
effect compared to the same carriers via non-magnetofection. Both MSPPs and SPPs exhibited 
higher inhibition effect against MDA-MB-231 breast cancer cells compared to human dermal 
fibroblast (HDF). Targeted ODN delivery can be achieved using MSPPs with the help of a magnet, 
making them promising candidates for gene therapy applications. 
Keywords: Silk, PEI, Magnetic nanoparticles, Gene delivery, Cancer, ODN, Magnetofection 
Abbreviations: 
PEI: polyethyleneimine 
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SF: silk fibroin 
ODN: c-myc antisense oligodeoxynucleotide 
HDF: human dermal fibroblasts 
MNPs: magnetic nanoparticles 
SPPs: silk-PEI nanoparticles 
MPPs: PEI coated magnetic nanoparticles 
SPPs: silk-PEI nanoparticles 
MSPPs: magnetic-silk / PEI core-shell nanoparticles 
SPP50: SPPs with 50% of SF 
MSPP50: MSPPs with 50% of SF 
SPP75: SPPs with 75% of SF 
MSPP75: MSPPs with 75% of SF 
SPP90: SPPs with 90% of SF 
MSPP90: MSPPs with 90% of SF 
5.1. Introduction 
Gene therapy has shown great potential in curing many diseases originating from defective genes 67, 
251-252. Efficient gene therapy demands the delivery of genes to the cell nucleus or cytoplasm 
replacing or silencing the defective genes 252. However, genes will have to overcome several 
intracellular barriers such as cell membrane and endosome membrane 253-254. Therefore, carriers 
are needed for the efficient gene delivery 252.  
Many gene delivery vectors have been developed including viral and non-viral delivery systems 143, 
255-256. Although viral carriers are known as the most effective gene vectors 252, the application of 
viral gene delivery systems has been limited by their potential toxicity and immunogenicity concerns 
41, 255, 257. Therefore, non-viral gene delivery systems have been explored as an alternative tool for 
gene therapy 41, 67, 252. Apart from non-immunogenicity, non-viral gene delivery systems also 
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possess advantages including low cost, ease of fabrication and modification and high in vivo 
stability 67. A variety of non-viral vectors have been developed 41, 258-259. One of the most efficient 
non-viral transfection agents is polyethyleneimine (PEI) 41-45. Once mixed with DNA, PEI will 
condense them into nanoparticles that are suitable for the internalization into cells through 
endocytosis 143, 252. In addition, PEI is able to destabilize the endosomal membrane by the ‘proton 
sponge effect’ to protect DNA against degradation and facilitate the release of DNA from 
endosomes into the cytoplasm 42-43, 143, 252. Despite its high transfection efficiency, the applications of 
PEI are still limited by its inherent problems such as high cytotoxicity and lack of targeting 44. 
Attempts have been made to improve targeting by developing PEI coated magnetic nanoparticles 
(MPPs) for gene delivery through a process called ‘magnetofection’ 67, 252, in which an external 
magnetic field was used to enhance the transfection efficiencies by rapidly concentrating the 
magnetic vectors on the cell surface 142. Moreover, it has been reported that the cytotoxicity of 
MPPs vectors is lower than that of PEI 143. 
However, MPPs still possess significant cytotoxic effects and lead to a decreased viability to many 
cell lines 260-263. Hoskins et al. investigated this by exposing MCF-7, SH-SY5Y and U937 cells to 100 
µg/ml of MPPs and observed cell viability decreased to 50%, 70% and 80% respectively after a 24 h 
incubation 260. When the incubation time was increased to 7 days, the cell viability of these cells 
decreased to 20%, 10% and 30% respectively 260. To further reduce the cytotoxicity of MPPs, 
various approaches have been investigated 260-263. Hoskins et al. reported that MCF-7, SH-SY5Y 
and U937 cells exhibited viabilities over 95% after 24 h incubating with MPPs-PEG and around 90% 
after 7 days 260. Strojan et al. fabricated glutathione modified PEI coated magnetic nanoparticles 
(GSH NPs) by adding glutathione during nanoparticle synthesis and reported that glutathione 
reduced 30% cytotoxic effects to CHO cells and decreased observed oxidative stress response 
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compared to standard formulation 262. Another example is Du et al., where PEI was modified with 
lactose at different lactosylation degrees (6.8% and 11.7%) and then coated onto magnetic 
nanoparticles (MNPs) 263. The resulting lactose modified MPPs showed reduced cytotoxicity to 
RAW 264.7 cells compared with unmodified MPPs.   
In this work, silk fibroin (SF) was used to reduce the cytotoxicity of MPPs. SF protein from cocoons 
of Bombyx mori is an FDA approved, natural derived material which has been widely used to form 
various biomaterials including gels, sponges and films for different medical applications such as 
drug delivery, tissue engineering and wound dressing 64. Excellent biocompatibility 180, tuneable 
biodegradability 181 and easy processing 64 of SF has made it a promising biomaterial for drug and 
gene delivery systems 64, 140, 264-266. For example , Antheraea pernyi silk fibroin (ASF) / PEI / DNA 
ternary complexes were fabricated by Liu et al. by coating PEI / DNA complexes with ASF 140. Cell 
viabilities of HEK 293 and HCT 116 cells incubated for 24 h with ASF / PEI / DNA complexes were 
over 10% higher than those incubated with PEI / DNA complexes. Yu et al. synthesized cationized 
ASF (CASF) nanoparticles by modifying ASF with spermine and suggested that CASF is a potential 
gene delivery carrier with the advantages of low cytotoxicity and biocompatibility 264. Although with 
great potential to be modified or in combination with other transfection agents to form gene delivery 
carriers with reduced cytotoxicity, the fabrication of magnetic-silk fibroin / polyethyleneimine 
core-shell nanoparticles (MSPPs) and their performance as gene delivery carriers through 
magnetofection has not yet been sufficiently reported. Therefore, in this study, MSPPs and 
SF-polyethyleneimine nanoparticles (SPPs) were fabricated for the transfection of c-myc antisense 
oligodeoxynucleotides (ODNs) into MDA-MB-231 breast cancer cells and human dermal fibroblast 
(HDF) cells. The size and zeta potential of SPPs and MSPPs with different SF percentages were 
analysed with DLS. The morphologies of naked ODNs, MPPs, SPPs, MSPPs, and MSPP-ODN 
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complexes were determined by AFM. TEM was also used to analyse the morphologies of MPPs, 
SPPs and MSPPs. Toxicities of MSPPs with different SF percentages and the growth inhibition 
effects using their ODN complexes against MDA-MB-231 cells and HDF cells were determined 
through the MTT assay. The uptake profiles of SPP-ODN and MSPP-ODN complexes were 
investigated by flow cytometry and the localizations of ODNs in MDA-MB-231 cells after treatment 
with naked ODNs and different transfection complexes were determined by confocal microscopy.  
5.2. Results and discussion 
5.2.1. Characterization of silk-polyethyleneimine and magnetic-silk / 
polyethyleneimine nanoparticles 
5.2.1.1. Size, zeta potential and morphology of silk-polyethyleneimine nanoparticles 
SF forms aggregates in salt solutions such as sodium phosphate. The salting out associated 
aggregation of SF in high concentration salt solutions is resulted from the adsorption of counterions 
to the SF peptides, leading to reduction of their net surface charge. During salting-out, micellar-like 
structures are first formed due to the enhancement of hydrophobic interactions between SF protein 
chains, followed by further aggregation and finally particulate SF globules 79.   
The addition of salt can also be used to induce the aggregation of PEI 267. PEI is a cationic polymer 
with hydrophobic backbones and closely-spaced amines making PEI a highly positive charged 
polymer 267. The intra-chain repulsion caused by the amine groups on the same chain keeps the 
polymer from aggregating 267. If the charge on the hydrophobic chains is insufficient e.g. by 
increasing salt concentration, the hydrophobic backbones will collapse and form aggregates 268-269. 
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Adding a small amount of salt into PEI solution increases the PEI solubility and prevents its 
aggregations due to the fact that the attractive interactions between hydrophobic chains are 
counterbalanced by the electrostatic repulsion at low ionic strength 267. The solubility of PEI reached 
a maximum at 150 mM NaCl concentration. Further increasing the salt concentration resulted in the 
salt screening the electrostatic repulsion therefore decreasing intra-chain repulsion, resulting in PEI 
aggregations via hydrophobic interactions 267.  
 
Fig. 5.1. Effect of SF (5 mg/ml) / PEI (5 mg/ml) ratio on the size and zeta potential of SPPs (a),  and 
MSPPs (b). The increase of SF ratio resulted in the increase of the size of SPPs and MSPPs also resulted in 
the decrease of the zeta potential of SPPs and MSPPs. The results are shown in mean ± SD, n ≥ 3. 
PEI particles were prepared by adding PEI solution (5 mg/ml) into sodium phosphate solution (pH 8) 
at an ionic strength of 1.25 M. After an incubation time of 6 h at room temperature aggregations 
were observed. The particle size was then analysed using DLS as shown in Fig. 5.1a, which 
indicated that the mean diameter of PEI particles was 85 nm. The addition of different ratios of SF 
into the PEI solution resulted in the increasing of particle size (Fig. 5.1a). Increasing the SF ratio 
leads to accelerated aggregation of SPPs as well as increased particle yield. When using a mixture 
containing 90% SF (5 mg/ml) and 10% PEI (5 mg/ml), the SPP aggregation was almost immediate 
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upon added into salt solution. As shown in Fig. 5.1a, the size of SPPs increased from 107 to 436 nm 
when increasing SF content from 10% to 90%.    
This phenomenon is most likely due to the inter-chain attractions between positively charged PEI 
chains and negatively charged SF chains. When a small amount of SF was added to PEI solutions, 
negative SF chains were attracted and electrostatically bound to positive PEI chains, weakening the 
charge density of PEI chains. With increasing amount of SF, PEI chains are neutralized and the 
backbone charge becomes insufficient to keep the molecules extended after the mixtures being 
added into salt solutions 267. This is supported by the SPPs zeta potential measurements (shown in 
Fig. 5.1a), where the zeta potential decreases with increasing SF content. A zeta potential of +50 
mV was observed for PEI particles. The strong electrostatic repulsions among PEI particles 
therefore resulted in small particles (85 nm). An addition of 10% SF in PEI solution reduced the zeta 
potential of SPPs to +45 mV, increasing the mean particle diameter to 107 nm (Fig. 5.1a). Further 
increasing the SF content lead to lower zeta potentials and larger SPP particle sizes, where 90% SF 
resulted in a zeta potential of +32 mV. At 95% SF content the SPPs were almost electroneutral (zeta 
potential: +7.3 mV) and large amount of precipitate was observed. The changes of particle size and 
zeta potential dependent on the SF/PEI ratio give strong indication of hybrid particle formation. 
In addition to DLS analysis the size and morphology of SPPs were also determined using AFM. As 
shown in Fig. 5.2a-f, spherical particles with smooth surfaces were observed. PEI-only particles (Fig. 
5.2a) showed diameters ~ 80 nm, in contrast to SPPs, where particles with diameters of over 400 
nm were observed for the highest SF content (90%, Fig. 5.2f), which is consistent with the particle 
sizes given by DLS. 
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Fig. 5.2. AFM and TEM images of the PEI particles (a&g) and SPPs (b-j)  with different amount of SF: 10% 
(b), 25% (c), 50% (d&h), 75% (e&i) and 90% (f&j).  
In order to reveal the structures of the SPPs, TEM analysis was undertaken. Fig. 5.2g shows small 
b. a. c. 
d. e. f. 
g. h. 
i. j. 
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PEI particles with diameters of ~30 nm aggregated to form larger particles (~100 nm). The 
structures of SPPs with 50%, 75% and 90% of SF are shown in Fig. 5.2h, i&j, respectively. 
Increasing diameters of ~200 nm, ~260 nm and ~400 nm were observed from these particles 
respectively, which was consistent with the results given by DLS and AFM. SPPs with 90% of SF 
(SPP90) shown in Fig. 5.2j clearly show that the particle formed by the aggregation of many smaller 
particles with diameters ranging from 30 – 100 nm, confirming that increasing SF content resulted in 
lower surface charge and lead to particle aggregation. 
5.2.1.2. Size, zeta potential and morphology of magnetic-silk / polyethyleneimine 
nanoparticles 
MPPs were fabricated by adding PEI (5 mg/ml) to MNPs suspended in sodium phosphate solution. 
Zeta potential measurements of MNPs revealed negative charges of -12.6 mV and high positive 
charges of +48.5 mV for MPPs (see Fig. 5.1b), which is in agreement with previously published data 
by Wang et al. and Zhao et al. 143,270. These measurements strongly suggest that negatively 
charged MNPs have been coated with positive PEI molecules, where PEI molecules would first 
adsorb onto the surface of MNPs through electrostatic attractions and Van der Waals forces 271 
before aggregating and entirely covering the MNP in the final salt solutions 267. DLS measurements 
of MNPs revealed average particle diameters of 109 nm and increased to 131 nm after PEI coating 
(see Fig. 5.1b) , similar to the results reported by Ota et al. previously. 61  
The particles were further characterised by AFM to investigate the morphologies of MNPs, MPPs 
and MSPPs. AFM revealed that the MNPs exhibited rough surfaces with particle sizes ranging 
between 10 - 30 nm (Fig. 5.3a), while MPPs were ~ 110 nm in diameter as well as showing 
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smoother surface morphologies (Fig. 5.3b) supporting the conclusion that the MNP surfaces were 
coated with PEI polymers. It has to be note that MNPs size measurements with AFM show a 
significantly smaller particle size than DLS measurement, which is most likely due to MNP particle 
aggregation occurred in the suspensions during the DLS measurement. Further to this, TEM 
analysis of MPPs reveals a core-shell type structure as shown in Fig. 5.3g. The core phase 
consisted of Fe3O4 nanoparticles, represented by the dark regions of the image compared to the 
shells structure of PEI polymer in grey. TEM images clearly revealed (Fig. 5.3g) that smaller MPPs 
of the order of ~20 nm aggregated and formed larger aggregated particles of ~100 nm in diameter, 
consistent with the AFM data. Steitz et al. previously reported that coating with PEI polymers can 
bridge two or more particles together and form larger aggregations through Van der Waals forces 272. 
On the other hand, MPPs are strongly positively charged due to a large amount of amine groups in 
PEI, resulting in strong electrostatic repulsions among MPPs and thus enabling better dispersion of 
these particles. The balance between Van der Waals forces and electrostatic repulsions resulted in 
such aggregate size of MPPs. Any change to the electrostatic charges on the surface of the 
polymer will however change this and lead to different aggregate sizes.   
Further to the synthesis of MPPs above, the PEI (5 mg/ml) was mixed with different ratios of SF (5 
mg/ml) before they were coated onto MNPs. The resulting particle sizes and zeta potentials 
measured (by DLS) were also shown in Fig. 5.1b. The mixed polymer shell of SF and PEI resulted 
in different surface charges and aggregation sizes of MSPPs. The addition of SF reduced the zeta 
potential of MSPPs compared with MPPs indicating negatively charged SF and positively charged 
PEI had co-aggregated on the surface of MNPs. By altering the SF / PEI ratio both particle size and 
zeta potential are controllable as shown in Fig. 5.1b. For example, 10% of SF in PEI resulted in a 
decreased zeta potential of +42 mV and an increased average diameter of 167 nm for MSPPs. 
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Increasing the SF to 90% resulted in even lower zeta potential (+29 mV) and larger particle 
diameter (319 nm). The increased aggregate size can be explained by reduced electrostatic 
repulsions between particles, causing MSPPs to form aggregates through Van der Waals forces 
more readily. At a SF content of 95% a near neutral sample was produced having a zeta potential of 
+5.7 mV with almost all the particles precipitated out, suggesting there was insufficient electrostatic 
repulsion between particles to keep them from aggregating. 
 148 
 
 
Fig. 5.3. AFM and TEM images of the MNPs (a), MPPs (b&g), and MSPPs  with 10% (c), 50% (d&h), 75% 
(e&i), and 90% (f&j) of SF.  
d. 
b. a. c. 
e. f. 
g. h. 
i. j. 
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Morphologies of MSPPs were analyzed by AFM and TEM. As shown in Fig. 5.3c-f, the size of 
MSPPs increased with increasing SF content, which is consistent with measurements by DLS. 
Spherical and smooth particles were observed, suggesting the surfaces of MNPs were coated by 
SF-PEI polymer mixture.  Similar to SPPs, AFM images for MSPPs revealed smaller particles 
around larger ones (Fig. 5.3c-f), suggesting the large particles were aggregations of small MSPPs. 
TEM images of MSPPs (at 50%, 75% and 90%) shown in Fig. 5.3h-j reveal that MSPPs were 
formed by multiple Fe3O4 cores covered by SF-PEI shells. The inset in Fig. 5.3j is an enlarged 
section of the image (red boxed area). Altering the SF content did not show any effect on the size of 
the smaller core-shell magnetic nanoparticles which is consistently around 20 nm in diameter. 
However, the increased SF percentage resulted in larger aggregates supporting the previous AFM 
and DLS data. 
Finally, it is worth to note that positive zeta potential in excess of +28 mV were observed even at low 
PEI contents (10%) in SF-PEI mixtures. This is due to the high charge density of PEI 273. This 
phenomenon is favorable for the fabrication of low toxic cationic carriers for DNA transfection. DNA 
is able to adsorb onto the carrier surface via electrostatic attractions between negatively charged 
DNA and positively charged carriers, demonstrating the importance of positive charges for DNA 
adsorption 67, 272. PEI, as a highly positively charged polymer is known to be efficient for DNA 
transfection 61, 143, 274, however it is also known to have a high toxicity to cells 275 making PEI 
generally less favorable. Therefore, a PEI-based transfection carrier system with reduced PEI 
content but sufficient positive charges is beneficial for transferring DNAs into nucleus while 
exhibiting much lower toxicity during transfection.  
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5.2.2. Interaction of magnetic-silk fibroin / polyethyleneimine nanoparticles with 
c-myc antisense oligodeoxynucleotides.  
For successful gene transfection, vectors are normally required to condense the DNAs 111-112, 276. 
The mechanisms by which DNAs form complexes with transfection vectors has been reported and 
morphologies of the complexes have been previously characterized by AFM 270, 276-278. Single 
stranded ODNs are different to plasmids and long linear DNAs in both molecular weight and 
topography which may result in different pathways in condensation and forming complexes 279. It is 
therefore important to investigate the formation of MSPP-ODN complexes and their assembly 
mechanism. The morphologies of naked ODNs and the resulting complexes were characterized by 
AFM. For the naked ODN, spherical structures with diameters ranging from 30 to 40 nm and heights 
of 2 to 3 nm were observed (see Fig. 5.4a), similar to the ODN self-assembled structures previously 
reported by Costa et al. 280. Nanowires were also observed, similar to the ones reported by Maria et 
al., having lengths of over 500 nm and heights ranging from 2.5 to 3.5 nm (Fig. 5.4a) 281. As the 
ODNs used in this research are small, single stranded human c-myc antisense ODNs made up of 
only 15 nucleotides (15-nt) in length (5'-AAC-GTT-GAG-GGG-CAT-3'), the large scaled 
nanostructure is most likely to be a higher order structure of self-assembled ODNs 279-282. The 
self-assembly of guanine (G) rich ODNs into higher order nanostructures such as networks and 
long nanowires 281 has been previously reported 279-282. 
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Fig. 5.4. AFM images of ODNs (a) and MSPP90-ODN complexes (b&c).  The AFM images were taken 
after 30 s (b) and 30 min (c) condensation respectively. MSPP90/ODN mass ratio was fixed at 12:1. (d) 
Schematic representation of the possible mechanism for the condensation of ODNs by MSPPs. ODN chains 
wrapped around the MSPPs to form spheroidal MSPP-ODN complexes. 
Fig. 5.4b&c are representative AFM images of ODNs that were mixed under gentle shaking with 
MSPPs with 90% SF (MSPP90) at a mass ratio of 12:1 after 30 s (b) and 30 min (c) condensation 
time. After 30 s, condensed nanofibre-like structures and aggregations of nanowires were observed 
(Fig. 5.4b), similar to the nanostructures reported by Chen et al. who mixed a 21-nt ODN with 
polypropyleneimine (PPI) followed by a 10 min condensation time 279. The height of the condensed 
nanofibres ranged from 2 to 15 nm and diameters of aggregated structures from 80 to 300 nm, 
suggesting that the free ODNs were condensed by MSPP90. After 30 min condensation time 
well-condensed MSPP-ODN complexes were formed as shown in Fig. 5.4c, consisting of 
spheroidal particles with diameters of 100 nm to 350 nm and heights ranging from 10 to 20 nm. 
a. b. c. 
d. 
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Rough surfaces morphologies were observed as a result of ODN complexation on particle surfaces. 
Comparable spheroidal condensates have also been reported in previous studies 276-280. Chen et al. 
analysed the condensates of PPI-ODN, and also observed similar nanofibre-shaped structures at 
the early stages of condensation and spheroidal particles after long term condensation time 279. 
They suggested that the PPI was acting like a ‘zipper’ in the condensation process. At early stage, 
the PPI electrostatically interacted with phosphate groups from different ODN chains and helped 
form end-to-end ODN chains. Dendrimers were then formed by those ODN chains and further 
aggregated to form nanofibres. Finally the nanofibres interacted with each other and formed 
spheroidal particles by multi-molecular associations 279. In our case, ODNs were most likely 
interacted with MSPPs through electrostatic attractions and produce nanofibres during the initial 
condensation process Fig. 5.4d. At longer condensation times (30 min), ODN chains tightly 
wrapped around the MSPPs and spheroidal MSPP-ODN complexes were formed. 
5.2.3. In vitro cytotoxicity assay 
5.2.3.1. Inhibition effect of MSPPs and MSPPs-ODN on MDA-MB-231 cells 
C-myc oncogene is an evolutionarily conserved gene expressed in many cell types including 
MDA-MB-231 breast cancer cells 283. It is often associated with many essential biological processes 
including cell growth, proliferation, transformation and apoptosis 283-284. Disordered expression of 
the c-myc gene will lead to malignant transformation of cells 283. Down regulation of the expression 
of c-myc by exposing the cancer cells to c-myc antisense ODN has been reported to be able to 
inhibit cancer cell growth 283, 285-286. c-myc antisense ODN is a single-stranded nucleic acid designed 
to specifically bind to the target mRNA through the Watson-Crick base pair complementarity to form 
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duplexes 287. This therefore blocks the translation of the target gene or alternatively, the RNase H 
can be activated to digest the specific mRNA 251, 287. High efficacy was expected for antisense ODNs 
due to its specificity to target mRNAs 287. However, the application of c-myc antisense ODNs is 
limited by major hurdles such as poor delivery and cellular uptake of naked ODNs into the target 
tissue along with their poor in vivo stability 251, 287-289. The inherent hydrophilicity and negative 
charges of ODNs make it very difficult for them to approach and cross the hydrophobic cell 
membranes into the cytoplasm or nucleus 290. Therefore, large amount of ODNs and long incubation 
times are needed for the observation of any cell growth inhibition effect when the cells are treated 
with naked ODN 285-286, 291. For example, in the study by Watson et al., 4 days were required for the 
observation of initial inhibition for MDA-MB-231 cells exposed to 5 μM c-myc antisense ODN 286. In 
another study, Leonetti et al. added 100 μg/ml c-myc antisense ODN to M14 cells and only after 4 
days growth inhibition could be observed 285. These illustrate the need for efficient transfection 
systems for antisense gene delivery to solve the above problems 292. Various vectors have 
previously been developed and have shown improved inhibition efficiency at lower ODN dosages 
251, 292-294. However, it is clear that vast improvement is still needed for efficient systems. 
In this study, the MTT assay was used to assess the growth inhibition effect of MSPP-ODN and 
SPP-ODN complexes on MDA-MB-231 and HDF cells. MDA-MB-231 cells were incubated with 
MPP-ODN, MSPP (50-90% SF)-ODN and SPP90-ODN in serum-free medium for 4 h with naked 
ODN as a negative control. The MPPs, MSPPs and SPPs were mixed with ODN at the selected 
mass ratios (1:1 - 100:1). The viabilities of cells after treatment with MSPPs, SPPs and MPPs with 
the dosages equivalent to the amounts used in complexes were also investigated. The ODN 
dosage was fixed at the final concentration of 1 μg/ml. All cells were exposed to a magnetic field for 
the first 20 minutes of the initial 4 h incubation. After the initial incubation, the cells were washed 
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with PBS buffer before incubated in complete mediums to a final duration of 3 days.  
 
Fig. 5.5. MTT assay of MDA-MB-231 cells after 72 h incubation  with different complexes: MPP-ODN (a), 
MSPP50-ODN (b), MSPP75-ODN (c), SPP90 and MSPP90-ODN (d) at different particle/ODN mass ratios 
(1:1-100:1). Complexes were added into serum-free MDA-MB-231 cell cultures for a 4 h transfection time, 
after which cells were washed with PBS and further incubated in complete mediums to a final duration of 3 
days. At the beginning of transfection, the cells were exposed to a magnetic field for 20 min. Corresponding 
carriers and ODN-only with the amounts equivalent to the dosages in complexes were also used as controls 
to investigate their toxicity to MDA-MD-231 cells. The dosages of ODN were fixed at 1 μg/ml. The results 
are shown in mean ± SD, n = 4. The statistical significance is expressed as ***p < 0.001, **p < 0.01, *p 
<0.05. 
MTT assay in Fig. 5.5 shows that negligible growth inhibition was observed for MDA-MB-231 cells 
treated with naked ODNs (red columns), indicating that efficient transfection was difficult for naked 
ODNs due to its poor cellular uptake. The increased dosage of MPPs and MSPPs resulted in 
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decreased viability of MDA-MB-231 cells treated with those particles, indicating that MPPs and 
MSPPs possessed dose-dependent cytotoxicity to MDA-MB-231 cells. The introduction of SF into 
the MPPs system reduced the cytotoxicity of MPPs. Cells treated with MSPPs (at 50%-90% SF) 
showed a higher viability than those treated with MPPs (blue columns). At the same MSPP dose, 
cell viability increased with the increase of SF content in MSPPs. For example, at the concentration 
of 50 μg/ml (associated with the MSPP / ODN ratio of 50:1) MDA-MB-231 cells showed the 
viabilities of 58%, 73%, 77% and 85% after treated with MPPs, and MSPPs with 50%, 75% and 90% 
of SF respectively, giving strong evidence that the addition of SF resulted in reduced cytotoxicity of 
MSPPs. 
By increasing mass ratios of MPPs / ODN from 1:1 to 100:1 a clear decrease in cell viability can be 
seen (Fig. 5.5a), where at lower mass ratios from 1:1 to 25:1, cells treated with MPP-ODN exhibited 
a significantly lower viability to those treated with MPPs. All these lowered cell viabilities indicate 
that c-myc antisense ODN induced cell growth inhibition occurred. However, at higher ratios (50:1 to 
100:1) no significant difference on viabilities were observed between cells treated with MPPs and 
MPP-ODN, suggests the inhibited cell growth mainly have been a result from the cytotoxicity of 
MPPs and shield the effect of ODNs. On the other hand, as shown in Fig. 5.5b-d, on average a ~20% 
lower viability for MDA-MB-231 cells treated with MSPPs (50% - 90% SF)-ODN to those treated 
with MSPPs (50 - 90% SF) was observed at the whole ratio range investigated, indicating that 
MSPPs with SF are capable of transfecting the ODN for the inhibition of cell growth. It is important 
to note that even at higher particle / ODN ratios (50:1 to 100:1) cells showed significantly lower 
viabilities after treated with MSPP-ODN to those treated with MSPPs (50 - 90% SF), suggesting the 
reduced viabilities were mainly attributed to the function of ODN instead of toxicity of MSPPs. These 
results indicated that with reduced cytotoxicity compared to MPPs, MSPPs (50 - 90% SF) allow the 
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efficient growth inhibition performance of ODN without bringing significant cytotoxicity of carriers to 
cells, which is desired in gene transfection. 
Since MSPP90 showed the lowest toxicity among these particles (MSPPs 50 - 90% SF) and is still 
capable of transfecting the c-myc antisense ODN to cause the growth inhibition of MDA-MB-231 
cells, it is of interest to investigate its optimum mass ratio with ODN to achieve high inhibition effect 
from ODN while avoid additional cytotoxicity from MSPP90. As shown in Fig. 5.5d, when the MSPP 
/ ODN mass ratio was 1:1, MSPP90-ODN exhibited the lower inhibition effect than other 
MSPP-ODN complexes, which was most likely because insufficient MSPP90 were provided at such 
mass ratio. Increased mass ratio from 1:1 to 12:1 resulted in decreased viabilities for cells treated 
with MSPP90-ODN, suggesting the growth inhibition effect was enhanced with increased amount of 
MSPPs in MSPP90-ODN, which is most likely because the increased surface charge of complexes 
making them easier to interact with cell membrane and to be internalized. Further increase the 
MSPP90 / ODN ratio from 12:1 to 25:1, the viability of cells treated with MSPP90 decreased from 96% 
to 90% without observation of significant viability decrease for cells treated with MSPP90-ODN 
complexes (only from 72% to 70%), indicated that the optimum MSPP90-ODN mass ratio for 
MDA-MB-231 cell growth inhibition at the ODN concentration of 1 μg/ml was 12:1. The further 
decreased viability of cells treated with MSPP90-ODN complexes at the mass ratio of 25:1 or over 
was most likely resulted from the cytotoxicity of MSPPs (90% SF) at higher dosages. MDA-MB-231 
cells treated with SPP90 and SPP90-ODN showed similar growth inhibition pattern to those treated 
with MSPP90 and MSPP90-ODN, suggesting both particles possess similar cytotoxicity towards 
MDA-MB-231 cells. On the other hand, lower viability was observed for cells treated with 
MSPP90-ODN complexes than those treated with SPP90-ODN complexes due to the higher 
transfection effect of MSPP90-ODN via magnetofection. 
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It has been previously reported that the significant cytotoxicity of PEI is thought to be mainly due to 
its high amine content that resulted in high cationic charge density 45, 136-138. Free PEI molecules can 
interact with negatively charged substances such as serum proteins or even red blood cells to form 
aggregates which can adhere to tissue surfaces to cause significant cell damage 136. PEI is also 
able to interact with proteins inside the cell and therefore interfere with critical intracellular 
processes 44. Many studies have been conducted to reduce the surface charge of PEI based 
transfection systems in order to minimum their cytotoxicity. For example, Xue et al. encapsulated 
hexadecylated-PEI polymers / siRNA complexes in negative charged lipids, the resulting surface 
charge of encapsulated complexes were decreased as well as the cytotoxicity compared with 
un-encapsulated PEI complexes 139. In another example, Liu et al. designed ASF / PEI / DNA 
ternary complexes by coating negatively charged Antheraea pernyi silk fibroin (ASF) onto the 
surface of PEI / DNA complexes 140. The coating of ASF resulted in fewer surface charges and 
therefore a higher viability of cells transfected with ASF / PEI / DNA ternary complexes was 
observed compared to those transfected by PEI / DNA complexes. Therefore, it is believed that the 
reduced cytotoxicity of MSPPs is resulted from the reduced surface charge on these particles. 
5.2.3.2. Concentration effect of particles/complexes on MDA-MB-231 and HDF cells 
To investigate the inhibition effect of MSPP-ODN and SPP-ODN at different concentrations on 
cancer and normal cells, MDA-MB-231 breast cancer cells and HDF cells were selected and treated 
with SPP90-ODN, MSPP90-ODN, SPP90 and MSPP90.  MSPP90 was chosen because it 
exhibited the lowest cytotoxicity among MSPPs with different SF percentages and SPP90 was 
chosen as a comparison with MSPP90.  MSPP90 and SPP90 were mixed with ODN at a mass 
 158 
 
ratio of 12:1 before incubating with MDA-MB-231 or HDF cells in serum-free medium for 4 h. The 
final concentrations of ODN in medium were 1, 5 and 10 μg/ml. A magnet plate was placed below 
the cells for the first 20 min of the initial incubation. After initial incubation, the cells were washed 
twice with PBS to remove any un-internalized particles and complexes before incubation in 
complete medium for a final duration of 3 days. 
 
Fig. 5.6. Concentration effect of particles and complexes on breast cancer cells (a) and HDF cells (b). 
MDA-MB-231 cells and HDF cells were incubated with ODNs, MSPP90, SPP90, MSPP90-ODN, 
SPP90-ODN complexes for 4 h in serum-free medium. At the beginning, the cells were treated with an 
external magnetic field for 20 min. After the initial transfection, cells were washed twice with PBS buffer 
and incubated in complete medium for a final duration of 3 days. [C]= 12 μg/ml MSPP90 or SPP90 + 1 
μg/ml ODN. Equivalent amount of ODN, MSPP90 and SPP90 were used as controls. The results are shown 
in mean ± SD, n = 4. The statistical significance is expressed as ***p < 0.001, **p < 0.01, *p <0.05. 
As shown in Fig. 5.6, naked ODN showed negligible growth inhibition effect on both MDA-MB-231 
cells and HDF cells at the concentrations studied, suggesting that the growth inhibition effect of 
naked ODN was poor to both cells due to its poor internalization properties 251, 287-289. Increasing the 
concentration of MSPP90 in medium resulted in decreased viability of MDA-MB-231 cells, which is 
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consistent with the previous results obtained (see Fig. 5.5). This result strongly suggests that 
MSPP90 possess dose-dependent cytotoxicity to MDA-MB-231 cancer cells. After treatment with 
MSPP90-ODN, MDA-MB-231 cells showed significantly lower viability than cells treated with naked 
ODN and MSPP90, suggesting the complexation with MSPP90 have improved the effect of ODN. 
With the increased concentration from 1 [C] to 5 [C] and 10 [C], the viability of MDA-MB-231 cells 
treated with MSPP90-ODN decreased from 72% to 57% and 41%. While cells treated with MSPP90 
showed the decreased viability of 96%, 82% and 75%. This result suggested that enhanced growth 
inhibition effect of MSPP90-ODN can be achieved without brought massive cytotoxicity from 
MSPP90.  
Fig. 5.6b presents the viability of HDF cells after being treated with naked ODNs, MSPP90, SPP90 
and their ODN complexes. It was observed that HDF cells were less affected by the particles and 
complexes. For example, after both cell lines being treated with MSPP90-ODN at the same 
concentration (1[C]), HDF cells exhibited a higher viability (92%) compared to that of MDA-MB-231 
cells (72%). This is because cancer cells tend to exhibit a higher uptake efficiency on particles than 
normal cells due to the higher metabolic activity of cancer cells 246 which leads to the 
overexpression of receptors on their surface and increases the available binding sites 246-248. 
Furthermore, it has been reported that differences in cell-cell interactions between normal cells and 
cancer cells can also lead to faster particle uptake for cancer cells than normal cells 295. Gal et al. 
compared the internalization of polystyrene particle by MDA-MB-231 breast cancer cells and 
MCF-10A benign cells 295. The result indicates that cancer cells uniformly internalize particles in 
larger amounts and higher rate. However, only cells at the edge of a growing colony of benign cells 
are able to internalize particles 295. This is due to the fact that normal, adherent cells maintain tight 
cell-cell connections 296. In contrast, cell-cell and cell-matrix interactions are less important for 
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cancer cells, and particles can thus be internalized into any cell on the plate at high rates 295-296. 
Therefore, it is fair to assume that MDA-MB-231 cancer cells have taken up more MSPP90-ODN 
compared to HDF cells, which in turn resulted in the lower viability of MDA-MB-231 cells. 
5.2.4. Cellular uptake assays 
5.2.4.1. Uptake efficiency of MSPPs-ODN and SPP 90-ODN on MDA-MB-231 cells 
Slow vector accumulation and the consequently low vector concentration at target tissues is 
reported as a strong obstacle for efficient gene transfection 297. By applying a magnetic field, 
magnetic vectors combining DNAs can be rapidly concentrated onto the surface of target cells 
which can facilitate complex internalization and enhance transfection efficiency 298. This is also 
known as ‘magnetofection’. For non-magnetofection vectors, their improved accumulation property 
is based on their designed biophysical properties or coupling with targeting ligands. However, in 
practice, it has been proved insufficient for rapid accumulation on target sites 298. On the other hand, 
magnetofection has shown outstanding performance in rapid transfection 150-151, 298. Mykhaylyk et al. 
compared the transfection performance of magnetic and non-magnetic complexes exposed to a 
magnetic field 150. Their data showed that the magnetic complexes concentrated onto the surface of 
target cells and consequently transfection efficiencies were found 1,000-fold higher than the 
transfections conducted with non-magnetic vectors 150. Krötz et al. reported that magnetic 
particle-ODN complexes can be transfected into 84% of human umbilical vein endothelial cells 
within 15 min followed by nuclear accumulation within 2 h when exposed to a magnetic field, this is 
substantially faster than non-magnetofection methods which generally require 24 h incubation times 
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151.   
To investigate the uptake kinetics of MPPs, MSPPs and SPPs, particles were complexed with 
fluorescence labelled ODNs at the mass ratio of 12:1. The final concentration of ODN was fixed at 1 
μg/ml. As shown in Fig. 5.7a, with magnetofection, 81% of MDA-MB-231 cells incubated with 
MPP-ODN took up the complexes with 5 min of incubation which was followed by washing the cells 
in PBS buffer twice and 24 h of further cultivation in complete medium. This resulted in a 3.1-fold 
increase of transfected cells (26%) compared with cells treated with MPP-ODN without a magnetic 
field. This result supports previous studies which claimed that magnetofection can provide 
outstanding performance in rapid transfection compared to non-magnetofection 150-151, 298. 
Increasing magnetofection time to 20 min only resulted in an increased uptake efficiency of 1% 
(from 81% to 82%).  A further increase to the magnetofection to 24 h finally resulted in the highest 
uptake efficiency of 88%. This indicated that most MPP-ODN complexes were concentrated on the 
surface of cells within the first 5 min and extending the magnetofection time did not significantly 
increase the uptake efficiency. The result is in agreement with Krötz et al. who found no further 
enhancement of uptake efficiency was observed when extending the magnetofection time from 15 
min to 24 h for human umbilical vein endothelial cells incubated with p22phox-antisens ODN 
containing magnetic vectors 151. For the MMDA-MB-231 cells treated with MPP-ODN without the 
presence of a magnetic field, increasing transfection time to 20 min increased the uptake efficiency 
by 43% (from 26% to 69%) and a further increase to a total of 86% was seen for a transfection time 
of 24 h, showing a clear time-dependent uptake of complexes through non-magnetofection. This is 
because the association of vectors to cells is a diffusion-limited process 257, which means only a 
fraction of the vectors interacted with the cells within the initial short period (e.g. 5 min). Therefore, 
increasing transfection time resulted in the significantly increase of complex uptake 257.  
 162 
 
After 4 h transfection with Oligofectamine-ODN, ODNs uptake was found 58.3% for cells exposed to 
the magnetic field and 57.5% for cells not exposed to a magnetic field. This clearly suggests that 
Oligofectamine-ODN transfection is not dependent on the presence of a magnetic field. The uptake 
efficiency of Oligofectamine-ODN transfection for 4 h is lower than that of MPP-ODN for 4 h without 
the presence of magnetic field, which is most likely due to the faster sedimentation of MPP-ODN 
than Oligofectamine-ODN due to the higher mass density of MPPs. No significant differences were 
observed for cells incubated with naked ODNs with or without the presence of a magnetic field. Only 
1.5% (M-) and 1.6% (M+) of total cells took up ODNs after being incubated with naked ODNs for 5 
min. The uptake efficiency appeared to be time dependent. However, only 12.3% (M-) and 11.6% 
(M+) uptake efficiencies were achieved when cells were incubated with naked ODNs for 24 h, 
indicating that it is difficult for naked ODNs to be taken up by MDA-MB-231 cells. This explains the 
negligible reduction of cell viability by naked ODNs.  
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Fig. 5.7. Cellular uptake assays of MPP-ODN (a), MSPP50-ODN (b),  MSPP75-ODN (c), MSPP90-ODN 
and SPP90-ODN (d) complexes for MDA-MB-231 cells. The cell only and ODNs only are used as negative 
controls with the dosages of ODNs equivalent to the amount of ODNs used for the complexes. 
Oligofectamine-ODN was used as a positive control with a standard transfection time of 4 h. The 
concentration of the complexes was fixed at 12 μg/ml MSPPs +1 μg/ml ODN.  Cells were incubated with 
ODN or transfection complexes for 5 min - 24 h with (M+) or without (M-) the presence of an external 
magnetic field for a maximum of 20 min. The cells were then washed twice with PBS buffer and cultured 
with complete medium until to a final duration of 24 h before the FACS analysis. The results are shown in 
mean ± SD, n ≥ 3. The statistical significance is expressed as ***p < 0.001, **p < 0.01, *p <0.05. 
The uptake kinetics of MSPP-ODN complexes are represented in Fig. 5.7b-d. With the short 
magnetofection time of 5 min, 67%, 64% and 59% uptake efficiencies were achieved by 
MDA-MB-231 cells treated with MSPP50, MSPP75 and MSPP90, respectively. In contrast, only 
23%, 18% and 17% of ODN uptake efficiencies were achieved for cells treated with MSPP50, 
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MSPP75 and MSPP90 through non-magnetofection. This clearly shows that the uptake efficiency of 
ODNs can be drastically improved by MSPPs trough magnetofection. 
On the other hand, Fig. 5.7b-d revealed that the uptake efficiencies of MSPP-ODN were time 
dependent. With increased magnetofection time from 5 min to 20 min, significant increased uptake 
efficiencies (over 70%) were observed for MDA-MB-231 cells treated with MSPP-ODN with 
magnetic field, suggesting longer transfection period helped the accumulation of MSPP-ODN to the 
cell surface. The difference in uptake over time is presumably due to the difference in positive 
surface charges between MPPs and MSPPs. As mentioned in Section 5.2.1.2, the positive charges 
of MSPPs are lower than those of MPPs due to the introduction of negatively charged SF and with 
the increase of SF the surface charges of MSPPs decrease further. The decreased surface charges 
of MSPPs may be the reason why longer magnetofection times are required for MSPP-ODN to 
achieve uptake efficiencies similar to MPP-ODN. However, it is worth to note that considerably high 
uptake efficiency (over 70% compare to ~ 80% final uptake efficiency at 24 h) was achieved by 
MSPP-ODN within 20 min. Moreover, when the magnetofection time was increased from 20 min to 
1 h, only limited improvements on uptake efficiency were observed for cells treated with 
MSPP-ODN through magnetofection. The uptake efficiencies obtained from MSPP-ODN were 
about the same level as those obtained from MPP-ODN, which required 24 h for MSPP-ODN 
through non-magnetofection. Extended magnetofection time from 1 h to 24 h did not lead to a 
significant increase of uptake efficiency for MSPP-ODN, suggesting almost all MSPP-ODN had 
been taken up by cells within 1 h of magnetofection. This result demonstrated that MSPPs were 
capable of rapidly delivering ODNs into cells through magnetofection. 
The uptake kinetics of MDA-MB-231 cells treated with SPP90-ODN was also investigated. As 
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shown in Fig. 5.7d. No significant differences on uptake efficiencies were observed for cells 
incubated with SPP90-ODN with or without magnetic field, suggesting a magnetic field had no effect 
to the performance of non-magnetic SPPs. After 5 and 20 min of transfection time, lower uptake 
efficiencies were observed for cells treated with SPP90-ODN (49%, 20 min) compared with 
MSPP90-ODN (51%, 20 min) when there was no magnetic field provided. However, slightly higher 
uptake efficiencies were obtained by SPP90-ODN (69%, 1 h) than MSPP90 (65%, 1 h) when the 
transfection time was extended to 1 h or over. This can be attributed to more PEI in SPP90 than that 
in MSPP90 with the same overall weight, therefore facilitate the internalization over time.  
5.2.4.2. Concentration effect on the uptake efficiency of MSPP90-ODN and SPP90-ODN on 
MDA-MB-231 cells and HDF cells 
The ODN uptake efficiency for MDA-MB-231 is shown in Fig. 5.8a. Cells were incubated with naked 
ODNs and complexes at different concentrations for 20 min before washed and further incubated 
for a final duration of 24 h. Fig. 5.8a clearly shows that increasing the concentration of 
MSPP90-ODN and SPP90-ODN lead to the improved uptake efficiencies for MDA-MB-231 cells, 
which explains why increased concentrations of transfection complexes resulted in decreased 
viability of cells as shown previously in Section 5.2.3.2. The uptake efficiencies obtained by 
Oligofectamine-ODN were 2.7, 5.7 and 3.7-fold higher than those obtained by naked ODNs at the 
concentration [C], 5[C] and 10[C] respectively, suggesting an enhanced uptake efficiency can be 
achieved by Oligofectamine within a short transfection time of 20 min. However, higher uptake 
efficiencies were obtained by MSPP90-ODN and SPP90-ODN with or without the presence of a 
magnetic field. In particular, with a magnetic field the uptake efficiency of MSPP90-ODN is much 
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higher. The uptake efficiencies by HDFs, as a control of non-cancer cells, are displayed in Fig. 5.8b 
and are significantly lower than that of MDA-MB-231 breast cancer cells. These results explain why 
both MSPP90-ODN and SPP90-ODN exhibited a lower growth inhibition effect to HDF cells 
compared with MDA-MB-231 cells (see Section 5.2.3.2).  
 
Fig. 5.8. Cellular uptake assays of MDA-MB-231 cells (a) and HDF cells  (b) after treated with 
MSPP90-ODN and SPP90-ODN at different concentrations. The cell-only and ODNs-only are used as 
negative controls with the ODN dosages equivalent to the amount used for the complexes. 
Oligofectamine-ODN was used as a positive control.  Cells were incubated with ODN or complexes for 20 
min with (M+) or without (M-) the presence of an external magnetic field. After the initial transfection, cells 
were washed twice with PBS and incubated in complete medium to a final duration of 24 h before the FACS 
analysis. The MSPP90 / ODN and SPP90 / ODN mass ratio was fixed at 12:1. [C]=12 μg/ml MSPP90 or 
SPP90 + 1 μg/ml ODN. The results are shown in mean ± SD, n = 3. The statistical significance is expressed 
as ***p < 0.001, **p < 0.01, *p <0.05. 
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5.2.5. Magnetically targeted delivery assay 
 
 
Fig. 5.9. Schematic diagram of magnetically targeted delivery of transfection complexes to MDA-MB-231 
cells. Cells were seeded in 6-well plates with 2 coverslips previously placed in each well and incubated for 
overnight to allow for cell attachment. Next, mediums were removed, and the cells were washed twice with 
PBS buffer before incubation in serum-free mediums. Naked ODN, Oligofectamine-ODN, SPP 90-ODN and 
MSPP 90-ODN were added into the serum-free mediums and incubated with cells for 4 h. A magnet was 
placed under one of the coverslips for the first 20 min of the 4-h initial incubation. After the initial incubation, 
the serum-free mediums were removed and replaced with complete medium and the cells were further 
incubated to a final duration of 24 h before analysis with a confocal microscope. 
To investigate the potential of MSPPs for magnetically targeted delivery of ODN, MSPP 90-ODN 
were incubated with MDA-MB-231 cells with or without the presence of a magnet as shown in Fig. 
5.9. Naked ODNs, Oligofectamine-ODN and SPP90-ODN were also incubated with cells as 
negative controls. As shown in Fig. 5.10a&b, fluorescence intensities of cells treated with naked 
ODNs were seen to be significantly lower than those cells treated with transfection complexes, 
suggesting naked ODNs were not efficiently internalized by cells, which is consistent with uptake 
efficiency shown in Fig. 5.7. Moreover, for cells treated with naked ODNs (Fig. 5.10a&b), 
Oligofectamine-ODN (Fig. 5.10c&d) and SPP90-ODN (Fig. 5.10e&f), the presence of the magnet 
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did not result in any significant difference to the fluorescence intensities, suggesting that the 
magnetic field did not change the cellular uptake of these complexes. Fig. 5.10g&h reveals the 
uptake of MSPP90-ODN without and with a magnet placed under the cells respectively. With the 
presence of the magnet the ODN uptake was significantly enhanced. The improved ODN uptake is 
because large amounts of MSPP90-ODN were concentrated at the area with a magnet. On the 
other hand, the local concentration of MSPP90-ODN at the areas without magnet was significantly 
reduced, therefore reduced the uptake. This result reveals that MSPPs have great potential to be 
used for magnetically targeted delivery of ODNs to desired sites.  
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Fig. 5.10. Confocal microscopic images of MDA-MB-231 cells  incubated with naked ODNs (a&b), 
Oligofectamine-ODN (c & d), SPP90-ODN (e&f) and MSPP90-ODN (g&h). ODNs were labelled with 
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5′-FAM (green). Cell nucleus and cytoskeleton were stained with DAPI (blue) and Alexa Fluor 568 
Phalloidin (red); all images were taken with the LSM510 confocal microscope (Zeiss). M+ indicates the 
presence of a magnet during the incubation and M- indicates the absence of the magnet. 
5.3. Conclusions 
In summary, SPPs and MSPPs with core-shell structures have been fabricated using biocompatible 
and biodegradable SF biomaterial in conjunction with PEI and MNPs. The particle size and zeta 
potentials are controllable by changing the percentage of SF during fabrication. SPPs and MSPPs 
are capable of delivering ODNs into MDA-MB-231 breast cancer cells and significantly inhibiting cell 
growth. In addition to this, MSPPs and SPPs showed significantly reduced cytotoxicity compared to 
MPPs. Both SPPs and MSPPs are less toxic to HDF cells than to MDA-MB-231 cancer cells. High 
uptake efficiency of ODNs (over 70%) can be achieved by MSPPs within a short time (20 min) 
through magnetofection. Moreover, with the presence of external magnetic fields, MSPPs can target 
deliver ODNs to the desired areas with reduced ODN concentration at non-targeting areas, thus 
avoiding undesirable side-effects of MSPPs to healthy tissue. SPPs and MSPPs therefore are 
promising candidates for targeted gene therapy. 
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6. Conclusions 
 
In this thesis, a variety of nanoparticles (SFPs, MSPs, MAPs, MACPs, SPPs, MPPs and MSPPs) 
have been fabricated and their performances for drug or gene delivery applications have been 
studied.  
SFPs, MSPs, MAPs and MACPs were used for the delivery of the anticancer model drug CUR. The 
nanoparticles were observed to be non-cytotoxic, which can be attributed to the selection of 
non-cytotoxic and biocompatible SF, SA and CHI as the coating materials. What is more, the in vitro 
cytotoxicity assay indicated that MSPPs exhibited significate lower cytotoxicity than MPPs, 
suggesting that the addition of biocompatible SF successfully reduced the cytotoxicity of MPPs. 
Significant higher uptake efficiencies of CUR or ODNs was observed when loaded into carriers 
(MSPs, MAPs, MACPs, SPPs, MPPs and MSPPs), compared to free CUR or ODNs. This is due to 
the size range of the nanocarriers (100-360 nm) as well as the fact that free CUR, which is highly 
hydrophobic, can easily aggregate in aqueous solution and in the case of free ODNs, 
self-assembled long nanowires formed. Because of the enhanced uptake of CUR or ODNs when 
they were loaded into nanoparticles, their cellular growth inhibition effect to cancer cells was also 
Improved.  
Moreover, a new method for the preparation of SFPs via salting out was developed in this project. 
Instead of using the conventional methods of salting out via potassium phosphate, sodium 
phosphate was employed and the resulting SFPs were observed to be significantly smaller in size 
(90 - 300 nm) than the SFPs (500 - 12000 nm) fabricated using potassium phosphate. The 
difference in the particle size is due to the different hydration properties of sodium and potassium 
ions and their different adsorption behaviour to SF polypeptides. Since smaller carriers (50 – 200 
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nm) are desired for cancer therapy, this new method is therefore promising for the fabrication of 
SFPs for future drug delivery applications.  
The CUR release rate can be controlled by altering the pH of the sodium phosphate solution for the 
preparation of CMSFPs. Further to this, the release rate is influenced by the outermost coating layer, 
suggesting specific drug release profiles can be achieved by carefully designing the drug carriers. 
In addition, the in vitro magnetically targeted delivery assay of MAPs, MACPs and MSPPs indicated 
that the magnetic nanocarriers allowed the targeted delivery of cargo to selected areas under a 
magnetic field, suggesting these nanocarriers are promising for targeted delivery of anticancer 
drugs or genes to cancer cells. 
In summary, in order to fabricate non-cytotoxic nanoparticles, the selection of non-cytotoxic and 
biocompatible materials in the particle preparation process is required. Smaller particle sizes 
generally benefit the internalization of the particles into cells. Meanwhile, particles within the 
optimum size range of 50 – 200 nm can specifically increase the uptake of these particles by cancer 
cells. Therefore, exploring of methods to prepare particles within the suitable size range is 
necessary. Moreover, encapsulation of magnetic cores enables the rapid accumulation and 
targeted delivery of the nanoparticles.  
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7. Future work 
The results from the previous experimental Chapters indicated that magnetic core-shell 
nanoparticles (MAPs, MACPs and MSPPs) are capable of in vitro targeted delivery to desired 
locations. However, the purpose of designing these magnetic nanoparticles is to target deliver 
anticancer drugs into tumour sites, which are located inside the human body. Therefore, it is 
required to test their in vivo targeting performance by running animal experiments.  
 
 
Fig. 7.1. Schematic representation of the experimental plan for the in vivo targeting performance of the drug 
loaded magnetic nanoparticles. 
The animal experiment plan is shown in Fig. 7.1. Initially, cancer cells are planted into two different 
sites of a mouse to allow the growth of tumours. Then, a small magnet is attached next to one of the 
tumours and an anticancer drug (e.g. CUR) is loaded into the magnetic nanoparticles. These are 
then injected into the mouse every 24 h. By monitoring the size of the tumours with or without the 
attached magnet, the targeting effect of the magnetic nanoparticles under a magnetic field can be 
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observed. Finally, dissect the tumours and analyse the concentration of the anticancer drug in each 
tumour site to quantitatively analyse the targeting effect of the magnetic nanoparticles under a 
magnetic field. 
In Chapter 3, the different salting out effects of sodium and potassium ions is explained due to the 
different adsorption behaviours of these ions to negatively charged SF polypeptides. The SF 
polypeptides are assumed as small, hydrophobic particles and sodium ions, which are more 
hydrated in aqueous solution than potassium ions, which are assumed less hydrophobic than 
potassium ions. Therefore, the potassium ions are believed more readily adsorbing onto SF, while 
sodium ions are more readily to stay closer to bulk of the water, leading to a stronger salting out 
effect of potassium ions. However, proteins contain both hydrophobic and hydrophilic sites. The 
hydrophobic amino acids are protected by hydrophilic ones in an aqueous solution. Therefore, it can 
be assumed that the salting out process of SF is expected to be more complex than the simplified 
model discussed in Chapter 3. It is likely that sodium ions are more rapidly adsorbed onto the 
hydrophilic amino acids and reduce their overall net surface charge, leading to the exposure of 
hydrophobic amino acids. These prefer the adsorption of potassium ions compared to sodium ions. 
It would therefore be beneficial to design an experiment test this hypothesis.   
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Fig. 7.2. Schematic representation of the experimental plan for the salting out process of SF via sodium (a) 
and potassium (b) phosphate solutions. 
As shown in Fig. 7.2, initially, SF solutions are added into sodium or potassium phosphate solution. 
Mixed SF / salt solutions are then taken from each tube at preselected time intervals (e.g. 15, 30 
min, 1, 2, 4, 8, 12, 24, 48 h). These are then analysed for their SF particle size and the sizes are 
plotted against time.   
If the previously mentioned hypothesis is correct then the initial aggregation of SF polypeptides will 
be first happening in the sodium phosphate solution, as the sodium ions would be more readily 
adsorbed onto the hydrophilic amino acids. This in turn would mean that the SF particles fabricated 
from sodium phosphate solutions would be expected to possess larger sizes than those fabricated 
from potassium phosphate solutions for the same time intervals. After the exposure of hydrophobic 
amino acids, potassium ions are expected more readily to adsorb to SF polypeptides, leading to a 
stronger salting out effect and larger size of SF particles fabricated from potassium phosphate 
solutions at the latter time intervals, as shown in Fig. 7.3. 
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Fig. 7.3. Prognostic graph of the size of SF particles prepared from sodium / potassium phosphate solutions 
as a function of salting out time. 
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